Rank,Title,Status,Study Results,Conditions,Interventions,Outcome Measures,Last Update Posted,URL1,Measuring the Impact of Cognitive and Psychosocial Interventions in Persons With Mild Cognitive Impairment,Completed,No Results Available,Mild Cognitive Impairment,Other: Cognitive intervention|Other: Psychosocial intervention,Change in memory measures|generalization of therapeutic gains to everyday life|Change in psychological health measures,27-Jan-16,https://ClinicalTrials.gov/show/NCT014481482,Aerobic Exercise Training in Mild Cognitive Impairment Study,Completed,No Results Available,Mild Cognitive Impairment,Behavioral: Exercise|Behavioral: Balance training,Cognitive function|Cerebrovascular function|Brain tissue volume and white matter integrity,26-Oct-16,https://ClinicalTrials.gov/show/NCT011467173,A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment,Completed,Has Results,Mild Cognitive Impairment,Drug: Aricept (donepezil hydrochloride)|Drug: placebo,Number of Participants With Treatment-Emergent Adverse Events,14-Jan-14,https://ClinicalTrials.gov/show/NCT009343754,A Combined Training Program for Veterans With Amnestic Mild Cognitive Impairment,Completed,No Results Available,Amnestic Mild Cognitive Impairment,Behavioral: Combined Aerobic and Resistance Exercise|Behavioral: Stretching Exercises|Behavioral: Cognitive Training,"Change from Baseline to 28 weeks in delayed recall of a word list|Change from Baseline to 28 weeks in Delayed Recall of Names-Face Task|Non-Cognitive Outcomes (Depression, Sleep, Quality of Life)",05-Apr-18,https://ClinicalTrials.gov/show/NCT019620385,Meaningful Activity Intervention for Persons With Mild Cognitive Impairment,Completed,No Results Available,Mild Cognitive Impairment,Behavioral: Daily Enhancement Meaningful Activity (DEMA)|Behavioral: Information Support (IS),Patient_Depression symptoms: Patient Health Questionnaire Depression Scale (PHQ-9)|Patient_satisfaction with communication: The subscale of Communication and Affective Responsiveness|Patient_Physical Function: Alzheimer disease cooperative study activities of daily living inventory.|Patient_Life satisfaction : Life Satisfaction Index for the Third Age-Short Form|Patient_Satisfaction with program: Satisfaction with Meaningful Activity Program Scale is adapted from the Caregiver Satisfaction Scale|Patient_ Meaningful activities engagement performance and satisfaction: Canadian Occupational Performance Measure & weekly log|Patient_Sense of confidence: Confidence Scale|Caregiver_Depressive Symptoms: PHQ-9|Caregiver_ Caregiver life changes: Caregiving Outcomes Scale|Caregiver_- Satisfaction with program: Satisfaction with Meaningful Activity Program Scale is adapted from the Caregiver Satisfaction Scale,25-Oct-16,https://ClinicalTrials.gov/show/NCT018432836,Intervention Program for Patients With Mild Cognitive Impairment,Completed,No Results Available,Mild Cognitive Impairment,Other: Family Caregiver Intervention Program,Caregivers' preparedness was measured by the 10-item Caregiver Preparedness Scale.|Caregivers' competence was measured by the 17-item Competence Scale.|Caregivers' quality of life was measured by the The 36-Item Short Form Health Survey (SF-36).|Caregivers' depressive symptoms was measured by the the Center for Epidemiologic Studies Depression Scale.,03-Feb-17,https://ClinicalTrials.gov/show/NCT026708507,Efficacy Study of Cognitive Intervention in Amnestic Mild Cognitive Impairment,Completed,No Results Available,Mild Cognitive Impairment,Other: group cognitive intervention|Other: Home-based cognitive intervention,Modified Alzheimer's Disease Assessment Scale-Cognitive subscale(ADAS-cog)|story recall test|Digit span forward and backward|Word fluency test|color-word stroop test|Digit symbol test|prospective memory test|Mini-Mental State Examination|CDR-SB|K-AD8|PRMQ|MMQ-Strategy|QOL-AD|Geriatric Depression Scale-short form|Bayer ADL|CGA-NPI|Subjective cognitive assessment,28-Aug-13,https://ClinicalTrials.gov/show/NCT013589558,Mindfulness Based Stress Reduction for Adults With Mild Cognitive Impairment,Completed,No Results Available,Mild Cognitive Impairment,Behavioral: Mindfulness Based Stress Reduction (MBSR),"Number of participants with adverse events|Feasibility: 85% completion|Change in fMRI Resting state|Change in Cognition|Change in Measures of ""well-being""|Qualitative Improvements",24-May-12,https://ClinicalTrials.gov/show/NCT016054489,Preventing Cognitive Decline in African Americans With Mild Cognitive Impairment,Completed,No Results Available,Mild Cognitive Impairment (MCI),Behavioral: Behavioral Activation (BA)|Behavioral: Supportive Therapy (ST),"Episodic Memory|Uniform Data Set (UDS) Neuropsychological Battery, Alzheimer's Disease Cooperative Study (ADSC) Measures",18-Jan-18,https://ClinicalTrials.gov/show/NCT0129976610,RIVastigmine In Vascular cognitivE Impairment,Completed,No Results Available,Cognitive Impairment,Drug: Exelon (rivastigmine)|Drug: Placebo,To evaluate the comparative change from baseline between treatment and placebo arms in the Ten Point Clock Drawing Test as well as Color Trails 1 and 2.|To evaluate the comparative change from baseline between treatment and placebo on cognitive function|To evaluate the comparative change from baseline between treatment and placebo on activities of daily living|To evaluate the comparative change from baseline between treatment and placebo on behavior and depression|To evaluate the safety and tolerability of treatment in comparison to placebo,10-Feb-17,https://ClinicalTrials.gov/show/NCT0066934411,Memory Training Versus Yogic Meditation Training in Older Adults With Mild Cognitive Impairment,Completed,No Results Available,Mild Cognitive Impairment,Behavioral: Kundalini yoga and meditation|Behavioral: Memory Training,Change in memory|Clinical Global Impression scale|Geriatric Depression scale|Change in fMRI connectivity,30-Jun-16,https://ClinicalTrials.gov/show/NCT0198393012,Memory Training in Patients With Amnestic Mild Cognitive Impairment,Completed,No Results Available,Mild Cognitive Impairment,Behavioral: Memory Training|Behavioral: Psychoeducation,Changes in memory measures|Changes in functional magnetic resonance imaging (fMRI)|Changes in perception of memory performance and mood|Changes in memory performance and perception of memory performance over time - follow up,26-Oct-15,https://ClinicalTrials.gov/show/NCT0197835313,Cognitive Intervention in Mild Cognitive Impairment With or Without White Matter Hyperintensities,Completed,No Results Available,Mild Cognitive Impairment,Behavioral: Computerized Cognitive Stimulation,Rey Auditory Verbal Learning test,22-Jun-17,https://ClinicalTrials.gov/show/NCT0319580314,Evaluation of Lithium as a Glycogen-Synthase-Kinase-3 (GSK-3) Inhibitor in Mild Cognitive Impairment,Completed,No Results Available,Mild Cognitive Impairment,Drug: Lithium Carbonate,GSK-3 activity in PBMC isolates,11-Apr-18,https://ClinicalTrials.gov/show/NCT0260185915,Vascular Alteration and Evolution of Cognitive Impairment,Completed,No Results Available,Cognitive Impairment,Biological: blood sampling|Procedure: brain MRI and TEP cerebral|Other: Assessment of cognitive functions|Other: Electrocardiogram and blood pressure|Procedure: Vascular explorations|Biological: Urine sample,"Global memory, visual retention and verbal fluency composite score|vascular exploration|white matter hyperintensities by fazekas score.",25-Feb-14,https://ClinicalTrials.gov/show/NCT0135196116,Computer-Based Therapy for Mild Cognitive Impairment,Completed,No Results Available,Mild Cognitive Impairment,Procedure: Computer-based training for Mild Cognitive Impairment (MCI),"The study investigates changes in a neuropsychological assessment battery pre-randomization|and upon the completion of training.|Early evaluations will be conducted from brain imaging; specifically, date|obtained via positron emission tomography (PET), magnetoencephalography (MEG),|electroencephalography (EEG), and functional magnetic resonance imaging (fMRI)|studies.",27-Apr-06,https://ClinicalTrials.gov/show/NCT0031994317,Identification of Biomarkers Sensitive to Disease Progression in Patients With Mild Cognitive Impairment,Completed,No Results Available,MILD COGNITIVE IMPAIRMENT,Procedure: Lumbar puncture,Part A: Magnetic Resonance Imagery protocol|Part B: Changes of the hippocampal volume|Part B: Clinical assessment|Part B: Neuropsychology|Part B: Neurophysiology|Part B: Magnetic Resonance Imagery and functional MRI|Part B: Blood drawing|Part B: Actigraphy|Adverse events,02-Nov-15,https://ClinicalTrials.gov/show/NCT0142595718,"Cognitive Impairment Following Sedation for Colonoscopy With Propofol, Midazolam and Fentanyl Combinations",Completed,No Results Available,Cognitive Impairment,"Drug: Propofol, midazolam, fentanyl","Cognitive impairment at hospital discharge after elective outpatient colonoscopy|Dreaming during sedation, intraoperative operating conditions and complications, satisfaction with care",30-May-13,https://ClinicalTrials.gov/show/NCT0044642019,Impact of Transcranial Direct Current Stimulation on Language Functions in Mild Cognitive Impairment,Completed,No Results Available,Mild Cognitive Impairment,Device: tDCS,Number of correct responses during word-generation tasks (max. 60)|Neural activity during word-generation task assessed by functional magnetic resonance imaging (fMRI),22-Aug-13,https://ClinicalTrials.gov/show/NCT0177121120,A Rehabilitation Intervention for Amnestic Mild Cognitive Impairment,Completed,No Results Available,Mild Cognitive Impairment,Behavioral: Memory Support System|Behavioral: Computer Training,"To assess participant adherence to Memory Support System (MSS) use at different levels (6 week, 10 day, or computer activity) of the training intervention. This will be measured by an overall adherence score (Adherence Assessment).|To assess participant adherence to (Memory Support System) MSS use at different levels (6 week, 10 day, or computer activity) of the training intervention. This will be measured by an overall adherence score (Adherence Assessment).|To assess participant adherence to (Memory Support System)MSS use at different levels (6 week, 10 day, or computer activity) of the training intervention. This will be measured by an overall adherence score (Adherence Assessment).",04-Dec-14,https://ClinicalTrials.gov/show/NCT0128326921,"ThinkingFit: Combined Physical, Cognitive and Social Treatment in Mild Cognitive Impairment (MCI)",Completed,No Results Available,Mild Cognitive Impairment,Procedure: ThinkingFit programme,Activity Compliance|Cardiovascular fitness measure|Cognitive measures|Measures of quality of life and everyday activities,28-Apr-14,https://ClinicalTrials.gov/show/NCT0160386222,Support Groups for Patients With Mild Cognitive Impairment and Their Partners,Completed,No Results Available,Mild Cognitive Impairment,Behavioral: support groups,"quality of life: RAND, GDS|caregiver: sense of competence (SCQ), burden of the problems in the Revised Memory and Behavioral Problems (RMBP)|Illness cognitions: Illness Cognitions Questionnaire (ICQ)|marital satisfaction: Maudsley Marital Questionnaire (MMQ)",21-May-08,https://ClinicalTrials.gov/show/NCT0028575323,Effects of Dietary Interventions on the Brain in Mild Cognitive Impairment (MCI),Completed,No Results Available,Mild Cognitive Impairment,Behavioral: caloric restriction|Behavioral: omega-3 supplementation|Behavioral: resveratrol supplementation|Behavioral: Placebo|Behavioral: 2nd step: intervention + physical / cognitive training|Behavioral: 2nd step: intervention + control,Alzheimer's Disease Assessment Scale - cognitive subscale|Functional/Structural brain changes|Plasma biomarkers,28-Jul-17,https://ClinicalTrials.gov/show/NCT0121924424,Effects of Mental Stimulation in Patients With Mild Cognitive Impairment,Completed,No Results Available,Mild Cognitive Impairment (MCI),Behavioral: mentally stimulating activities,Self-Ordered Pointing Task|Trail-Making|Timed Instrumental Activities of Daily Living|Rey Auditory Verbal Learning Test|Self-ordered pointing task|Clinical Dementia Rating Scale|Digit Symbol Substitution Test|Digit Span|Verbal Fluency Test|Geriatric Depression Scale|Neuropsychiatric Inventory|Recollection Task|N-Back|Rivermead Behavioral Memory Test|Instrumental Activities of Daily Living|Functional Capacities for Activities of Daily Living|Multifactorial Memory Questionnaire,09-Dec-15,https://ClinicalTrials.gov/show/NCT0121269225,Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI),Completed,Has Results,Post-Stroke Cognitive Impairment (PSCI),Drug: Actovegin|Drug: Placebo,"Change From Baseline in Alzheimer's Disease Assessment Scale + Cognitive Subscale Extended Version (ADAS-cog+) at Month 6|Change From Baseline in ADAS-cog+ at Month 3 and Month 12|Change From Baseline in Montreal Cognitive Assessment Scale (MoCA) at End of Infusion Period, Months 3, 6 and 12|Percentage of ADAS-cog+ Responders at Time Points 3, 6 and 12 Months|Percentage of Participants With a Diagnosis of Dementia|Change From Baseline in National Institutes of Health Stroke Scale (NIHSS) at End of Infusion Period, Months 3, 6 and 12|Barthel Index at Months 3 and 6|EuroQol EQ-5D (EQ-5D) at Month 6|EuroQol EQ-5D (EQ-5D) at Month 12|EuroQol EQ-5D (EQ-5D) General Health at Months 6 and 12|Beck Depression Inventory, Version II (BDI-II) at Months 3, 6 and 12",22-Feb-16,https://ClinicalTrials.gov/show/NCT0158285426,"Cog-VACCINE: Cognitive Training in Patients With Vascular Cognitive Impairment, no Dementia",Completed,No Results Available,Vascular Cognitive Impairment no Dementia,Behavioral: multi-domain internet-based adaptive training program|Behavioral: placebo program,the Montreal Cognitive Assessment (MoCA)|the Trail Making Test (TMT) B-A|neuroplasticity outcome,15-Dec-17,https://ClinicalTrials.gov/show/NCT0264071627,"Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery",Completed,No Results Available,Mild Cognitive Impairment,Drug: AL-208|Drug: Placebo,The primary objective of this study was to compare mild cognitive impairment in the AL-208 group with the placebo group at 14å±3 days after coronary artery bypass graft (CABG) surgery.|The safety profile of AL-208 in subjects undergoing CABG surgery|The effect of treatment with AL-208 on postoperative personality changes in subjects undergoing CABG surgery|Concentration of AL-208 in plasma in subjects undergoing CABG surgery,24-Oct-12,https://ClinicalTrials.gov/show/NCT0040401428,Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.,Completed,No Results Available,Mild Cognitive Impairment,Drug: CX516 (Ampalexå¨),,24-Jun-05,https://ClinicalTrials.gov/show/NCT0004044329,Art Therapy and Music Reminiscence Activity in the Prevention of Cognitive Decline,Completed,No Results Available,Mild Cognitive Impairment,Behavioral: Art Therapy|Behavioral: Music Reminiscence Activity,Neuropsychological Test: Change from baseline in Rey Auditory Verbal Learning Test scores at 3 months and 9 months|Neuropsychological Test: Change from baseline in Digit Span Task scores at 3 months and 9 months|Neuropsychological Test: Change from baseline in Colour Trails Test scores at 3 months and 9 months|Neuropsychological Test: Change from baseline in Block Design Test scores at 3 months and 9 months|Change from baseline fMRI scan at 3 months|Change from baseline telomere lengths at 3 months and 9 months,26-Jan-18,https://ClinicalTrials.gov/show/NCT0285408530,Effects of Green Tea Consumption on Homocysteine Metabolism and Cognitive Dysfunction,Completed,No Results Available,Cognitive Impairment,Dietary Supplement: green tea powder,Changes in the serum homocysteine levels|Changes in serum lipid levels|Changes in serum folic acid levels|Changes in mini mental state examination (MMSE) scores,16-Jul-13,https://ClinicalTrials.gov/show/NCT0159408631,"The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment",Completed,No Results Available,Cognitive Impairment,Drug: Aricept,Cognitive function.,03-Nov-15,https://ClinicalTrials.gov/show/NCT0010394832,"Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment",Completed,No Results Available,"Mild Cognitive Impairment, So Stated",Drug: AL-108|Drug: Placebo,"Change from baseline to Week 12 on the Composite Memory Variable|Changes in the Composite Memory Variable from baseline to weeks 4, 8, and 16|Changes in test battery individual items from baseline to endpoints (weeks 4, 8, 12, and 16).",24-Oct-12,https://ClinicalTrials.gov/show/NCT0042298133,NMDA-enhancing Agent for Treatment of Mild Cognitive Impairment and Mild Alzheimer's Disease,Completed,No Results Available,Alzheimer's Disease|Mild Cognitive Impairment,Drug: DAOI-B|Other: Placebo,"Change from baseline in Alzheimer's disease assessment scale-cognitive subscale in week 8, 16 and 24|Change from baseline in Mini Mental Status Examination at week 8, 16 and 24|Change from baseline in Instrumental Activities of Daily Living at week 8, 16 and 24|Change from baseline in Verbal learning and memory at week 24|Change from baseline in Digit Span subtest of the Wechsler Memory Scale at week 24",04-Jun-13,https://ClinicalTrials.gov/show/NCT0160046934,Effects of Exercise Training in Patients With Mild Cognitive Impairment and Early Alzheimer's Disease,Completed,No Results Available,Mild CognitIve Impairment|Alzheimer's Disease,Other: Aerobic exercise|Other: Stretch exercise,Change from baseline in Color Trails Test at week12 and Week24|Change from baseline in walking speed at week12 and Week24,21-Apr-14,https://ClinicalTrials.gov/show/NCT0211954635,Efficacy and Safety Study of Shenwu Capsule,Completed,Has Results,Mild Cognitive Impairment,Drug: Shenwu Capsule|Drug: Donepezil,Change in Cognitive Scores: Alzheimer Disease Assessment Scale-cognitive. Subscale (ADAS-cog)|Change in Memory Scores: The Delayed Story Recall (DSR) Test From the Adult Memory and Information Processing Battery (AMIPB)|Change in Functional Scores: Instrumental Activities of Daily Living (IADL).,10-Oct-14,https://ClinicalTrials.gov/show/NCT0145174936,A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease,Completed,No Results Available,Parkinson's Disease With Cognitive Impairments,Drug: safinamide|Drug: placebo,Parkinson's Disease Cognitive Rating Scale (PD-CRS)|PD-CRS subscale scores|PD-CRS total score|Dementia Rating Scale - 2 (DRS-2) total score|DRS-2 total score|DRS-2 subscale scores|Clinical Global Impression (CGI) Change in Cognitive Dysfunction (CGI-C Cognition)|CGI-C Cognition|CGI-Severity in Cognitive Dysfunction (CGI-S Cognition)|CGI-S Cognition|Patient's Clinical Global Impression of Change in Cognitive (PCGI-C Cognition)|PCGI-C Cognition|Grid-Hamilton Depression Rating Scale (Grid-HAMD)|Grid-HAMD|Parkinson's Disease Sleep Scale (PDSS)|PDSS|Apathy Scale (AS)|AS,29-Mar-13,https://ClinicalTrials.gov/show/NCT0121158737,"Caloric Restriction in Obese Patients With Mild Cognitive Impairment: Effects on Adiposity, Comorbidity and Cognition",Completed,No Results Available,Mild Cognitive Impairment|Obesity,Other: medical care|Behavioral: caloric restriction,Neuropsychological test performance|Diagnosis of dementia|Weight loss|plasma biomarkers|Genotyping apolipoprotein E|Charlson comorbidity index|International physical activity questionnaire- short version (IPAQ)|Evaluation of Food Consumption|SPPB- Short physical performance battery|Blood pressure,05-Nov-14,https://ClinicalTrials.gov/show/NCT0128638938,A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment,Completed,Has Results,Mild Cognitive Impairment|Mild Alzheimer's Disease,Drug: AZD5213|Other: Placebo,"Change From Baseline in Total Sleep Time (TST) After 4 Weeks of Treatment, Based on PSG Measurement.|Change From Baseline in Sleep Efficiency After 4 Weeks of Treatment, Based on PSG Measurements.|Change From Baseline in Latency to Persistent Sleep After 4 Weeks of Treatment, Based on PSG Measurements.|Change From Baseline in Night Total Sleep Time After 4 Weeks of Treatment, Based on Actigraphy Recording.|Change From Baseline in Latency of Persistent Sleep After 4 Weeks of Treatment, Based on Actigraphy Recording.|Change From Baseline in Sleep Efficiency After 4 Weeks of Treatment, Based on Actigraphy Recording.",07-Feb-17,https://ClinicalTrials.gov/show/NCT0154828739,A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment,Completed,Has Results,Mild Cognitive Impairment|Dementia,Drug: ladostigil hemitartrate|Drug: Placebo,Conversion From Mild Cognitive Impairment to Alzheimer's Disease Compared to Placebo|Change in Geriatric Depression Scale for Ladostigil Versus Placebo Population|Change in Neuropsychiatric Test Battery for Ladostigil Versus Placebo Population|Change in Disability Assessment in Dementia for Ladostigil Versus Placebo Population,15-Jun-17,https://ClinicalTrials.gov/show/NCT0142962340,Mild Cognitive Impairment in Parkinson's Disease,Completed,Has Results,Parkinson's Disease|Mild Cognitive Impairment,Drug: Exelon Patch (rivastigmine transdermal system)|Drug: Placebo Patches,Alzheimer's Disease Cooperative Study- Clinical Global Impression Change (ADCS-CGIC)|Montreal Cognitive Assessment (MoCA),07-Apr-17,https://ClinicalTrials.gov/show/NCT0151927141,Memory Encoding Strategies for People With Mild Cognitive Impairments,Completed,No Results Available,Mild Cognitive Impairment|Mild Dementia,Other: Behavioral: perceptual-based memory encoding training|Other: Behavioral: semantic-based memory encoding training|Other: Behavioral: Cognitive stimulation group (control group),Change in Disability Assessment for Dementia|Change in Instrumental Activities of Daily Living Scale|Change in Cognistat|Change in Digit Span Test|Change in Consortium to Establish a Registry for Alzheimer's Disease,03-Nov-16,https://ClinicalTrials.gov/show/NCT0295396442,Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog),Completed,No Results Available,Parkinson's Disease|Cognitive Impairment,Drug: Atomoxetine|Drug: Placebo,Neuropsychological Testing Battery|Safety measures,16-Mar-16,https://ClinicalTrials.gov/show/NCT0173819143,Effects of Tai Chi Exercise on Cognition and Serum Biomarkers of Individuals With MCI,Completed,No Results Available,Mild Cognitive Impairment,Other: Tai Chi exercise,Change from baseline in cognitive functions at 6 months|Change from baseline in serum biomarkers at 6 months|Change from baseline in fall risk at 6 months|Change from baseline in quality of life at 6 months|Change from baseline in cognitive functions at 3 months|Change from baseline in fall risk at 3 months,28-Jul-16,https://ClinicalTrials.gov/show/NCT0255232944,Protocol of Virtual Interactive Memory-Training Program,Completed,No Results Available,Mild Cognitive Impairment,Behavioral: Virtual interactive memory training|Behavioral: Passive information activities,Change in objective memory performance as measured by the Chinese version of the Wechsler Memory Scale-III (WMS-III).|Change in subjective memory complaints as measured by the Multifactorial Memory Questionnaire (MMQ).,15-Dec-17,https://ClinicalTrials.gov/show/NCT0246213545,Study of the Effect of the Cognitive Orientation to Daily Occupational Performance (CO-OP) on Cognitive Impairment in Parkinson's Disease,Completed,No Results Available,Parkinson's Disease|Cognitive Impairment,Behavioral: CO-OP treatment protocol,"Change from Pre-Intervention Phase Baseline Pattern (2 week duration) on Canadian Occupational Performance Measure (COPM) score pattern at Intervention Phase (6 week duration), Post-Intervention Phase (2 week duration), and 3-Month Follow-up|Change from Pre-Intervention Phase Baseline Pattern (2 week duration) on Parkinson Disease Questionnaire - 39 (PDQ-39) score pattern at Intervention Phase (6 week duration), Post-Intervention Phase (2 week duration), and 3-Month Follow-Up|Change from Pre-Intervention Phase Baseline Pattern (2 week duration) on Zarit Burden Interview score pattern at Intervention Phase (6 week duration), Post-Intervention Phase (2 week duration), and 3-Month Follow-Up|Change from Pre-Intervention Baseline Observations (2 week duration) on Direct Observation Record at Intervention Phase (6 week duration), Post-Intervention Phase (2 week duration), and 3-Month Follow-Up|Change from Pre-Intervention Baseline Observations (2 week duration) on Semi-Structured Interview at Intervention Phase (6 week duration), Post-Intervention Phase (2 week duration), and 3-Month Follow-Up|Reflective Journal Log",19-Oct-15,https://ClinicalTrials.gov/show/NCT0200778546,Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease,Completed,Has Results,Mild Cognitive Impairment|Alzheimer's Disease,Drug: Flutemetamol (18F) Injection,Hazard Ratio (HR) by PET Scan Readers for Conversion to Probable Alzheimer's Disease Based on Visual Image Interpretation.|The of Normal and Abnormal Subjects Who Convert to Probable Alzheimer's Disease (pAD) Within the Follow up Period.,11-Sep-14,https://ClinicalTrials.gov/show/NCT0102805347,Sensory-cognitive and Physical Fitness Training in Mild Cognitive Impairment,Completed,No Results Available,Mild Cognitive Impairment (MCI)|Mild Alzheimer's Disease,Other: auditory discrimination training|Other: physical movement training,"Change in global cognition|electrophysiological, MRI, blood and liquor correlates",14-Jul-16,https://ClinicalTrials.gov/show/NCT0106148948,Pioglitazone Or Exercise to Treat Mild Cognitive Impairment (MCI),Completed,Has Results,Mild Cognitive Impairment,Drug: Pioglitazone|Drug: Placebo|Behavioral: Endurance Exercise Training,Change in Cognitive Performance|Change in Insulin Resistance|Change in Peak Oxygen Uptake (VO2 Peak),15-Jan-16,https://ClinicalTrials.gov/show/NCT0073699649,Dual Task Aerobic Exercise for Older Adults With Cognitive Impairment (HM2),Completed,No Results Available,Cognitive Impairment,Behavioral: Exercise Intervention|Behavioral: Exercise Control,Global cognitive functioning|Executive Function/Mental Flexibility|Processing Speed|Verbal Learning and Memory|Verbal Fluency|Gait variability (step length) under dual-task conditions|Gait variability (step length) under single-task conditions|Gait speed under dual-task conditions|Gait speed under single-task conditions|Double support (seconds and % gait cycle time) under dual-task conditions|Double support (seconds and % gait cycle time) under single-task conditions|Step length under dual-task conditions|Step length under single-task conditions|Carotid artery compliance|Carotid artery Intima-media thickness (IMT)|Ambulatory systolic blood pressure|Clinic systolic blood pressure|Ambulatory diastolic blood pressure|Clinic diastolic blood pressure|Total balance score|Total Falls Self-Efficacy score,28-Oct-14,https://ClinicalTrials.gov/show/NCT0157231150,Mild Cognitive Impairment and Obstructive Sleep Apnea,Completed,No Results Available,Obstructive Sleep Apnea|Mild Cognitive Impairment,Device: Continuous Positive Airway Pressure [CPAP],Hopkins Verbal Learning Test-Revised [HVLT-R]|Everyday Cognition [E-Cog]|Digit Symbol-Coding [DSC]|Mini Mental State Exam (MMSE)|Stroop Color and Word Test [SCW]|The Psychomotor Vigilance Task (PVT)|Epworth Sleepiness Scale [ESS]|Functional Outcomes Sleep Questionnaire [FOSQ]|Alzheimer's Disease Cooperative Study - Clinicians' Global Impression of Change Scale [ADCS-CGIC]|Clinical Dementia Rating Scale [CDR]|Neuroimaging Biomarker: Hippocampal Volume|Neuroimaging Biomarker: Regional Brain Volume and Thickness.|Neuroimaging Biomarker: Hippocampal Subfield Volumes.|Neuroimaging Biomarker: Ischemic Lesion Volume.|Neuroimaging Biomarker: Cerebral Blood Flow.,17-Mar-15,https://ClinicalTrials.gov/show/NCT0148235151,The Efficacy of Robot Assisted Group Cognitive Training in Elderly Adults Without Cognitive Impairment,Completed,No Results Available,Age-Related Cognitive Decline,Behavioral: Robot assisted cognitive training|Behavioral: Conventional cognitive training group,the change in cortical thickness between the baseline and the post-intervention assessment.,10-May-12,https://ClinicalTrials.gov/show/NCT0159620552,"Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease",Completed,No Results Available,Mild Cognitive Impairment|Alzheimer's Disease,Drug: EVP-0962|Drug: Placebo,"The number of adverse experiences reported by subjects and/or observed by investigator and repeated clinical evaluations of physical examinations, vital signs, 12-lead ECG (electrocardiogram), and lab tests (hematology, chemistry, urinalysis)|To measure the rate of synthesis of Amyloid Beta in cerebral spinal fluid of healthy subjects|To measure the concentration of Amyloid Beta in cerebral spinal fluid|To measure the rate of synthesis of Amyloid Beta and steady-state levels in the cerebral spinal fluid in MCI or early Alzheimer's disease patients|To determine single-and repeat-dose EVP-0962 pharmacokinetics in cerebral spinal fluid and plasma",13-Jan-14,https://ClinicalTrials.gov/show/NCT0166167353,Calligraphy Writing for Cognitive and Emotional Enhancement Among Older MCI People,Completed,No Results Available,Mild Cognitive Impairment,Behavioral: Calligraphy Training|Behavioral: iPad Training,"Change in Digit span backward test (DSB) from baseline, after end of training, and 6-month follow-up.|Color Trails Test (CTT)|Symbol-digit Modalities Test (SDMT)|Heart rate and heart rate variability.|Blood pressure.|Geriatric Depression Scale - Short Form (GDS-SF)|Consortium to Establish a Registry for Alzheimer's Disease - Neuropsychological Assessment Battery (CERAD-NAB)",29-Apr-16,https://ClinicalTrials.gov/show/NCT0275579254,PROMOTE: Promotion of the Mind Through Exercise,Completed,No Results Available,Vascular Cognitive Impairment,Behavioral: Aerobic-based exercise training|Behavioral: CON (control; usual care),This is a proof-of-concept study. The primary endpoints are: ADAS-Cog|EXIT-25|ADCS-ADL|Secondary outcomes of interest include: performance of specific executive processes|Physical function|Inflammatory biomarkers|Serum glucose and lipids. These will be assessed at 6 and 12 months.,04-Oct-17,https://ClinicalTrials.gov/show/NCT0102785855,"A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)",Completed,Has Results,Alzheimer's Disease|Mild Cognitive Impairment,Drug: florbetapir (18F),Qualitative Amyloid Image Assessment|Mean Cortical to Cerebellum SUVR,19-Sep-13,https://ClinicalTrials.gov/show/NCT0166288256,Brain and Cognitive Changes After Reasoning Training in Individuals With Mild Cognitive Impairment,Completed,No Results Available,Mild Cognitive Impairment,Device: tDCS|Device: Sham tDCS,Changes in memory or thinking after brain training|Brain connectivity and activation changes from Pre-treatment to Post-treatment|Changes in brain wave activity from Pre-Treatment to Post-Treatment,18-May-18,https://ClinicalTrials.gov/show/NCT0259690657,Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil,Completed,Has Results,Mild Cognitive Impairment,Drug: Donepezil|Drug: Atropine,Selective Reminding Test (SRT)|Total Number of Errors Measured Using the Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog)|Pfeffer Functional Activities Questionnaire (FAQ)|Measurement of Everyday Cognition (Ecog)|Clinician's Interview Based Impression of Change Plus Caregiver Input (CIBIC-plus),13-Mar-18,https://ClinicalTrials.gov/show/NCT0184563658,NMDA-enhancing Agent for the Treatment of Mild Cognitive Impairment,Completed,No Results Available,Mild Cognitive Impairment,Drug: DAOIB|Drug: Placebo,"Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24|Change from baseline in speed of processing (Category Fluency) at week 24|Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input at week 8, 16 and 24|Change from baseline in working memory (Wechsler Memory Scale, Spatial Span) at week 24|Change from baseline in verbal learning and memory tests (Wechsler Memory Scale, Word Listing) at week 24",24-Jan-18,https://ClinicalTrials.gov/show/NCT0223900359,The Efficacy of Gliatilineå¨ on Post-stroke Patients With Vascular Cognitive Impairment no Dementia,Completed,No Results Available,Cognitive Impairment|Stroke,Drug: choline alfoscerate|Drug: placebo (for choline alphoscerate),the change of K-TMT-e A of K-VCIHS-NP in the choline alfoscerate vs the placebo groups.|the change of other determinants of K-VCIHS-NP in the choline alfoscerate vs the placebo groups,14-Oct-13,https://ClinicalTrials.gov/show/NCT0136364860,Feasibility Study of a Computerized Cognitive Stimulation,Completed,No Results Available,"Mild Cognitive Impairment, So Stated",Behavioral: Computerized Cognitive Stimulation|Behavioral: Multimedia-based internet,GROBER-BUSCHKE TEST|Technologies Acceptation Questionnaire,22-Jun-17,https://ClinicalTrials.gov/show/NCT0319582961,Impact of Grape Consumption on Brain Metabolism and Cognitive Function,Completed,No Results Available,Mild Cognitive Impairment,Dietary Supplement: Grape Powder|Dietary Supplement: Placebo Powder,"Change from baseline in neuropsychological (cognitive, functional) test results|Change from baseline in regional cerebral metabolism",04-Dec-14,https://ClinicalTrials.gov/show/NCT0157361162,"A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)",Completed,Has Results,Alzheimer's Disease|Mild Cognitive Impairment,Drug: florbetapir F 18,Qualitative Amyloid Image Assessment|Mean Cortical to Cerebellum SUVR|Proportion of Positive Florbetapir-PET Scans,10-May-12,https://ClinicalTrials.gov/show/NCT0070214363,"Effects of Tai Chi on Cognition, I-ADLs, and HRQOL in Older People With MCI",Completed,No Results Available,Mild Cognitive Impairment,Behavioral: Tai Chi,Change from baseline C-MMSE score at four months|Change from baseline IADL-CV score at four months|Change from baseline SF-12 score at four months,19-Jan-18,https://ClinicalTrials.gov/show/NCT0340476564,Efficacy of Ubiquitous SR-based Memory Advancement and Rehabilitation Training (U-SMART),Completed,No Results Available,Mild Cognitive Impairment,Device: Phase I U-SMART (4 wks)|Other: Washout (2 wks)|Device: Phase II U-SMART (4 wks),"Change in the Word List Test (memory, recall, recognition) of the CERAD Neuropsychological Assessment Battery before and after phase I intervention and before and after phase II intervention (crossover part of the study)|Change in the Subjective Memory Complaints Questionnaire (SMCQ) before and after phase I intervention and before and after phase II intervention (crossover part of the study)|Change in the Geriatric Depression Scale (GDS) before and after phase I intervention and before and after phase II intervention (crossover part of the study)|Change in the Mini-Mental State Examination before and after phase I intervention and before and after phase II intervention (crossover part of the study)",20-Apr-16,https://ClinicalTrials.gov/show/NCT0168812865,Ubiquitous Spaced Retrieval-based Memory Advancement and Rehabilitation Training,Completed,No Results Available,Mild Cognitive Impairment,Device: U-SMART,the five-point Likert scales for satisfaction and compliance|Word List Memory Test of the CERAD Neuropsychological Assessment Battery|Mini-Mental State Examination (MMSE),27-Jun-12,https://ClinicalTrials.gov/show/NCT0162865366,"Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers",Completed,No Results Available,Alzheimer's Disease|Amnestic Mild Cognitive Impairment,Drug: AH110690 (18F) Injection,"Examine the efficacy and determine visual assessment of raised [18F] brain uptake for separating subjects with probable Alzheimer's Disease from healthy volunteers and assigning amnestic mild cognitive impairment cases to an AD or HV category.|Examine the efficacy and parameters of brain [18F] uptake for separating 25 subjects with probable AD from 25 HV, assigning 20 amnestic MCI cases to an AD or HV category by measuring ranges of regional cerebral to cerebellum tracer uptake ratios.",07-Dec-09,https://ClinicalTrials.gov/show/NCT0078575967,Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI),Completed,Has Results,Mild Cognitive Impairment (MCI),Drug: Levetiracetam 62.5mg|Drug: Levetiracetam 125mg|Drug: Levetiracetam 250mg|Drug: Placebo,Brain Activity in the Dentate Gyrus / CA3 Subregion of the Hippocampus Measured With Blood Oxygenation Level Dependent (BOLD) Functional MRI|Behavioral Performance as Assessed in the Functional Magnetic Resonance Imaging (fMRI) Memory Task,21-Aug-17,https://ClinicalTrials.gov/show/NCT0104475868,Brazil Nuts Effects on Selenium Status and Cognitive Performance,Completed,No Results Available,Mild Cognitive Impairment,Dietary Supplement: Brazil nut|Dietary Supplement: selenium,Selenium level in plasma and erythrocyte|cognitive performance,23-Apr-14,https://ClinicalTrials.gov/show/NCT0212145769,Rehabilitation of Attention in Patients With MCI and Brain Subcortical Vascular Changes Using the APT-II,Completed,No Results Available,Mild Cognitive Impairment,Behavioral: Attention Process Training-II,Functionality in activities of daily living and quality of life|Cognitive performance|Transition to dementia|Cognitive plasticity,15-Jul-16,https://ClinicalTrials.gov/show/NCT0203385070,Metformin in Amnestic Mild Cognitive Impairment,Completed,No Results Available,Amnestic Mild Cognitive Impairment,Drug: metformin|Drug: placebo,Total Recall in the Selective Reminding Test|ADAS-cog|rCMRgl in the posterior cingulate-precuneus.,14-Mar-13,https://ClinicalTrials.gov/show/NCT0062019171,Cognitive Effects of Aerobic Exercise for MCI Adults,Completed,No Results Available,Mild Cognitive Impairment,Behavioral: Aerobic exercise,"Change in cognitive scores|Change in insulin sensitivity|Change in biomarkers associated with Alzheimer's disease progression|Correlation between cognitive scores, insulin sensitivity, & biomarkers",30-Jul-08,https://ClinicalTrials.gov/show/NCT0022046772,Polyamine-enriched Diet in Healthy Older Adults With Subjective Cognitive Decline,Completed,No Results Available,Subjective Cognitive Decline,Dietary Supplement: Polyamine supplementation|Dietary Supplement: Placebo supplementation,Change in Cognitive Function (from neuropsychological test battery)|Laboratory parameters|Vascular parameters,22-Dec-16,https://ClinicalTrials.gov/show/NCT0275524673,Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia,Completed,Has Results,Parkinson's Disease|Cognitive Impairment|Dementia,Drug: Memantine|Drug: Placebo Oral Tablet,Change in Dementia Rating Scale (DRS) Memory Subscore|CIBIC-Plus Score,12-Sep-17,https://ClinicalTrials.gov/show/NCT0029455474,Dexamethasone for the Prevention of Postoperative Cognitive Dysfunction,Completed,No Results Available,Postoperative Cognitive Dysfunction,Drug: Dexamethasone|Other: control group,Score in neuropsycological tests.,10-Sep-15,https://ClinicalTrials.gov/show/NCT0133281275,"Mild Cognitive Impairment, Buddy Supported Exercise/ My Buddy Study",Completed,No Results Available,Mild Cognitive Impairment|Cognitive Disorders,Behavioral: 5-month aerobic exercise intervention,"Adherence (number of sessions attended and exercise duration in targeted heart rate zone)|Change in score on Digit Symbol Coding Test|Change in 400m walk time (from randomization to 5 months)|Change in Trail Making Test part B score|change in memory, measured by Rey AVLT delayed recall score, at 5 months",20-Dec-17,https://ClinicalTrials.gov/show/NCT0156182076,Effects of a Complex Cognitive Training in Mild Cognitive Impairment and Mild Alzheimer's Disease,Completed,No Results Available,Alzheimer's Disease|Cognitive Impairment,Behavioral: complex cognitive training,"cognition: MMSE, ADAS-cog.|quality of life",29-Jan-09,https://ClinicalTrials.gov/show/NCT0054485677,Non-pharmacological Interventions on Cognitive Functions in Older People With Mild Cognitive Impairment,Completed,No Results Available,Mild Cognitive Impairment|TTM|Physical Activity|Cognitive Rehabilitation,Behavioral: Exercise,Mini-Mental State Examination|The Alzheimer's Questionnaire|Taiwan version of Prospectiv and Retrospective Memory Questionaire (PRMQ)|Mobility|Depressive symptoms|Quality of life,04-Jun-18,https://ClinicalTrials.gov/show/NCT0354515278,Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI,Completed,Has Results,Traumatic Brain Injury|Cognitive Impairment,Drug: Rivastigmine Transdermal Patch,Number of Participants With Demonstrated Improvement From Baseline on the Hopkins Verbal Learning Test-Revised (HVLT-R) Total Recall|Twelve-week Change in University of California San Diego Performance-based Skills Assessment - Brief (UPSA-B)|Twelve-week Change in The PTSD Symptom Checklist-Military Version (PCL-M)|Twelve-week Change in Beck Depression Inventory-II (BDI-II),27-Feb-18,https://ClinicalTrials.gov/show/NCT0167052679,Early Postoperative Cognitive Dysfunction After Closed Loop Anesthesia vs Inhalational Anesthesia or TIVA,Completed,No Results Available,Postoperative Cognitive Dysfunction,Device: auto total endovenous anesthesia|Device: Manual Desflurane anesthesia|Device: Manual Sevoflurane anesthesia|Device: Manual total endovenous anesthesia,Change from baseline of the Mini-Mental test examination score 15 min post anesthesia,06-Jul-16,https://ClinicalTrials.gov/show/NCT0265690180,To Study the Effect of Sevoflurane and Propofol V Sevoflurane and Dexmedetomidine on Postoperative Cognitive Dysfunction,Completed,No Results Available,Postoperative Cognitive Dysfunction,Drug: Maintainance of anesthesia with Intravenous Propofol infusion|Drug: Maintainance of anesthesia with Intravenous Dexmedetomidine,Postoperative Cognitive Dysfunction (POCD) after major noncardiac surgery under general anesthesia in Propofol and Dexmedetomidine Group|Recovery time from the stopping of anesthetics agents to eye opening in both Propofol and Dexmedetomidine Group,29-Sep-17,https://ClinicalTrials.gov/show/NCT0314571481,Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults,Completed,No Results Available,Cognitive Impairment|Schizophrenia,Drug: Eltoprazine|Drug: Placebo,MATRICS Consensus Cognitive Battery (MCCB)|Continuous Performance Test-AX Version (CPT-AX)|N-Back|Brief Psychiatric Rating Scale (BPRS)|Calgary Depression Scale (CDS)|Scale for Assessment of Negative Symptoms (SANS)|Simpson-Angus Extrapyramidal Symptom Rating Scale (SAS)|Abnormal Involuntary Movement Scale (AIMS)|Barnes Akathisia Scale (BAS)|Columbia Suicide Severity Rating Scale (C-SSRS),14-Apr-15,https://ClinicalTrials.gov/show/NCT0126617482,Ascending Dose Study of CT1812 in Healthy Volunteers,Completed,No Results Available,Cognitive Impairment,Drug: CT1812|Drug: Placebo,Incidence and review of Treatment Emergent Adverse Events [Safety and Tolerability],07-Sep-16,https://ClinicalTrials.gov/show/NCT0257099783,Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD,Completed,No Results Available,Mild Cognitive Impairment|Alzheimer Disease,Drug: Allopregnanolone injection (intravenous solution)|Drug: Placebo injection (intravenous solution),Safety profile: Adverse events|Safety profile: Clinical laboratory measurements|Safety profile: ARIA|Safety profile: Physical and neurological examination|Tolerability - Maximum tolerated dose (MTD)|Pharmacokinetic profile after single and multiple doses: Maximum Concentration (Cmax)|Pharmacokinetic profile after single and multiple doses: time attain to Cmax (Tmax)|Pharmacokinetic profile after single and multiple doses: Area under the curve (AUC)|Pharmacokinetic profile after single and multiple doses: Drug Clearance (CL)|Pharmacokinetic profile after single and multiple doses: apparent volume of distribution at steady state (Vss)|Cognitive tests (ADAS-Cog; MMSE/MoCA; ADCS-CGIC; CogState)|Brain MRI volumetrics,04-Jun-18,https://ClinicalTrials.gov/show/NCT0222162284,ENLIGHTEN: Exercise and NutritionaL Interventions for coGnitive and Cardiovascular HealTh ENhancement,Completed,No Results Available,"Cognitive Impairment, no Dementia (CIND)",Behavioral: Aerobic Exercise|Behavioral: DASH diet|Other: Health education control,Change in Executive Function|Change in Memory|Change in Language|Inflammation|Functional Capacity|Blood Pressure|Flow-mediated dilation of the brachial artery|Arterial Stiffness|Intima-medial thickness|Fasting glucose|Cholesterol,18-Apr-18,https://ClinicalTrials.gov/show/NCT0157354685,Effect of Blueberries on Cognition and Body Composition in Elderly With Mild Cognitive Decline,Completed,No Results Available,Mild Cognitive Decline,Dietary Supplement: Freeze-dried blueberries|Dietary Supplement: Dextrose Placebo,Change in cognitive test performance|Change in body mass distribution|Change in oxidative stress and inflammatory markers as measured in blood and urine,14-May-15,https://ClinicalTrials.gov/show/NCT0151509886,Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline,Completed,Has Results,Progressive Cognitive Decline,Drug: florbetapir F 18,Percentage of Subjects Who Undergo a Hypothetical Change in Clinical Diagnosis and Physician Management Plan After Obtaining a Negative Florbetapir F 18 PET Scan.|Percentage of Subjects Who Undergo a Hypothetical Change in Clinical Diagnosis and Physician Management Plan After Obtaining a Positive Florbetapir F 18 PET Scan|Change in Confidence of the Clinical Diagnosis|Change in Physician Management Plans,29-Mar-13,https://ClinicalTrials.gov/show/NCT0140042587,Cognitive Assessment of Elderly Primary Care Patients,Completed,No Results Available,Mild Cognitive Impairment,Behavioral: Cognitive Report|Behavioral: Treatment As Usual,Scores on a comprehensive battery of neuropsychological tests.,14-Jan-16,https://ClinicalTrials.gov/show/NCT0149233588,Recollection Training in Healthy Older Adults and Older Adults With Amnestic Mild Cognitive Impairment,Completed,No Results Available,Amnestic Mild Cognitive Impairment|Aging,Behavioral: Recollection Training|Behavioral: Control,Recollection estimates|Brain activation as assessed by functional magnetic resonance imaging,22-Dec-16,https://ClinicalTrials.gov/show/NCT0064326689,Efficacy and Safety of Ginkgo Biloba Extract in Mild Cognitive Impairment and Cerebrovascular Insufficiency,Completed,No Results Available,Mild Cognitive Impairment|Cerebrovascular Insufficiency,Drug: Ginkgo biloba standardized extract 24/6|Drug: Ginkgo Biloba standardized extract 24/6|Drug: placebo,"Changes of MDRS|Changes of VFT|Changes of CGI|Changes of SCAG|Changes of MMSE|Changes of TCD, and color Doppler of carotid arteries|Changes of platelets, hematocrit, prothrombin time, and activated partial tromboplastin time|Changes of total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides|Safety will be assessed according to occurrence of adverse events during the trial",28-Sep-15,https://ClinicalTrials.gov/show/NCT0044648590,Effect of Ginkgo Biloba Special Extract LI 1370 on Dual-tasking in Patients With MCI,Completed,No Results Available,Mild Cognitive Impairment,Drug: Ginkgo biloba,gait speed|cycle time variability,14-Oct-15,https://ClinicalTrials.gov/show/NCT0104629291,Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment,Completed,Has Results,Mild Cognitive Impairment|Major Depressive Disorder|Alzheimer's Disease,Drug: es-citalopram|Drug: Memantine,Change in Selective Reminding Test - Total Immediate Recall (SRT-IR)|Change in Wechsler Memory Scale-III (WMS-III)|Change in Selective Reminding Test - Delayed Recall (SRT-DR)|Change in Trails B|Change in Trails A,24-Oct-14,https://ClinicalTrials.gov/show/NCT0187682392,e-CHAMP: Enhancing Care for Hospitalized Older Adults With Memory Problems,Completed,No Results Available,Cognitive Impairment|Delirium,Behavioral: e-CHAMP (Enhancing Care for Hospitalized Older Adults with Cognitive Impairment)|Behavioral: Standard Care,"Use of potentially inappropriate medications, urinary catheter or physical restraints, and length of time in initiating a referral order, as recorded in the electronic medical record|Total number of hospital acquired complications recorded in the medical record that may be related to cognitive impairment (CI)|Length and cost of hospital stay from discharge records and billing system",13-Apr-16,https://ClinicalTrials.gov/show/NCT0018283293,Effects of Multimodal Cognitive Enhancement Therapy (MCET) for Ealy Dementia,Completed,No Results Available,"Mild Cognitive Impairment|Dementia, Mild",Other: Period I MCET (8 wks)|Other: Washout (4 wks)|Other: Period II MCET (8 wks),Change in the Mini-Mental State Examination for dementia screening before and after period I and before and after period II intervention (crossover part of the study)|Change in the Korean version of Alzheimer's Disease Assessment Scale -cognitive subscale of Korean version (ADAS-KCog) before and after period I and before and after period II intervention (crossover part of the study)|Change in the Disability Assessment for Dementia (DAD-K) before and after period I and before and after period II intervention (crossover part of the study)|Change in the Revised Memory and Behavior Problems Checklist (RMBPC) before and after period I and before and after period II intervention (crossover part of the study)|Change in the Quality of Life-AD (QoL-AD) of patients before and after period I and before and after period II intervention (crossover part of the study)|Change in the Quality of Life-AD (QoL-AD) of caregivers before and after period I and before and after period II intervention (crossover part of the study),28-Jul-15,https://ClinicalTrials.gov/show/NCT0235073894,The Aerobic & Cognitive Exercise Study,Completed,No Results Available,Mild Cognitive Impairment|Healthy,Behavioral: Cybercycle-Game|Behavioral: Cybercyle-Tour|Behavioral: Game Only,Change from baseline in executive function at 6-months|Change in weight|Change in mood|Change from baseline in executive function at 3-months|Change from baseline in executive function at 1-year follow-up,03-May-18,https://ClinicalTrials.gov/show/NCT0223756095,EXCEL: Exercise for Cognition and Everyday Living for Seniors With Memory Complaints,Completed,No Results Available,Mild Cognitive Impairment,Behavioral: Exercise program (AT)|Behavioral: Exercise training (RT)|Behavioral: Exercise training (S & R; control),"Cognitive performance after 3 and 6 months of training|Everyday problem-solving ability after 3 and 6 months of exercise training, brain function after 6 months of training and physical function after 3 and 6 months of training",04-Oct-17,https://ClinicalTrials.gov/show/NCT0095886796,The Use of Duloxetine for Cognition Improvement in Individuals With Mild Cognitive Impairment,Completed,No Results Available,Mild Cognitive Impairment|Depression,Drug: Duloxetine|Drug: Placebo,Change in scores for the Repeatable Battery for Neuropsychological Status (RBANS) from baseline to 16 weeks.|Evaluation of the relative dominance of the verbal-reading system from baseline at 16 weeks through the Stroop Color and Word Test,19-Feb-18,https://ClinicalTrials.gov/show/NCT0259087497,"Piedmont Aging, Cognition & Exercise Study-2",Completed,No Results Available,Mild Cognitive Impairment|Prediabetes,Behavioral: Exercise/Aerobic|Behavioral: Exercise/Stretching,Change in cognitive performance from baseline following 6 month of high or low intensity exercise regimen|Change from baseline in blood sugar concentration and cerebrospinal fluid glucose measures during an oral glucose tolerance test following 6 months of high or low intensity exercise,07-Nov-17,https://ClinicalTrials.gov/show/NCT0231284398,Energy Metabolism and Cognitive Aging,Completed,No Results Available,Mild Cognitive Impairment,Other: Ketogenic diet|Other: Healthy high carbohydrate diet,"improvement in memory testing|correlation between diet, metabolic factors, memory performance, and cerebral activation",24-Mar-17,https://ClinicalTrials.gov/show/NCT0077701099,Combination Treatment Study for Memory Impairment and Depression,Completed,Has Results,Depression|Mild Cognitive Impairment,Drug: Donepezil|Drug: Placebo|Drug: Citalopram|Drug: Venlafaxine,Selective Reminding Test (SRT) Total Recall|Selective Reminding Test (SRT) Delayed Recall|Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog),17-Oct-17,https://ClinicalTrials.gov/show/NCT01658228100,The Effect of Daily Consumption of Eggs on Cognitive Function in the Elderly,Completed,No Results Available,Mild Cognitive Impairment,Other: eggs or egg whites,cognition|inflammation,01-Sep-17,https://ClinicalTrials.gov/show/NCT01621646101,Preliminary Study of Fish Oil and Dementia,Completed,No Results Available,Alzheimer's Disease|Mild Cognitive Impairment,Dietary Supplement: omega-3 polyunsaturated fatty acids ( EPA+DHA),the Clinician's Interview-Based Impression of Change Scale (CIBIC-plus)|the cognitive portion of the Alzheimer's Disease Assessment Scale (ADAS-cog)|Mini Mental Status Examination (MMSE) scores|17-item Hamilton Depression Scale (HDRS)|adverse events,04-Mar-08,https://ClinicalTrials.gov/show/NCT00628017102,Involving Family to Improve Communication in Primary Care,Completed,No Results Available,Cognitive Impairment,Other: Pre-visit patient-family agenda-setting checklist|Other: Usual care,Patient-centered communication|Visit duration|Patient and companion verbal activity|Subjective rating of visit communication|Discussion of patient memory,15-Feb-18,https://ClinicalTrials.gov/show/NCT02986958103,Cognitive Remediation for HIV-associated Neurocognitive Dysfunction,Completed,No Results Available,HIV-associated Neurocognitive Dysfunction,Other: Computerized plasticity-based adaptive cognitive training,Computerized Exercise-based Assessment,23-Nov-16,https://ClinicalTrials.gov/show/NCT02671526104,An Investigation of Chemotherapy Induced Cognitive Impairments in Breast Cancer Survivors,Completed,No Results Available,Breast Cancer,Other: Brain Fitness Program (BFP),Change in Wechsler Test of Adult Reading (WTAR)|Change in Processing Speed (PS)|Change in Executive Functions|Change in Working Memory and Attention|Change in Visual and Verbal Memory|Change in Depression|Change in Anxiety|Change in Frontal Systems Behavior Scale (FRSBE)|Change in Cognitive Self-Report Questionnaire (CSRQ)|Change in Functional Assessment of Cancer Therapy-Cognitive Scale (FACT-Cog)|Change in Functional Assessment of Cancer Therapy - Fatigue scale (FACIT-F),06-Feb-18,https://ClinicalTrials.gov/show/NCT02515487105,Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects,Completed,No Results Available,Cognitive Impairment,Drug: CEP-26401|Drug: donepezil hydrochloride|Drug: modafinil|Drug: Placebo,Paired Associate Learning (PAL) Test|Rapid Visual Information Processing (RVIP) Test|Spatial Working Memory Test|Stop Signal Task (SST)|Adaptive tracking Test|Body sway Test|Leeds Sleep Evaluation Questionnaire (LSEQ)|Leiden Maze Test (LMT)|n-Back Working Memory Test|Polysomnography (PSG) Test|Saccadic Eye Movements|Single-Choice Reaction Time|Smooth Pursuit Eye Movements|Visual Analog Scales (VAS)|area under the drug concentration-time curve (AUC0-t)|maximal observed plasma drug concentration (Cmax)|time to maximum observed plasma drug concentration (tmax)|Summary of participants with Adverse Events,03-Apr-14,https://ClinicalTrials.gov/show/NCT01903824106,Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45),Completed,Has Results,Alzheimer's Disease|Mild Cognitive Impairment,Drug: florbetapir F 18,Change in ADAS-Cog for MCI Subjects|Cognitive Decline in MCI Subjects|Change in ADAS-Cog in CN and AD Subjects|Cognitive Decline in CN and AD Subjects|Covariate Adjusted Psychometric Score Change|Correlation of Change in ADAS-Cog and SUVR,28-Mar-13,https://ClinicalTrials.gov/show/NCT00857506107,Does Zumba Improve Cognition in Healthy APOE e4 Carriers and Noncarriers,Completed,No Results Available,Cognitive Impairment,Other: Zumba exercise,"To examine the feasibility of doing exercise intervention studies in presymptomatic, at risk individuals and determine the optimal outcome measure with minimal practice effect.|To examine whether forty 60 minute sessions of Zumba are associated with cognitive changes in healthy women between 55 and 80 years of age.",03-May-12,https://ClinicalTrials.gov/show/NCT01012791108,Cognitive Screening and Cognitive Training in Seniors,Completed,No Results Available,Mild Cognitive Impairment,Behavioral: Strategic Memory Advanced Reasoning Training|Behavioral: Brain Health Workshop,Improvement in memory or thinking after brain training|Measures changes in brain wave activity,07-Dec-17,https://ClinicalTrials.gov/show/NCT02588209109,Cognitive Ability Training in Seniors,Completed,No Results Available,Mild Cognitive Impairment,Device: Verum tDCS|Device: Sham tDCS,Neuropsychological performance in neuropsychological tests|Brain activation measured with NIRS,10-Apr-18,https://ClinicalTrials.gov/show/NCT02587338110,The Mental Activity and eXercise Trial for Seniors,Completed,No Results Available,Cognitive Impairment,Behavioral: Group 1|Behavioral: Group 2|Behavioral: Group 3|Behavioral: Group 4,"Change in cognitive function summary score|Visual processing speed summary score (mental activity group), executive function summary score (exercise group), other measures (e.g., leisure activity, physical performance, physical function, depressive symptoms, sleep quality)",09-Apr-12,https://ClinicalTrials.gov/show/NCT00522899111,Dual Task Training in Elderly Using the BioRescue,Completed,No Results Available,Mild Cognitive Impairment,Other: Biorescue training,"Static balance|Dynamic Balance|instrumented timed Up-and-Go test while dual-tasking|""stops walking while talking"" test|fall incidence|cognitive function",14-Jun-16,https://ClinicalTrials.gov/show/NCT02681354112,Enhanced External Counterpulsation and Its Effects on Vascular Hemodynamics in Cognitively Impaired Patients,Completed,No Results Available,Mild Cognitive Impairment,Device: External Counterpulsation (EECP),Change in Cognitive Function|Change in Ophthalmic blood flow (OBF)|Change in Blood Viscosity|Cholesterol composition of the blood,13-Jan-16,https://ClinicalTrials.gov/show/NCT01659398113,Oral Health Intervention Pilot Study for Individuals With Memory Problems,Completed,No Results Available,Mild Cognitive Impairment,Behavioral: Oral Health Intervention,Change in oral health|Changes in subjects' self-efficacy,30-Mar-17,https://ClinicalTrials.gov/show/NCT01808235114,"A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease",Completed,No Results Available,Alzheimer's Disease,Drug: BAN2401 2.5 mg/kg|Drug: BAN2401 5 mg/kg|Drug: BAN2401 10 mg/kg|Drug: Placebo,"Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Pharmacokinetics of BAN2401: Maximum Concentration (Cmax)|Pharmacokinetics of BAN2401: time attain to Cmax (tmax)|Pharmacokinetics of BAN2401: Area under the curve (AUC)|Pharmacokinetics of BAN2401: Drug Clearance (CL)|Pharmacokinetics of BAN2401: apparent volume of distribution at steady state (Vss)|Investigation of the effect of repeated intravenous infusions of BAN2401 on the immunogenicity and CSF biomarkers|Investigation of the effect of apolipoprotein allele4 (ApoE4) on the safety, tolerability and pharmacodynamic (PD) response of repeated intravenous infusions of BAN2401",08-Jun-15,https://ClinicalTrials.gov/show/NCT02094729115,Retaining Cognition While Avoiding Late-Life Depression,Completed,No Results Available,Mild Cognitive Impairment,Behavioral: Problem Solving Therapy|Behavioral: Problem Solving Therapy + Exercise|Other: Enhanced Usual Care,Incidence of depression or anxiety disorders|Change in cognitive function measured by RBANS and DKEFS,14-Nov-17,https://ClinicalTrials.gov/show/NCT01886586116,Effects of Cognitive Intervention for Older Adults With Memory Decline: A Pilot Study,Completed,No Results Available,Mild Cognitive Impairment,"Behavioral: MEMO programme (Inst Universitaire de Geriatrie, Montreal)|Behavioral: External memory aids training",Rey Auditory Verbal Learning Test|Wechsler Memory Scale - Logical Memory|Face-name associations test|Multifactorial Memory Questionnaire - Ability subscale|Rivermead Behavioural Memory Test|FAS test (non-memory)|Category fluency (non-memory test)|Victoria Stroop Test (non-memory test)|Digit Span (non-memory test)|Multifactorial Memory Questionnaire - Strategies and Contentment subscales,02-Jun-10,https://ClinicalTrials.gov/show/NCT00609427117,18-Month Study of Memory Effects of Curcumin,Completed,Has Results,Age-associated Cognitive Impairment|Mild Cognitive Impairment (MCI),Drug: Curcumin|Other: Placebo,"Change From Baseline to 18 Months on Brief Visual Memory Test-Revised, Recall|Change From Baseline to 18 Months on Brief Visual Memory Test-Revised, Delay|Change From Baseline on Buschke Selective Reminding Task, Consistent Long-Term Retrieval|Change From Baseline on Buschke Selective Reminding Task, Total Score|Change From Baseline to 18 Months on Trail Making Test, Part A|Change From Baseline to 18 Months on Beck Depression Inventory (BDI)",19-Mar-18,https://ClinicalTrials.gov/show/NCT01383161118,A Randomized Controlled Pharmacist Intervention Study to Reduce Drug-related Problems and Readmissions Among Old People With Dementia,Completed,No Results Available,Cognitive Impairment,Other: Medication review,Frequency of drug related readmissions|Cost for visits for readmissions and to the Emergency Department compared between patients in the control group and intervention group.|Time until institutionalization after discharge compared between control group and intervention group.|Frequency of hospital visits (readmissions and emergency department) during the 6-month follow-up.|Time from discharge to readmission|Adherence to the quality indicators published by the Swedish National Board of Health and Welfare,02-Dec-15,https://ClinicalTrials.gov/show/NCT01504672119,Effect of Exercises Training in Patients With Mild Cognitive Impairment and Early Alzheimer's Disease,Completed,No Results Available,Alzheimer's Disease,Other: Aerobic exercises|Other: Stretch exercise,Changes of Memory and executive function related neuropsychological test|Changes of muscle strength of upper and lower extremity and walking speed,28-Feb-14,https://ClinicalTrials.gov/show/NCT02074215120,Depth of Anaesthesia and Postoperative Cognitive Decline in Patients Undergoing Heart Surgery,Completed,No Results Available,Cardiac Bypass Surgery in Adult Patients 65 Years and Older|Postoperative Cognitive Dysfunction|Postoperative Delirium,Other: Targeted intra-operative depth of anaesthesia,"Incidence of postoperative cognitive decline after bypass surgery|Incidence of postoperative cognitive decline 5 days and 1 year after bypass surgery|Difference in degree of postoperative cognitive decline at 5 days, 6 weeks or 1 year after bypass surgery|Postoperative Delirium|Postoperative central nervous system and myocardial biochemical markers",14-May-15,https://ClinicalTrials.gov/show/NCT01743456121,Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors,Completed,No Results Available,Brain Tumor|Brain Cancer|Cns Cancer|Cognitive Dysfunction,Other: donepezil and questionaires,"The primary goal of this study is to assess the efficacy of donepezil in improving executive abilities and psychomotor speed in adult brain tumor patients who have undergone cranial irradiation and/or chemotherapy.|This study will also assess the efficacy of donepezil in improving other cognitive domains such as attention, memory, and general cognition in this population.|The study will also explore the possibility that the possession of the apolipoprotein E (APOE) Ó-4 allele is associated with the development of cognitive difficulties following cranial radiation and/or chemotherapy treatments.",14-Jan-16,https://ClinicalTrials.gov/show/NCT00594633122,Health Care Courses of Elderly Hospitalized Patients for Inappropriate Reasons: Qualitative and Economic Analyzes,Completed,No Results Available,Cognitive Impairment,Other: Qualitative research,90 semi-structured interviews|Demographic and socio-economic questionnaires of 15 patients|Caregiver Reaction Assessment (CRA) scale,01-Feb-17,https://ClinicalTrials.gov/show/NCT02749669123,Usability of Virtual Reality in Subjects With Mild Cognitive Impairment or Alzheimer's Disease,Completed,No Results Available,MCI|Alzheimer's Disease,Other: Condition virtual reality (VR) then Condition classic cognitive stimulation (CCS)|Other: Condition classic cognitive stimulation (CCS) then Condition virtual reality (VR),"Evaluate the acceptability of the RV|Evaluate the motivation of subjects (interest, cognition) is greater in the virtual environment during the VR experience compared to a conventional cognitive stimulation activity (CSC).",01-Sep-15,https://ClinicalTrials.gov/show/NCT02176629124,TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia,Completed,No Results Available,Cognitive Dysfunction|Schizophrenia,Drug: TC-5619|Drug: Placebo,"To assess the efficacy of TC-5619 as augmentation therapy to quetiapine or risperidone, to improve cognition in stable outpatients with Cognitive Dysfunction in Schizophrenia (CDS), using the GML test of the CogState Schizophrenia Test Battery (CSTB).|Assess the efficacy, safety and tolerability of TC-5619 administered adjunctively with quetiapine or risperidone, evaluate the pharmacokinetics of TC-5619 and plasma levels of quetiapine and risperidone/9-OH-risperidone.",13-Sep-13,https://ClinicalTrials.gov/show/NCT01003379125,Move for Your Mind - Pilot Trial,Completed,No Results Available,Mild Cognitive Impairment|Mild Dementia|Fall Prevention,Drug: Vi-De 3|Other: Jaques-Dalcroze eurhythmics|Other: Home exercise program,"Rate of falls (any falls, low trauma falls, injurious falls) during 12 month follow-up|Number of participants who fell at least once during 12 months of follow up|Gait variability (stride time, stride length and gait speed)|Cognitive function|Alertness|Quality of life",17-Nov-16,https://ClinicalTrials.gov/show/NCT02279316126,Exercise and Activities for Independent Living With Mild Cognitive Impairment (MCI),Completed,No Results Available,Mild Cognitive Impairment|Dementia,Behavioral: Resources and Activities for Life Long Independence (RALLI)|Behavioral: Social Walking program (SW),"Changes in cognitive status|Changes in health, affective, and functional status",19-Oct-12,https://ClinicalTrials.gov/show/NCT00446394127,Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia,Completed,No Results Available,Cognitive Deficits in Schizophrenia,Drug: ABT-126|Drug: Placebo,"Cognition: MCCB|Functioning: UPSA-2|Cognition: CANTAB|Symptom Severity: PANSS, NSA-16, CGI-S",07-Jan-13,https://ClinicalTrials.gov/show/NCT01095562128,Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia,Completed,No Results Available,Cognitive Deficits in Schizophrenia,Drug: ABT-288 Low Dose|Drug: Placebo|Drug: ABT-288 High Dose,"Cognition: MCCB|Functioning: UPSA-2|Cognition: CANTAB|Symptom Severity: PANSS, NSA-16, CGI-S",05-Apr-13,https://ClinicalTrials.gov/show/NCT01077700129,Phenytoin for Memory Impairment Secondary to Megestrol,Completed,No Results Available,Cognitive Impairment,Drug: Phenytoin|Drug: Megestrol Acetate|Drug: Placebo,Rey Auditory Verbal Learning Test (RAVLT)|Digit Span Backwards|The Sternberg Memory Task (SMT)|The Running Memory Continuous Performance Task (RMCPT),29-Dec-16,https://ClinicalTrials.gov/show/NCT02595723130,The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI),Completed,No Results Available,Memory Loss,Drug: Donepezil Hydrochloride|Drug: Placebo,"Assessment of cognitive and global function in subjects with MCI.|Behavioral, global and cognitive outcomes; Neuroimaging",01-Apr-11,https://ClinicalTrials.gov/show/NCT00293176131,Comprehensive Cognitive Remediation as a Strategy to Prevent Cognitive Impairment Associated With Age and Disability With the REHACOP Program,Completed,No Results Available,Aging,Behavioral: Cognitive Remediation Program (REHACOP)|Other: Occupational Therapy,Change from baseline performance on Brief Test of Attention (BTA) (Neuropsychological test)|Change from baseline performance on Forward Digits (Neuropsychological subtest)|Change from baseline performance on Calibrate Ideational Fluency Assessment (CIFA) (Neuropsychological test)|Change from baseline performance on Hopkins Verbal Learning Test (HVLT) (Neuropsychological test)|Change from baseline performance on Brief Visual Memory Test (BVMT) (Neuropsychological test)|Change from baseline performance on Taylor Complex Figure Test (TCF) (Neuropsychological test)|Change from baseline performance on Clock Drawing Test (CDT) (Neuropsychological test)|Change from baseline performance on Visual Object and Space Perception Battery (VOSP) (Neuropsychological test)|Change from baseline performance on Trail Making Test (TMT-A/B) (Neuropsychological test)|Change from baseline performance on Backward Digits (Neuropsychological subtest)|Change from baseline performance on Salthouse Perceptual Comparison Test (Neuropsychological test)|Change from baseline performance on Stroop Test (Neuropsychological test)|Change from baseline performance on Modified Wisconsin Card Sorting Test (M-WCST) (Neuropsychological test)|Change from baseline score on Geriatric Depression Scale (GDS)|Change from baseline score on Neuropsychiatric Inventory Questionnaire (NPI-Q)|Change from baseline score on Lille Apathy Rating Scale (LARS)|Change from baseline score on Multidimensional Fatigue Inventory (MFI)|Change from baseline score on Satisfaction With Life Scale (SWLS)|Change from baseline score on Subjective Questionnaire on Cognitive and Functional Difficulties of the patient and caregivers,03-May-18,https://ClinicalTrials.gov/show/NCT03435029132,Study on the Effectiveness of EGb 761å¨ Vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis,Completed,No Results Available,"Multiple Sclerosis, Relapsing-Remitting",Drug: EGb 761å¨ (Tanakanå¨),"Evolution of Paced Auditory Serial Addition Test 3 and 2 seconds between baseline and week 24|Evolution of the following tests between baseline and week 24:|Multiple Sclerosis Functional Composite Test|Selective Reminding Test|10/36 Visual-Spatial Recall Test|Symbol Digit Modalities Test|Trail Making Test A and B|Verbal Fluency Test|Empan Test|Evolution of the following scales between baseline and week 24:|Cognitive Deficit Interview based screen|Anxiety Brief Scale|Beck Depression Inventory Scale|Modified Fatigue Impact Scale|Evolution of Quality of Life|Evolution of the following between baseline, week 12, and week 24: Kurtzke Extended Disability Status Scale, and Clinician Interview Based Impression of Change",16-May-06,https://ClinicalTrials.gov/show/NCT00276341133,Video-Enhanced Care Management for Medically Complex Veterans,Completed,No Results Available,Multimorbidity|Cognitive Impairments,Behavioral: Care management via videoconference|Behavioral: Care management via telephone calls,Acceptability of care management program for medically complex Veterans with CI|Perceived value of video-enhanced care management for medically complex Veterans with CI|Feasibility of care management program for medically complex Veterans with CI|Usability of video-enhanced care management for medically complex Veterans with CI,21-Mar-18,https://ClinicalTrials.gov/show/NCT02962687134,Does Cognitive Impairment Affect Rehabilitation Outcome in Parkinson's Disease?,Completed,No Results Available,Parkinson's Disease,Behavioral: MIRT,Unified Parkinson's Disease Rating Scale|Berg Balance Scale,25-Mar-16,https://ClinicalTrials.gov/show/NCT02719470135,An Extension Study Evaluating the Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury (TBI) With Persistent Cognitive Deficits,Completed,No Results Available,Traumatic Brain Injury With Persistent Cognitive Deficits,Drug: Rivastigmine,Improvement in cognitive functioning in the areas of attention or verbal memory from baseline to week 26|Safety and tolerability of 26 week's of treatment with rivastigmine in patients with traumatic brain injury with persistent cognitive impairment|Changes in cognitive functioning from baseline to week 26|Changes in behavior from baseline to week 26|Changes in depression from baseline to week 26|Changes in quality of life from baseline to week 26|Changes in overall functioning from baseline to week 26,17-Nov-11,https://ClinicalTrials.gov/show/NCT00219245136,Vitamin B12 Supplement to Prevent Cognitive Decline,Completed,No Results Available,Cognitive Decline,Dietary Supplement: Vitamin B12|Dietary Supplement: Placebo,Change in Clinical Dementia Rating Scale (CDR)|Change in Neurocognitive test battery (NTB) score|Change in serum homocysteine (åµmol/L),28-Jan-16,https://ClinicalTrials.gov/show/NCT02457507137,Computer-based Cognitive Training for Individuals With Parkinson's Disease,Completed,No Results Available,Parkinson's Disease|Mild Cognitive Impairment,Behavioral: Brain Fitness|Behavioral: InSight|Behavioral: Active Control,Percent Accuracy on Cognitive Training Quizzes|Parkinson's Disease Quality of Life Questionnaire-39 (PDQ-39)|California Verbal Learning Test-II Long Delay Free Recall Scaled Score Change Over 3 Months,08-Jan-16,https://ClinicalTrials.gov/show/NCT02225314138,Comparison of PET Amyloid Imaging in Japanese and Western Subjects,Completed,Has Results,Mild Cognitive Impairment|Alzheimer's Disease|Healthy,Drug: [18F] Flutemetamol,Blinded Visual Assessment of Positron Emission Tomography (PET) Imaging and Clinical Diagnosis by Non-Japanese Readers|Blinded Visual Assessment of Positron Emission Tomography (PET) Imaging and Clinical Diagnosis by Japanese Readers,05-Jun-17,https://ClinicalTrials.gov/show/NCT02813070139,A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy,Completed,No Results Available,Parkinson's Disease,Drug: Rasagiline/Placebo|Drug: Rasagiline,Montreal Cognitive Assessment,16-Dec-15,https://ClinicalTrials.gov/show/NCT01497652140,Placebo-Controlled Crossover Study to Evaluate Donepezil and MK-3134 for Reversal of Cognitive Impairment Associated With Scopolamine Administration (3134-005)(COMPLETED),Completed,No Results Available,Dementia,Drug: A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine|Drug: B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg|Drug: C: MK-3134 25 mg + Scopolamine 0.5 mg|Drug: D: Donepezil 10 mg + Scopolamine 0.5 mg|Drug: E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg,"CogState Early Phase Battery, Groton Maze Learning Test (GMLT) as measured by the number of errors on the GMLT over time (area under the GMLT-time curve) over hours 1-12.",06-Nov-15,https://ClinicalTrials.gov/show/NCT01181310141,Brain Gymå¨ Exercises for Institutionalized Elderly People With Cognitive Impairment,Completed,No Results Available,Cognition Disorders in Old Age|Physical Activity,Behavioral: Brain Gym Exercises|Behavioral: Standard exercise program for institutionalized older adults.,Assessment of the changes in participants' cognitive function.|Assessment of the changes in participants' functional independence.|Assessment of the changes in participants' health-related self-perceived quality of life.|Assessment of the changes in participants' fitness level.,11-Dec-17,https://ClinicalTrials.gov/show/NCT03368482142,A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment,Completed,No Results Available,Dementia|Alzheimer Disease,Drug: Galantamine hydrobromide,"Memory and cognition (ADAS-COG/MCI and CDR-SB scores), global functional skills and overall severity of dementia (the CDR-SB and the overall Clinical Dementia Rating) measured at 12 and 24 months.|Digit Symbol Coding and Alzheimer's Disease Cooperative Study-ADL scale (MCI version) at 12 and 24 months. Safety assessment (reports of adverse events, laboratory values, results of physical examinations, and electrocardiograms) throughout the study.",08-Jun-11,https://ClinicalTrials.gov/show/NCT00236431143,A Study to Measure CSF Proteins in Elderly Healthy Volunteers and Volunteers With Mild Cognitive Impairment or Alzheimer's Disease,Completed,No Results Available,Healthy|Alzheimer Disease,Procedure: Standard CSR sampling procedure|Procedure: Alternate frequency CSR sampling procedure|Procedure: Standard frequent CSR sampling procedure with 800 mg ibuprofen|Procedure: Alternative lower frequency CSR sampling procedure,Measurement of CSF proteins|The number of volunteers with adverse events,18-Mar-14,https://ClinicalTrials.gov/show/NCT01436188144,Computer-Based Training in Patients With Post-Chemotherapy Cognitive Impairment,Completed,No Results Available,Breast Cancer|Cognitive Symptoms|Memory Disorders,Device: Computer-based Cognitive Training,Examination of the quantitative training program progression data|Safety|Quality of life health assessments|Functional outcomes assessments|Perceived stress assessments,24-Jun-08,https://ClinicalTrials.gov/show/NCT00387062145,"The Effects of Diet on Mood, Cognition and Appetite",Completed,No Results Available,Mild Cognitive Impairment,Other: High Fat Low Carbohydrate Diet|Other: Low fat High Carbohydrate Diet,Clear-headedness|Reaction time,27-Mar-18,https://ClinicalTrials.gov/show/NCT01201616146,Efficacy of Fish Oil Supplementation on Cognition in MCI Patients and the Influence of the APOE4 Allele,Completed,No Results Available,Mild Cognitive Impairment,"Dietary Supplement: fish oil|Dietary Supplement: placebo, sunflower oil","cognitive performance|blood flow-velocity in the middle cerebral arteries (assessed with TCD) and cortical tissue oxygenation, cerebral autoregulation, cerebral blood volume (assessed with NIRS",12-Jan-11,https://ClinicalTrials.gov/show/NCT00746005147,Conversations as a Means to Delay the Onset of Alzheimer's Disease,Completed,No Results Available,Cognitive Impairment,Behavioral: Active social engagement group|Behavioral: Control group,Cognitive functions measured by neuropsychological tests|Psychological well-being|Levels of social engagement,10-Aug-16,https://ClinicalTrials.gov/show/NCT01571427148,BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.,Completed,No Results Available,Alzheimer Disease,Drug: Placebo|Drug: BI 409306|Drug: Donepezil,Cognition as measured by change from baseline in Neuropsychological Test Battery (NTB) in total z-score|Change from baseline in Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS-ADL) total score|Change from baseline in Alzheimer's Disease Assessment Scale-cognitive subscale 11 item (ADAS-cog11)|Change from baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) total score,08-Dec-17,https://ClinicalTrials.gov/show/NCT02337907149,Optimized Anesthesia to Reduce Postoperative Cognitive Impairment in the Elderly,Completed,No Results Available,Elderly ; Moderate Risk Surgery,"Device: Depth of anesthesia monitoring (BIS, Covidien USA) and Continus non invasive blood pressure monitoring (Clearsight, Edwards LifeScience, USA)|Procedure: moderate risk surgery",postoperative delirium detected by the Confusion Assessment Method (CAM)|postoperative change in cognitive function detected by a battery of neuropsychological test.,26-Dec-17,https://ClinicalTrials.gov/show/NCT02698982150,Compensatory Strategies Applied to Cognitive Impairment in Schizophrenia,Completed,No Results Available,Schizophrenia,Behavioral: Cognitive Adaptation Training,Changes in Social functioning assessed by Global Assessment of Function test and Health of the Nation Outcome Scales item 9-12 concerning social problems.|Changes in Social Functioning using Camberwell Assessment of Need questionnaire. Symptoms using Positive and Negative Syndrome Scale. Quality of Life using Lehman Quality of Life Interview-brief version. Relapse and frequency of hospitalization.,28-Jun-13,https://ClinicalTrials.gov/show/NCT01055509151,Virtual Reality Based Balance Training in People With Mild Cognitive Impairment,Completed,No Results Available,Distorted; Balance|Motor Deficit|Cognitive Deficit,Other: Balance Training,Postural Balance|Gait performance|Cognitive status|Fear of falling|User experience|Depressive signs,16-Dec-14,https://ClinicalTrials.gov/show/NCT02214342152,Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome,Completed,Has Results,Chronic Fatigue Syndrome|Cognitive Impairments,"Drug: Lisdexamfetamine Dimesylate|Drug: Placebo ""30, 50 or 70 mg""",BRIEF-A|Fatigue Severity Scale (FSS)|Hamiliton Anxiety Inventory|Short Form McGill Pain Questionnaire|Fibromyalgia Impact Questionnaire (FIQ)|Attention-Deficit Hyperactivity Disorder Rating Scale (ADHD-RS)|Clinical Global Impression (Severity),03-Apr-15,https://ClinicalTrials.gov/show/NCT01071044153,"Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD",Completed,Has Results,Alzheimer's Disease,Drug: VX-745,Percent Change From Baseline to End of Treatment in Cerebrospinal Fluid Levels of Cytokines|Severe or Serious Adverse Events|Maximal CSF VX-745 Concentration|Episodic Memory Function,03-Apr-18,https://ClinicalTrials.gov/show/NCT02423200154,Memory Impairment Study (Mild Cognitive Impairment Study),Completed,No Results Available,Alzheimer Disease,Drug: Donepezil|Drug: Vitamin E,,11-Dec-09,https://ClinicalTrials.gov/show/NCT00000173155,Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders,Completed,No Results Available,Anxiety Disorders,Drug: Mifepristone,"Drug acceptability, as measured by self-reported side effects and number of dropouts|Drug tolerability, as measured by self-reported side effects and drop-out rates|Cognitive changes over time, as measured by between group and within-subjects comparison of neuropsychological measures.|anxiety and depressive symptoms",20-Mar-14,https://ClinicalTrials.gov/show/NCT01333098156,Effect of EGb761å¨ on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions,Completed,Has Results,Alzheimer's Disease|Cognitive Impairment,Drug: EGb761å¨|Drug: Placebo,Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)|Change in Brain Glucose Metabolism in the MC and CNE Groups|Change in Cognitive Tests-Clinical Dementia Rating (CDR) Score in MC and CNE Groups|Change in Cognitive Tests-Geriatric Depression Scale (GDS) Score in MC and CNE Groups|Change in Cognitive Tests-Verbal Fluency in MC and CNE Groups|Change in Cognitive Tests-Mini Mental Status Examination (MMSE) Score in MC and CNE Groups|Change in Cognitive Tests-Clock Drawing Test Score in MC and CNE Groups|Change in Cognitive Tests-Cube Drawing Test Score in MC and CNE Groups|Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of the Free and Cued Selective Reminding Test (FCSRT)|Change in Cognitive Tests-Age-Adjusted Logical Memory (MEM III) in MC and CNE Groups|Change in Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS) in MC and CNE Groups|Change in Cognitive Tests-Time to Perform Trail Making Test (TMT) in MC and CNE Groups|Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to the DSM IV (Diagnostic of Dementia)|Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to NINCDS-ADRDA (Diagnostic of Alzheimer's)|Change in Cognitive Tests-CDR Score in MC and CNE Groups|Change in Cognitive Tests-GDS Score in MC and CNE Groups|Change in Cognitive Tests-MMSE Score in MC and CNE Groups|Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of FCSRT|Change in Cognitive Tests-Age-Adjusted WAIS in MC and CNE Groups|Change in Cognitive Tests-Time to Perform TMT in MC and CNE Groups|Incidence of Adverse Events (AEs)|Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel Size,28-Mar-16,https://ClinicalTrials.gov/show/NCT00814346157,The Activity Intervention for Chemobrain,Completed,No Results Available,Cancer|Chemotherapy|Cognitive Impairment,Behavioral: Exercise|Behavioral: Usual Care,"Objective measures of cognitive function (a test battery)|Exploratory analyses of psychological status, cardiorespiratory fitness, and inflammatory markers in blood.",04-Apr-17,https://ClinicalTrials.gov/show/NCT00495703158,ABILITY - TelerehABILITation: TechnologY-enhanced Multi-domain at Home Continuum of Care Program,Completed,No Results Available,Cognitive Impairments|Dementia|Alzheimer Disease,Other: Ability platform program|Other: Usual care program,activities of daily living|behavioral symptoms|cognitive domain (long-term memory)|cognitive domain (language)|cognitive domain (frontal-executive functions)|quality of life|coping strategies|global cognitive level|conversion rate MCI versus AD|cognitive domain - long term memory|cognitive domain - language|cognitive domain - frontal executive functions|caregiver quality of life|caregiver coping strategies|caregiver burden|caregiver affect,18-Jan-17,https://ClinicalTrials.gov/show/NCT02746484159,Behavioral and Neuroimaging Changes After Cognitive Rehab in Traumatic Brain Injuries (TBI) and Mild Cognitive Impairment (MCI),Completed,Has Results,Mild Cognitive Impairment|Alzheimer's Disease|Traumatic Brain Injury,Behavioral: Mnemonic strategy training (MST)|Behavioral: Repeated exposure (XP)|Behavioral: Subtracting Cues training,Memory Test Accuracy on Trained Stimuli,04-Jan-17,https://ClinicalTrials.gov/show/NCT00714571160,Molecular Hydrogen for Cognitive Function and Performance in Elderly,Completed,No Results Available,Cognitive Impairments|Aging,Other: Molecular Hydrogen,ADAS-Cog score for cognitive function,28-Oct-16,https://ClinicalTrials.gov/show/NCT02830854161,Austrian Polyintervention Study to Prevent Cognitive Decline After Ischemic Stroke,Completed,No Results Available,Ischemic Stroke|Cognitive Decline|Dementia,Behavioral: Motivation and lifestyle intervention,Number of persons having cognitively declined at 24 months|Cognitive decline measured on the Cognitive Subscale of the Alzheimer's disease assessment scale (ADAS-cog) at 24 months|Number of persons having cognitively declined 12 months after randomization|Cognitive decline on the Cognitive Subscale of the Alzheimer's disease assessment scale (ADAS-cog) at 12 months|Cognitive impairment on the Mini-Mental-State-Examination (MMSE) scale at 12 months|Cognitive impairment on the Mini-Mental-State-Examination (MMSE) scale at 24 months|Change in cognitive abilities measured by composite scores for each of 5 cognitive domains|Composite outcome for vascular events|Neurological status on the National Institute of Health Stroke Scale (NIHSS) score|Functional status on the modified Rankin Scale|Activities of daily living on Barthel Index|Quality of life on the EQ-5D|Depression on the Center for Epidemiologic Studies Depression Scale (CESD)|All cause mortality|Neurological status on the National Institute of Health Stroke Scale (NIHSS)score,13-Jan-15,https://ClinicalTrials.gov/show/NCT01109836162,Post-stroke Cognitive Impairment and Dementia,Completed,No Results Available,Stroke|Cognitive Disorders|Behavioral Disorders,Behavioral: French adaptation of NINDS-Canadian Stroke Network battery,determine the frequency of cognitive and behavioral disorders 6 months post-stroke assessed with this new NINDS-Canadian Stroke Network battery|determine the proportion of patients with dementia|determine the value of cognitive screening tests,31-Jan-17,https://ClinicalTrials.gov/show/NCT01339195163,Lacunar Intervention Trial 1 (LACI-1),Completed,No Results Available,Cerebral Small Vessel Diseases|Cognitive Impairment|Stroke,Drug: isosorbide mononitrate|Drug: cilostazol,Tolerability proportion of patients able to tolerate the target dose|Safety - bleeding|Safety - recurrent stroke|Safety - death|Safety - blood pressure|Efficacy - cerebrovascular function|Efficacy - systemic arterial stiffness|Tolerability Proportion of patients with headache that interferes with daily activities|Tolerability Proportion of patients with dizziness that interferes with daily activities|Tolerability Proportion of patients with nausea that interferes with daily activities|Tolerability Proportion of patients with palpitations|Tolerability Proportion of patients with loose stools|Tolerability Tablet count,19-Jan-18,https://ClinicalTrials.gov/show/NCT02481323164,Evaluation Prospectively the Level of Reduction in Cognitive Functions of Cancer Patients Who Are on Active Oncology Treatments and Use Cannabis. The Second Goal is to Identify High-risk Groups for Cognitive Impairment Due to Cannabis Use.,Completed,No Results Available,1- Cancer Patients During Chemotherapy Treatment|2- Use of Cannabis Comparing to Control Without Cannabis Use,Drug: cannabis,Cannabis effect on cognitive function during chemotherapy,08-May-17,https://ClinicalTrials.gov/show/NCT01983267165,Impact of a Memory Group for Older Adults Reporting Memory Difficulties,Completed,No Results Available,Mild Cognitive Impairment|Alzheimer's Disease,Behavioral: Memory group,Neuropsychological measures of memory and attention|Self-report on memory performance in everyday activities|Self-report on use of memory strategies|Informant report on memory performance in everyday activities|Informant report on use of strategies|Assessment of psychological wellbeing,02-Dec-13,https://ClinicalTrials.gov/show/NCT01998711166,Efficacy and Safety of Piracetam Taken for 12 Months in Subjects Suffering From Mild Cognitive Impairment (MCI),Completed,No Results Available,Memory Disorders,Drug: Piracetam,Cognitive Battery Composite Score over a 52-week period|safety of piracetam for 12 months,16-Dec-13,https://ClinicalTrials.gov/show/NCT00567060167,Influence of Beta Amyloid Imaging on Care of Patients Cognitive Complaints.,Completed,Has Results,Alzheimer's Disease|Mild Cognitive Impairment,Device: Beta amyloid imaging,Influence of the Neuroimaging Test on a Finding of Alzheimer's Disease as the Underlying Cause of the Mild Memory Loss|Likelihood of Recommending a Medication Indicated for Alzheimer's Disease|Likelihood of Recommending That Spouse Take Various Cognitive Deficit Disease Management Measures,10-Apr-17,https://ClinicalTrials.gov/show/NCT02309723168,Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase,Completed,No Results Available,Alzheimer's Disease,Drug: CHF 5074 1x|Drug: CHF 5074 2x|Drug: CHF 5074 3x,Determine maximum tolerated dose of CHF 5074 after multiple oral once daily administration to patients with mild cognitive impairment,06-Feb-14,https://ClinicalTrials.gov/show/NCT01602393169,A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment,Completed,No Results Available,Dementia|Alzheimer Disease,Drug: Galantamine hydrobromide,"Memory and cognition (ADAS-cog/MCI and CDR-SB scores) at 12 months and Global functional skills and the overall severity of dementia (the CDR-SB and the overall CDR) at 24 months.|Brain atrophy assessed by MRI, Digit Symbol Coding, Alzheimer's Disease Cooperative Study-ADL scale(MCI version) at 24 months. Safety evaluations (adverse event reports, vital signs, laboratory tests, physical examination, electrocardiograms) throughout.",08-Jun-11,https://ClinicalTrials.gov/show/NCT00236574170,Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP),Completed,No Results Available,Alzheimer's Disease,Drug: CHF 5074 1x|Drug: CHF 5074 2x|Drug: CHF 5074 3x,Determine maximum tolerated dose of CHF 5074 after multiple oral once daily administration to patients with mild cognitive impairment,06-Feb-14,https://ClinicalTrials.gov/show/NCT01421056171,Effects of a Nutraceutical Preparation on Cognitive Impairment in Hypertensive Patients,Completed,No Results Available,Hypertension,Dietary Supplement: Nutraceutical compound|Dietary Supplement: Placebo,Cognitive function assessed by neuropsychological tests,14-Mar-17,https://ClinicalTrials.gov/show/NCT02572219172,Walnuts and Healthy Aging,Completed,No Results Available,Age Related Cognitive Decline|Age Related Macular Degeneration,Dietary Supplement: Walnuts|Other: habitual diet,% Change in cognitive decline from baseline|% change in macular degeneration from baseline,20-Jun-16,https://ClinicalTrials.gov/show/NCT01634841173,Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images,Completed,Has Results,Alzheimer's Disease|Mild Cognitive Impairment,Drug: [18F]Flutemetamol,Summary of Sensitivity of the Blinded Visual PET Image Interpretations Without Anatomic Images.|Summary of Specificity of Blinded Visual PET Image Interpretations Without Anatomic Images.|Inter-Reader Agreement of PET Images Without Anatomic Images,24-Jan-14,https://ClinicalTrials.gov/show/NCT01672827174,Ketamine and Changes of the Short Portable Mental Status Questionnaire,Completed,No Results Available,Postoperative Cognitive Dysfunction,Drug: Ketamine|Drug: physiological solution,Change from baseline to postoperative endpoint error scores on the Short Portable Mental Status Questionnaire (SPMSQ) in both groups|Change in Hemodynamic measures|Change in respiratory rate measures|Changes in oxygen saturation measures|Change in Ramsey Sedation Scale|Change on intraocular pressure measures|Analgesia,25-Nov-14,https://ClinicalTrials.gov/show/NCT02049411175,Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120),Completed,Has Results,Alzheimer's Disease|Mild Cognitive Impairment,Drug: Saline|Drug: Insulin detemir|Drug: Insulin,Verbal Memory Composite|Cerebral Spinal Fluid (CSF) Biomarkers of AD|Cerebral Spinal Fluid (CSF) Biomarkers of AD TTau-P181/Abeta42 Ratio|Functional Ability|The Alzheimer's Disease Assessment Scale-Cognitive [ADAS-Cog/Alzheimer's Disease Cooperative Study (ADCS)] - MCI Revision,22-May-18,https://ClinicalTrials.gov/show/NCT01595646176,Optimization of Desflurane in Elderly Patients,Completed,Has Results,Postoperative Cognitive Dysfunction,Drug: Desflurane|Drug: Sevoflurane,The Time From the End of Anesthesia to Extubation|The Time From the End of Anesthesia to Eye Opening|The Time From the End of Anesthesia to Following Commands|Cognitive Function|The Incidence of Postoperative Delirium,27-Nov-14,https://ClinicalTrials.gov/show/NCT01700907177,Cognitive Rehabilitation in Schizophrenia,Completed,Has Results,Cognitive Impairment|Schizophrenia,Behavioral: Cognitive Rehabilitation Therapy (CRT) + Skill Training (SDG)|Behavioral: Individual Computer Based Cognitive Rehabilitation (ICBCR) and Skills Training (SDG)|Behavioral: Skills Group (SDG),Wisconsin Card Sort Percent Perseverative Errors (Standard Score)|Bell Lysaker Emotion Recognition Test|Continuous Performance Task X/A Version|Hopkins Verbal Learning Test- Total Recall Variable|Independent Living Skills Survey,25-May-16,https://ClinicalTrials.gov/show/NCT00248794178,Physical Activity and Cerebral Metabolism in the Elderly: a Randomised Controlled Trial,Completed,No Results Available,Dementia|Cognitive Impairment,Other: Individualised aerobic exercise training|Other: Waiting Control,"Change in cerebral metabolism (assessed by MRSI)|Cardiopulmonary exercise test (Aerobic exercise capacity is determined by a physician-supervised CPET)|Psychometric testing 1 (verbal declarative memory [Verbal Learning and Memory test; adapted German version of the Rey Auditory Verbal Learning test]|Psychometric testing 2 (frontal executive control [Colour-Word-Interference test; adapted German version of the Stroop test; Trail-Making-Test Part B]|Psychometric testing 3 (working memory [Digit Span Test forward and backward]|Psychometric testing 4 9semantic and phonematic fluency, nonverbal declarative memory and visual-constructive abilities by means of the CERAD-Plus (Consortium to Establish a Registry for Alzheimer's Disease) Neuropsychological Battery)|Psychometric testing 5 (speed of cognitive processing is assessed by means of the Trail-Making-Test Part A)|Psychometric testing 6 (depressive disorders: Geriatric Depression Scale)|Psychometric testing 7 (Age-associated subjective memory impairment is assessed using a memory complaint questionnaire [MAC-Q]|Psychometric testing 8 (cristalline intelligence is assessed by means of a verbal intelligence test [Multiple-Choice Word Test: MWT-B]|Psychometric testing 9 (dementia and mild cognitive impairment using the Mini Mental State Examination and the Instrumental Activities of Daily Living Questionnaire)|Balance and strength (postural sway (balance) and gait data acquisition via the capacitive force-measuring platform (30 Hz) WinFDM v0.0.41å¨ (Zebriså© GmbH, Isny, Germany)|Pain Assessment (German Pain Questionnaire)|History of diet (Food frequency questionnaire DEGS1)|History and fear of falling (German version of the Falls-Efficacy-Scale International Version)|Physical activity (International Physical Activity Questionnaire, Lifetime Total Physical Activity Questionnaire and Accelerometry)",02-Sep-15,https://ClinicalTrials.gov/show/NCT02343029179,Home Care Medication Management Program for the Frail Elderly,Completed,No Results Available,Chronic Illness|Cognitive Impairment,Other: MD2 machine and nurse care coordination|Other: Medplanner and Nurse Care Coordination,Geriatric Depression Scale|Physical Performance Test (PPT)|SF-36 Health Survey|Mental Mental Status Exam (MMSE)|Hospitalization|Hospital Days|Emergency Department Visits|Medicare Costs,06-Jan-12,https://ClinicalTrials.gov/show/NCT01321853180,Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients,Completed,Has Results,Alzheimer Disease|Amyloid Beta-Protein,Drug: Florbetaben (BAY94-9172),"Quantitative Assessment of Neocortical SUVRs (Mean Standard Uptake Value Ratios) as a Measure of Florbetaben Uptake|Number of Normal and Abnormal Scans in Patients With MCI Progressing to AD and Those Who do Not Progress Based on a Threshold of Neocortical SUVR=1.4|Number and Proportion of Normal and Abnormal Scans Based on Brain ÌÙ-amyloid Plaque Load (BAPL) in Subjects With MCI Converting to AD and Those Who do Not Progress|Sensitivity/Specificity/Negative Predictive Value (NPV)/Positive Predictive Value (PPV) at Baseline, 12, and 24 Months in the Detection of Significant Brain ÌÙ-amyloid Plaque Load in Patients With MCI Progressing to AD Compared to Those Who do Not Progress",25-Jun-14,https://ClinicalTrials.gov/show/NCT01138111181,An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.,Completed,No Results Available,Mild Cognitive Impairment|Dementia,Drug: GSK239512,"Receptor occupancy in the brain after receiving a dose of GSK239512, measured using calculations from PET images at 4 hours and 24 hours post dose|Safety of drug and concentration of GSK239512 in the blood at various timepoints. Using vital signs and ECG, clinical laboratory assessments and PK sampling.",04-Jun-12,https://ClinicalTrials.gov/show/NCT00474513182,Cognitive Impairment Following Cardiac Arrest and Target Temperature Management,Completed,No Results Available,Heart Arrest|Out-of-hospital Cardiac Arrest|Cognition Disorders|Brain Injury,Other: Temperature treatment,Rivermead Behavioural Memory Test (RBMT)|Frontal Assessment Battery (FAB)|Symbol Digit Modalities Test (SDMT)|Mayo-Portland Adaptability Inventory-4 (MPAI-4)|Short-Form Questionnaire 36 version 2 (SF-36v2)|Zarit Burden Interview|Hospital Anxiety and Depression rating Scale (HADS)|Two Simple Questions (TSQ)|Informant Questionnaire on Cognitive Decline (IQCODE)|MiniMental Status Examination (MMSE)|Cerebral Performance Category (CPC)|modified Rankin Scale,05-Dec-13,https://ClinicalTrials.gov/show/NCT01946932183,Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02),Completed,No Results Available,Alzheimer's Disease,Drug: E2609|Drug: Placebo for E2609,Percent change from baseline in cerebrospinal fluid amyloid-beta levels|Incidence of adverse events,30-Dec-16,https://ClinicalTrials.gov/show/NCT01600859184,An Intervention Programme to Reduce Cognitive Impairment Due to Cancer,Completed,No Results Available,Breast Neoplasms|Colorectal Neoplasms,Behavioral: Countering cognitive impairment,Feasibility of intervention implementation|Hopkins Verbal Learning Test|Reitan's Trail Making Test (TMT) A and B|Controlled oral Word Association (COWA) sub-test of the Multilingual Aphasia Examination|Neuropsychological Assessment Battery Digit Span sub-test|STROOP test|Functional Assessment of Cancer Therapy- Cognitive Subscale (FACT-Cog)|Short form health survey (SF-36)|Centre for Epidemiological studies Depression- Revised scale (CESD-R)|Hospital Anxiety and Depression Scale- Anxiety sub-scale (HADS-A)|Functional Assessment of Chronic Illness Therapy- Fatigue sub-scale (FACIT-F)|Pittsburgh Sleep Quality Index (PSQI)|Cognitive Reserve Scale,10-Apr-18,https://ClinicalTrials.gov/show/NCT02581709185,The Efficacy And Cognitive Impairment Of Modified Electroconvulsive Therapy,Completed,No Results Available,Major Depressive Disorder,Drug: Etomidate|Drug: Propofol|Device: Bilateral temporal MECT|Device: The right temporal MECT|Device: Bilateral frontal MECT,Change in Hamilton Depression Scale(HAMD) Scores|Change in Wechsler Memory Scale (WMS) Scores as a Measure of Safety|Young Manic Rating Scale(MMSE) as a Measure for Evaluation of Mania State|Resting-state/Task-state functional magnetic resonance imaging (fMRI)|Change in Hamilton Anxiety Scale(HAMA) Scores|Change in Clinical Global Impression-severity of illness(CGI-SI) Scores as a Measure of Efficacy|Change in Wisconsin Card Sorting Test(WCST) Scores as a Measure of Safety|Change in P300/P50 Event-Related Potentials(ERP),23-Apr-18,https://ClinicalTrials.gov/show/NCT02066077186,Minocycline in Patients With Alzheimer's Disease,Completed,Has Results,Mild Cognitive Impairment|Alzheimer's Disease,Drug: Minocycline,"Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|Hippocampal Volumes Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC).|Biomarker NAA/mI Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC)",25-Sep-14,https://ClinicalTrials.gov/show/NCT01463384187,Hormone and Information Processing Study,Completed,Has Results,Mild Cognitive Impairment|Alzheimer's Disease,Drug: testosterone gel|Drug: placebo gel,Behavioral & Mood Measure: Profile of Mood States (POMS)|Cognitive Changes Measured by Neuropsychological Tests: Rey Auditory Verbal Learning Test|Geriatric Depression Scale (GDS)|Short-Form Health Survey (SF-36),14-Jul-14,https://ClinicalTrials.gov/show/NCT00539305188,Attention Training for Learning Enhancement and Resilience Trial,Completed,No Results Available,Age-related Cognitive Decline,Other: Computerized Plasticity-Based Adaptive Cognitive Training|Other: Commercially available computerized training,Attention Measures aimed to test attention|Executive Function|Functional Capacity|Quality of Sleep,09-Jan-18,https://ClinicalTrials.gov/show/NCT02416401189,Trial of a Brain Preservation Diet in Preventing Cognitive Decline in Old Age Hostel Residents,Completed,No Results Available,Cognitive Decline|Dietetic Intake,"Other: ""brain preservation' diet",cognitive decline|Change in MMSE test|% subjects meeting targets of brain preservation diet,28-May-10,https://ClinicalTrials.gov/show/NCT01132261190,An Investigation Into the Effects of a Wild Blueberry Powder and a Wild Blueberry Extract on Cognition in Older Adults,Completed,No Results Available,Cognitive Decline,Dietary Supplement: Placebo|Dietary Supplement: Wild Blueberry Powder - 450mg|Dietary Supplement: Wild Blueberry Powder - 900 mg|Dietary Supplement: Wild Blueberry extract 100mg,Cognitive Performance|Mood|Heart Rate|Blood Pressure,17-Aug-17,https://ClinicalTrials.gov/show/NCT02446314191,A Trial of Neurocognitive and Supportive Therapy Interventions for Individuals With Parkinson's Disease,Completed,No Results Available,Parkinson's Disease|Mild Cognitive Impairment,Behavioral: Memory and Problem-Solving Intervention|Behavioral: Supportive Therapy,California Verbal Learning Test-II Long Delay Free Recall Scaled Score Change Over 10 Weeks|Linear Analog Scale Assessment Overall Well Being Raw Score Change Over 10 Weeks,08-Jan-16,https://ClinicalTrials.gov/show/NCT01646333192,"SMART: Somatotrophics, Memory, and Aging Research Trial",Completed,No Results Available,Aging|Mild Cognitive Impairment,Drug: TH9507 human growth hormone releasing hormone (GHRH),"Change in declarative memory, including total recall scores on three tests of memory and on dual task response time (RT), a test of executive function.|Changes in other areas of cognitive function, including other tests of executive function, tests of lexical access, and tests of cognitive and perceptual-motor processing speed.",19-Dec-13,https://ClinicalTrials.gov/show/NCT00257712193,Effects of Cognitive Behavioural Therapy and Exercise on Stress and Cognitive Deficits in Multiple Sclerosis,Completed,No Results Available,"Multiple Sclerosis|Cognitive Deficits|Stress, Psychological",Behavioral: Cognitive Behavioural Therapy|Behavioral: Aerobic Exercise,Change from Baseline in General Health Questionnaire (GHQ-28) at 12 Weeks|Change from Baseline in the Minimal Assessment of Cognitive Function in MS at 12 Weeks,17-Oct-16,https://ClinicalTrials.gov/show/NCT01763983194,Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury and Cognitive Impairment,Completed,No Results Available,Traumatic Brain Injury,Drug: Rivastigmine,"20 week's treatment with rivastigmine on selective attention compared with placebo in patients with TBI and cognitive impairment|Safety of rivastigmine|Change from baseline to week 20 in cognitive functioning including selective attention, memory, executive function, and global clinical rating",23-Nov-11,https://ClinicalTrials.gov/show/NCT00171795195,"Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease",Completed,Has Results,Alzheimer Disease|Cognitive Impairment,Drug: Sodium oligo-mannurarate 600mg|Drug: Sodium oligo-mannurarate 900mg|Drug: Placebo,Change of Alzheimer's Disease Assessment Scale-cognitive Subscale(ADAS-cog)/12 After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule|Change of Clinician's Interview-Based Impression of Change Plus(CIBIC-plus) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule|Change of Alzheimer's Disease Cooperative Study/Activities of Daily(ADCS-ADL) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule|Change of Neuropsychiatric Inventory(NPI) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule,27-Jan-15,https://ClinicalTrials.gov/show/NCT01453569196,Taiwan Health Promotion Intervention Study for Elders,Completed,No Results Available,Frail Elderly Syndrome|Cognitive Impairment|Cognitive Decline,Behavioral: Multidomain intervention|Behavioral: Active control,Change from baseline frailty score at 12 months,17-Feb-17,https://ClinicalTrials.gov/show/NCT03056768197,Randomized Trial of Low-dose Naproxen in Cognitively Intact Persons at Risk of Alzheimer's Dementia,Completed,No Results Available,Alzheimer Disease|Cognitive Decline Due to Alzheimer Disease|Mild Cognitive Impairment Due to Alzheimer Disease,Drug: Naproxen|Drug: Placebo,Trajectory of composite Alzheimer Progression Score (APS) from multiple cognitive and biomarker measures of pre-clinical Alzheimer's disease|frequency and severity of treatment-emergent adverse events|trajectory of cognitive abilities measured by global score on Repeatable Battery for Assessment of Neuropsychological Status|ratio of total and protein-bound naproxen concentrations as well as kinetics of drug accumulation and washout|biomarkers of inflammatory processes|CSF biomarkers of AD pathogenesis,01-Aug-17,https://ClinicalTrials.gov/show/NCT02702817198,A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers,Completed,No Results Available,Schizophrenia,Drug: PF-04958242|Drug: Ketamine|Drug: Placebo,Test score on the Hopkins Verbal Learning Test - Immediate Recall|Test score on the Weschler Digit Span Test|Test score on the CogState N-back test|Test score on the CogState Spatial Working memory test|Test score on the CogState One Card Learning test|Test score on the Hopkins Verbal Learning test - Delayed Recall|Retrospective rating on the Positive and Negative Syndrome Scale -modified scale`,10-Mar-14,https://ClinicalTrials.gov/show/NCT01749098199,Lidocaine For Neuroprotection During Cardiac Surgery,Completed,Has Results,Cognitive Decline,Drug: Lidocaine|Drug: Placebo,"Change in Cognitive Function From Baseline Characterized as Continuous Cognitive Change|Count of Participants With a Decline of Greater Than or Equal to One Standard Deviation in One or More of Five Cognitive Domain Scores Reported as a Dichotomous Post-operative Cognitive Deficit (POCD) Outcome|Transcerebral Activation Gradients of Platelets|Transcerebral Activation Gradients of Neutrophils|Transcerebral Activation Gradients of Monocytes|Transcerebral Activation Gradient of Platelet-neutrophil Conjugates|Change in Cognitive Function From Baseline|Change in Duke Activity Status Index (DASI)|Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)|Change in Center for Epidemiological Studies Depression Scale (CES-D)|Change in Spielberger State Anxiety Inventory (STAI)|Change in Symptom Limitations|Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)|Change in the Cognitive Difficulties Scale|Change in Perceived Social Support|Change in Social Activity|Change in Study 36-Item Short Form Health Survey (SF-36)|Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)",04-Oct-17,https://ClinicalTrials.gov/show/NCT00938964200,Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED),Completed,Has Results,Schizophrenia,Drug: MK5757|Drug: Comparator: Placebo,Mean Change From Baseline in the Composite Score From the Brief Assessment of Cognition in Schizophrenia (BACS) Battery After 2 Weeks of Treatment|Mean Change From Baseline After 2 Weeks of Treatment in the CogState Composite Score|Mean Change From Baseline After 2 Weeks of Treatment in the Executive Functioning Composite Score|Mean Change From Baseline After 2 Weeks of Treatment in the Episodic Memory Composite Score|Mean Change From Baseline After 2 Weeks of Treatment in the Working Memory Composite Score|Mean Change From Baseline After 2 Weeks of Treatment in the Attention/Processing Speed Composite Score,02-Nov-15,https://ClinicalTrials.gov/show/NCT00848484201,Pharmacological Management of Delirium,Completed,Has Results,Delirium|Cognitive Impairment,Behavioral: Reduced exposure to anticholinergics|Procedure: Reduced exposure to benzodiazepines|Drug: Haloperidol|Procedure: Usual care,Days Free of Delirium and Coma|Hospital Length of Stay Post Randomization|Mortality,24-Mar-17,https://ClinicalTrials.gov/show/NCT00842608202,Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Oxytocin|Drug: Galantamine|Other: Placebo-Oxytocin|Other: Placebo-Galantamine,Scale for the Assessment of Negative Symptoms (SANS) Total Score|Mean Z-Scores for Composite Cognitive Primary Outcome* by Treatment Group and Week|Scale for the Assessment of Negative Symptoms (SANS) - Avolition|Scale for the Assessment of Negative Symptoms (SANS) - Anhedonia|Scale for the Assessment of Negative Symptoms (SANS) - Alogia|Scale for the Assessment of Negative Symptoms (SANS) - Blunted Affect|Brief Psychiatric Rating Scale (BPRS) - Total Score|Brief Psychiatric Rating Scale (BPRS) - Psychosis Score|Calgary Depression Scale (CDS) - Total Score|Arizona Sexual Experience Questionnaire (ASEX) Female|Arizona Sexual Experience Questionnaire (ASEX) Male|Vital Signs - Diastolic Blood Pressure|Vital Signs - Systolic Blood Pressure|Vital Signs - Weight|Vital Signs - Pulse|Simpson-Angus Scale (SAS)|Abnormal Involuntary Movement Scale (AIMS)|Electrocardiogram (EKG)|Barnes Akathisia Scale (BAS) - Global Score|Blood Oxytocin Levels|Laboratory Measures - ALT/SGPT|Laboratory Measures - AST/SGOT|Laboratory Measures - Alkaline Phosphatase|Laboratory Measures - Calcium|Laboratory Measures - Sodium|Laboratory Measures - Potassium|Laboratory Measures - Chloride|Laboratory Measures - CO2|Laboratory Measures - Cholesterol|Laboratory Measures - HDL|Laboratory Measures - LDL|Laboratory Measures - Triglycerides|Laboratory Measures - VLDL|Laboratory Measures - Glucose|Laboratory Measures - Albumin|Laboratory Measures - Globulin|Laboratory Measures - A/G Ratio|Laboratory Measures - Bilirubin|Laboratory Measures - Protein|Laboratory Measures - BUN|Side Effect Checklist (SEC) - Abdominal Pain|Side Effect Checklist (SEC) - Anorexia|Side Effect Checklist (SEC) - Bruising Easily|Side Effect Checklist (SEC) - Constipation|Side Effect Checklist (SEC) - Diarrhea|Side Effect Checklist (SEC) - Dizziness|Side Effect Checklist (SEC) - Dry Eye|Side Effect Checklist (SEC) - Dry Mouth|Side Effect Checklist (SEC) - Enuresis|Side Effect Checklist (SEC) - Excessive Tearing of the Eye|Side Effect Checklist (SEC) - Fever|Side Effect Checklist (SEC) - Headache|Side Effect Checklist (SEC) - Hyperhydrosis|Side Effect Checklist (SEC) - Hypersalivation|Side Effect Checklist (SEC) - Insomnia|Side Effect Checklist (SEC) - Malaise|Side Effect Checklist (SEC) - Mucosal Ulceration|Side Effect Checklist (SEC) - Nasal Irritation|Side Effect Checklist (SEC) - Nausea|Side Effect Checklist (SEC) - Rash|Side Effect Checklist (SEC) - Restlessness|Side Effect Checklist (SEC) - Sedation|Side Effect Checklist (SEC) - Sore Throat|Side Effect Checklist (SEC) - Stiffness|Side Effect Checklist (SEC) - Tinnitus|Side Effect Checklist (SEC) - Tremor|Side Effect Checklist (SEC) - Urticaria|Side Effect Checklist (SEC) - Uterine Contractions|Side Effect Checklist (SEC) - Vomiting|Side Effect Checklist (SEC) - Weight Loss|Side Effect Checklist (SEC) - Wheezing|Neurocognitive Assessment Battery (MCCB) - Composite Score|Neurocognitive Assessment Battery (MCCB) - Attention Vigilance|Neurocognitive Assessment Battery (MCCB) - Processing Speed|Neurocognitive Assessment Battery (MCCB) - Reasoning/Problem Solving|Neurocognitive Assessment Battery (MCCB) - Social Cognition|Neurocognitive Assessment Battery (MCCB) - Verbal Learning|Neurocognitive Assessment Battery (MCCB) - Visual Learning|Neurocognitive Assessment Battery (MCCB) - Working Memory|Positive and Negative Affect Schedule (PANAS) - Negative|Positive and Negative Affect Schedule (PANAS) - Positive|Reactions to Partner|Willingness to Interact,02-Jun-17,https://ClinicalTrials.gov/show/NCT01012167203,Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose Using Positron Emission Tomography (PET) Scanning,Completed,No Results Available,Alzheimer Disease|Mild Cognitive Impairment,Other: Low-Carbohydrate Diet|Other: Low-Fat Diet,Brain biodistribution of [11C]AcAc/[18F]FDG,24-Oct-17,https://ClinicalTrials.gov/show/NCT03130036204,The Efficacy of Omega-3 Fatty Acids in Maintaining Optimal Mental Health in Elderly People,Completed,No Results Available,Cognitive Impairment|Depression,Behavioral: n-3 Fatty Acid Supplementation,Cognitive function|Depression|Quality of life,12-Jan-11,https://ClinicalTrials.gov/show/NCT00124852205,Effective Strategies for Dementia Care,Completed,No Results Available,Dementia|Cognitive Impairment,Behavioral: Snoezelen å©|Behavioral: structured reminiscence therapy|Behavioral: 10-minutes activation|Behavioral: Unstructured verbal communication,Apathy Evaluation Scale (Marin et al. 1991)|Neuropsychiatric Inventory (Cummings 1997)|Staff Observation Aggression Scale (Nijman et al. 1997)|Nottingham Health Profile (Bureau-Chalot et al. 2002) staff-related measurement|Smiley Analogue Scale for Well-Being|PASTA (Zimber 2001) staff-related measurement,31-Aug-11,https://ClinicalTrials.gov/show/NCT00653731206,Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia,Completed,No Results Available,Schizophrenia|Schizoaffective Disorder,Drug: galantamine,Neuropsychological test battery composite score at 12 weeks; p50 T/C ratio at 12 weeks; P300 amplitude at 12 weeks|Smooth pursuit eye movement gain at 12 weeks|Positive symptoms as measured by the BPRS positive symptom item total score; Negative symptoms as measured by the SANS total score; Side effects as measured by the Side Effect Checklist|Smoking behavior as measured by the Fagerstrom Nicotine Dependency Test at 12 weeks.,27-Jun-07,https://ClinicalTrials.gov/show/NCT00176423207,Passport to Brain Wellness in Sedentary Adults,Completed,No Results Available,Mild Cognitive Impairment|Alzheimer's Disease,Behavioral: Guided|Behavioral: Self-directed,We will use this pilot to determine the feasibility of carrying out a full-scale randomized trial to test the efficacy of our intervention.,18-Sep-09,https://ClinicalTrials.gov/show/NCT00979446208,Attention & Memory Impairments in Menopausal Women,Completed,Has Results,Symptomatic Menopause|Cognitive Impairments,Drug: Lisdexamfetamine|Drug: Placebo,Brown Attention Deficit Disorder Scale (BADDS)|Penn Continuous Performance Test|NYU Paragraph Recall Task,28-Jun-17,https://ClinicalTrials.gov/show/NCT01324024209,"The Impact of Renin-angiotensin System on Brain Activation During Hypoglycaemia in Healthy Men, a PET Study",Completed,Has Results,Hypoglycemia|Cognitive Impairment,Drug: Human insulin,Cerebral Activation During Hypoglycaemia,29-Mar-17,https://ClinicalTrials.gov/show/NCT00264641210,Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days,Completed,No Results Available,Alzheimer's Disease|Mild Cognitive Impairment,Drug: Placebo Comparator|Drug: insulin detemir,Verbal Memory Composite|Neuropsychological Test of Executive Function 1|Glucose Tolerance|Functional Ability|Plasma biomarkers of AD|Neuropsychological Test of Executive Functioning 2|Neuropsychological Tests of Visual Working Memory,18-Dec-12,https://ClinicalTrials.gov/show/NCT01547169211,Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis,Completed,Has Results,Multiple Sclerosis|Cognition,Drug: lipoic acid and omega-3 fatty acids|Drug: Placebo,Paced Auditory Serial Addition Task (PASAT)|Stroop Color-Word Test|California Verbal Learning Test-II (CVLT-II)|Controlled Oral Word Association Test (COWAT),02-Jun-17,https://ClinicalTrials.gov/show/NCT02133664212,FluoroAv45 Imaging Research-in Alzheimer's Disease,Completed,No Results Available,Alzheimer's Disease|Mild Cognitive Impairment,Other: neuropsychologic assessment|Radiation: [18F]AV-45 PET|Radiation: 18-FDG PET|Other: MRI,Standard Uptake Value Ratios (SUVr),08-Feb-16,https://ClinicalTrials.gov/show/NCT01325259213,A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease,Completed,No Results Available,Alzheimer's Disease|Mild Cognitive Impairment,Dietary Supplement: Nutriceutical formulation|Other: Placebo,cognitive improvement or maintenance of cognitive performance|behavioral/psychotic symptoms,03-Mar-16,https://ClinicalTrials.gov/show/NCT01320527214,An Open-Label Trial of Memantine for Cognitive Impairment in Patients With Post-Traumatic Stress Disorder,Completed,No Results Available,PTSD,Drug: Memantine,RBANS,02-Nov-16,https://ClinicalTrials.gov/show/NCT02258828215,The Effects of Anaesthesia on Cerebral Oxygenation and Cognitive Function in Carotid Endarterectomy,Completed,No Results Available,Endarterectomy|Postoperative Cognitive Dysfunction,Drug: Propofol|Drug: Sevoflurane|Procedure: Elective carotid endarterectomy,Early postoperative cognitive dysfunction|Cerebral desaturation,22-Sep-16,https://ClinicalTrials.gov/show/NCT02771418216,SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days),Completed,No Results Available,Mild Cognitive Impairment|Alzheimer's Disease,Drug: Regular Insulin|Drug: Placebo,Changes in cognition|glucose metabolism|plasma biological markers|CSF biological markers|cerebral glucose metabolism,14-Sep-12,https://ClinicalTrials.gov/show/NCT00438568217,Cognitive Stimulation in Elderly Individuals at Risk to Develop Dementia (Allena-Mente).,Completed,No Results Available,Mild Cognitive Impairment|Healthy Subjects With Family History for Dementia,Other: Cognitive stimulation|Other: Sanitary education,Long-term change from Baseline in Mini Mental State Examination (MMSE)|Change from Baseline in Mini Mental State Examination at 2-weeks after the intervention|Change from Baseline in Montreal Cognitive Assessment (MoCA) at 2-weeks after the intervention|Change from Baseline in Corsi test at 2-weeks after the intervention|Change from Baseline in Walking While Talking Dual Task at 2-weeks after the intervention,17-Aug-15,https://ClinicalTrials.gov/show/NCT01793493218,Cerebral Oximetry and Neurological Outcomes in Aortic Arch Surgery Patients,Completed,Has Results,Postoperative Cognitive Dysfunction,Device: INVOS Somanetics Cerebral Oximeter,Mini Mental State Examination (MMSE),28-Apr-15,https://ClinicalTrials.gov/show/NCT01149148219,Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis,Completed,No Results Available,Relapsing Remitting MS|Secondary Progressive MS|Primary Progressive MS,Dietary Supplement: Caprylic Triglyceride|Dietary Supplement: Placebo,Change in Total Learning (Trials 1-5) on the California Verbal Learning Test-2nd Edition (CVLT-II) (range from 0 to 80)|Change in Symbol Digit Modalities Test (SDMT) (range from 0-110)|Number of participants reporting adverse events|Change in EDSS|Change in Beck Depression Inventory -2nd edition (BDI-II)|Change in Multiple Sclerosis Quality of Life Inventory (MSQOL-54)|Change in Modified Fatigue Impact Scale (MFIS),25-Jan-18,https://ClinicalTrials.gov/show/NCT01848327220,Effects of Dietary Nitrate From Vegetable/Fruit Juice on Cerebral Blood Flow Parameters,Completed,No Results Available,Cerebrovascular Circulation|Cognitive Impairment,Dietary Supplement: Vegetable/fruit juice|Dietary Supplement: Placebo juice,"Change from baseline cerebral blood flow|Change from baseline cognitive function|Change from baseline mood|Change from baseline blood pressure, heart rate and venous nitrate and nitrite levels",13-Oct-10,https://ClinicalTrials.gov/show/NCT01169662221,Can Exercise Improve Cancer Associated Cognitive Dysfunction?,Completed,No Results Available,Breast Cancer,Behavioral: Exercise,Stroop Test|FACT-Cog|fMRI analyses|Graded exercise test|Hopkins Verbal Learning Test|Trail Making A & B,07-Jun-16,https://ClinicalTrials.gov/show/NCT01296893222,Sugammadex and Cognitive Function,Completed,No Results Available,Post Operative Cognitive Dysfunction,Drug: Sugammadex|Drug: Neostigmine/atropine,Change in the Mini-Mental State Evaluation test|Change in the clock-drawing test|Change in the Isaacs set test|Time from reversal agent administration to extubation,30-Dec-15,https://ClinicalTrials.gov/show/NCT02419352223,[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001),Completed,No Results Available,Alzheimer's Disease|Amnestic Mild Cognitive Impairment,Drug: [18F]MK-6240,"Number of Participants With Adverse Events (AEs)|Number of Participants Who Discontinued Study Due to an AE|Effective Dose of [18F]MK-6240|Organ Effective Dose of [18F]MK-6240|Volume of Distribution (VT) or Surrogate (e.g., SUVR) of [18F]MK-6240 in Brain Regions of Interest|Intra-subject T-RT Variability of [18F]MK-6240 in Brain Regions of Interest",28-Jul-17,https://ClinicalTrials.gov/show/NCT02562989224,Do Apolipoprotein E Polymorphisms Influence Risk of Cognitive Decline by Modulating Omega-3 Fatty Acid Metabolism?,Completed,No Results Available,Healthy,Dietary Supplement: omega-3 fatty acid,13C-DHA incorporation into plasma lipids or beta-oxidation.|Cognitive performance compared to baseline,13-Apr-12,https://ClinicalTrials.gov/show/NCT01577004225,Cognitive Remediation and Work Therapy in the Initial Phase of Substance Abuse Treatment,Completed,Has Results,Substance Abuse|Substance Dependence|Cognitive Impairment,Behavioral: Cognitive Training + Work Therapy|Behavioral: Work Therapy,Days of Sobriety in First 90 Days|Days of Use in Prior 30 Days|Weeks of Sobriety|Attention Index|Processing Speed Index|Verbal and Visual Learning and Memory|Verbal and Visual Working Memory|Executive Function|Global Index,19-Jan-15,https://ClinicalTrials.gov/show/NCT01410110226,MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016),Completed,Has Results,Paranoid Schizophrenia,Drug: MK0249|Drug: Comparator: Placebo (unspecified),Mean Change From Baseline at 4 Weeks of Treatment in Total Cognitive Score on the Brief Assessment of Cognition in Schizophrenia (BACS) Battery.|Mean Change From Baseline at 4 Weeks of Treatment in Attention/Processing Speed Composite Score|Mean Change From Baseline at 4 Weeks of Treatment in Episodic Memory Composite Score|Mean Change From Baseline at 4 Weeks of Treatment in Working Memory Composite Score,03-Aug-15,https://ClinicalTrials.gov/show/NCT00506077227,MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027),Completed,No Results Available,Paranoid Schizophrenia|Schizophrenia,Drug: MK0557|Drug: Comparator: Placebo (unspecified),"Mean change from baseline at 4 weeks of treatment on a sequence of cognitive tests and that MK0557 generally well tolerated|Mean change from baseline at 4 weeks of treatment on neuropsychological tests for executive functioning, episodic memory and working memory",21-Aug-15,https://ClinicalTrials.gov/show/NCT00482430228,"GAit, MEmory, Dietary and Vitamin D",Completed,No Results Available,Memory Complaint Without Cognitive Decline,Dietary Supplement: Yogurt supplemented with vitamin D and calcium|Dietary Supplement: Yogurt not supplemented with vitamin D and calcium,"Change in spatiotemporal gait, and in particular in the variability of stride time|Change in posture|Change in grip strength|Change in executive performance|Change in other cognitive scores|Change in the serum concentration of 25 OHD|Compliance to intervention",22-Sep-16,https://ClinicalTrials.gov/show/NCT02086409229,Elder Surgery - Functional Recovery Following Beta Blockade,Completed,No Results Available,Post Operative Cognitive Dysfunction,Drug: Atenolol,Long Term Functional Recovery|Timed Up and Go test|Hand grip strength,16-Mar-16,https://ClinicalTrials.gov/show/NCT00507663230,Brain-Computer Interface System for Training Memory and Attention in Elderly,Completed,No Results Available,Alzheimer's Disease|Mild Cognitive Impairment|Age-Related Cognitive Decline|Dementia,Device: Brain-Computer Interface,Total Score of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|Sum of Scaled Score of the Rivermead Behavioral Memory Test-II|Number of Adverse Events/Serious Adverse Events Reported|Usability Measure of the Brain-Computer Interface training system,02-Aug-17,https://ClinicalTrials.gov/show/NCT02228187231,A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.,Completed,No Results Available,Schizophrenia,Drug: Extended-release galantamine hydrobromide,"The key exploratory efficacy end points are the change from baseline to Week 8 in total PANSS score, total BACS score, and CGI global improvement and severity of illness scores.|Additional efficacy assessments included subscore analyses for LSFT, CPT, RTT and FTT.",24-May-11,https://ClinicalTrials.gov/show/NCT00077727232,"A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)",Completed,No Results Available,Alzheimer's Disease|Mild Cognitive Impairment,Drug: VX-745,Percent change from Baseline in amyloid plaque burden by 11C-PiB PET|Number of adverse events,17-Apr-17,https://ClinicalTrials.gov/show/NCT02423122233,Cognitive Training for the Remediation of Functional Brain Health in HIV,Completed,No Results Available,HIV - Human Immunodeficiency Virus|Cognitive Impairment,Behavioral: Plasticity-based Adaptive Cognitive Remediation (PACR),Brief Cognitive Ability Measure (B-CAM)|Change in Brain Health Indicators|Perceived Deficits Questionnaire,21-Sep-17,https://ClinicalTrials.gov/show/NCT02571504234,A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment,Completed,No Results Available,Cognition Disorder|Nervous System Diseases|Mental Disorders|Brain Diseases,Drug: galantamine hydrobromide,"Incidence of adverse events; Changes in laboratory tests, ECGs, and physical examinations|Change in CDR, ADAS-Cog/MCI version, CDR-SB and SF-36 scores from baseline to end of treatment; resource use; time to conversion to dementia",18-May-11,https://ClinicalTrials.gov/show/NCT00240695235,Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.,Completed,Has Results,HIV Infections|Cognition Disorders,Drug: Peptide T|Drug: Placebo,Change in Global Neurocognitive Performance z Score From Baseline|Change in Neurocognitive Performance Domain z Scores From Baseline,28-Feb-17,https://ClinicalTrials.gov/show/NCT00000392236,Investigate the Effect of Tart Montmorency Cherry Juice (Prunus Cerasus) on Cerebral Blood Flow and Cognitive Function,Completed,No Results Available,Cognitive Decline,Other: Placebo|Dietary Supplement: 60mL tart Montmorency cherry juice,Changes in Cerebral Blood Flow|Changes in Cognitive Function,03-Nov-15,https://ClinicalTrials.gov/show/NCT02381860237,Characterizing and Predicting Drug Effects on Cognition,Completed,No Results Available,Cognitive Deficits,Drug: Topiramate|Drug: Lorazepam|Other: Placebo,Relationship between neurocognitive performance and study drug plasma concentration|Neurophysiological effect of study drug on working memory,14-Sep-16,https://ClinicalTrials.gov/show/NCT01889602238,Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus,Completed,No Results Available,Diabetic Neuropathy|Cognitive Impairment,Dietary Supplement: Tocotrienol|Dietary Supplement: Placebo,"Total Symptoms Score (TSS) (pain, paresthesia, burning, and numbness)of patients with diabetes type 1 and 2 neuropathy.|Neuropathy Impairment Score (NIS) of patients with diabetes type 1 and 2 neuropathy",04-May-17,https://ClinicalTrials.gov/show/NCT01973400239,A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis,Completed,No Results Available,Cognition Disorders|Multiple Sclerosis,Drug: C105,"Symbol Digit Modalities Test, Oral Version (SDMT) - Total # Correct|Subject's Global Assessment of Cognitive Change",28-May-08,https://ClinicalTrials.gov/show/NCT00529581240,An Inpatient Rehabilitation Model of Care Targeting Patients With Cognitive Impairment,Completed,No Results Available,Hip Fracture,Behavioral: Rehabilitation Model of Care,Change from baseline in mobility at 6 months|Change from baseline in physical functioning at 6 months,24-Apr-14,https://ClinicalTrials.gov/show/NCT01566136241,N-acetylcysteine and NMDA Antagonist Interactions,Completed,Has Results,Cognitive Dysfunction,Drug: N-acetylcysteine and ketamine|Drug: placebo and ketamine,Target P300|Novel P300|Mismatch Negativity (MMN) Intensity|Mismatch Negativity (MMN) Frequency|Mismatch Negativity (MMN) Duration,08-May-15,https://ClinicalTrials.gov/show/NCT00611897242,Reconstructing Consciousness and Cognition,Completed,No Results Available,Postoperative Cognitive Dysfunction,Drug: ISOFLURANE- Experimental Arm|Other: Control Group: Cognitive Testing,Neurocognitive scores|Brain network connectivity,30-Nov-17,https://ClinicalTrials.gov/show/NCT01911195243,Effects of Whole Grain Rye on Metabolic Risk Markers and Mood,Completed,No Results Available,Metabolic Disorders and Cognitive Decline,Other: whole grain|Other: reference,cognitive performance|glucose tolerance,04-Oct-17,https://ClinicalTrials.gov/show/NCT03275948244,Perfusion Pressure Cerebral Infarction Trial (PPCI),Completed,No Results Available,Embolic Stroke|Postoperative Cognitive Dysfunction,Procedure: Increased bloodpressure during CPB.,Total volume of new ischemic cerebral lesions|Total number of new ischemic cerebral lesions|Magnetic resonance spectroscopy - change from baseline N-acetylaspartate-creatine (NAA/Cr) ratio at day 6|Magnetic resonance spectroscopy - change from baseline MRS Choline-creatine (Cho/Cr ratio) at day 6|Postoperative cognitive dysfunction (POCD) - change from baseline neuropsychological test performance at day 5-8|Postoperative cognitive dysfunction (POCD) - change from baseline neuropsychological test performance at 3 months|Peak value of biochemical markers of brain injury|Near Infrared Spectroscopy (NIRS) - lowest value|Near Infrared Spectroscopy (NIRS) - total time below 25% of the baseline value on right and left side|Change from baseline performance at neurological examination day 6,11-Apr-16,https://ClinicalTrials.gov/show/NCT02185885245,Home-Based Assessment for Alzheimer Disease Prevention,Completed,No Results Available,Mild Cognitive Impairment|Alzheimer's Disease,Behavioral: Mail and Live Phone|Behavioral: Interactive Voice Response (IVR)|Behavioral: Home-based Computer Kiosk|Behavioral: Traditional Evaluation Instruments,"Feasibility Data -- the number of subjects recruited, screened, enrolled, and retained|Efficiency Data -- staff time required to successfully complete data collection|Transition from cognitive health to impairment|Method-Specific Adherence, including medication adherence|Rate of change in domains of assessment|Research blood samples|Safety Assessments: symptom checklist and adverse event checklist",16-Sep-14,https://ClinicalTrials.gov/show/NCT00546767246,Donepezil in the Prevention of Post-Operative Cognitive Decline,Completed,No Results Available,Postoperative Complications|Delirium,Drug: Donepezil,Changes in the International Study of Post-Operative Cognitive Decline (ISPOCD) and the CogHealth computerized battery tests at 1 week and 12 weeks after surgery|Delirium status measured by the Confusion Assessment Method (CAM) and the Memorial Delirium Assessment Scale (MDAS) daily during the post-operative period|Global cognitive status assessed using the Mini Mental Status Exam (MMSE)|Length of stay in the hospital post-operatively|Discharge site|Adverse effects,03-Mar-08,https://ClinicalTrials.gov/show/NCT00182845247,Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline,Completed,Has Results,Alzheimer's Disease,Drug: florbetapir (18F),Clinical and Diagnostic Change in Patient Management|Change in ADAS-Cog 11 Total Score|Change in Patient's Clinical Diagnosis|Change in Diagnostic Confidence|Change in Patient Management: Advice/Counseling|Change in Caregiver Self-efficacy|Change in Patient Management: Individual Categories,17-Aug-16,https://ClinicalTrials.gov/show/NCT01703702248,Effectiveness of a Multifactorial Intervention on Frailty,Completed,No Results Available,Frail Elderly|Cognitive Impairment|Dependence,Other: Multifactorial intervention,"Change from Baseline in Short Physical performance battery at 3 and 18 months|Change from Baseline in Muscle strength at 3 and 18 months|Change from Baseline in Cognitive Performance (Barcelona test) at 3 and 18 months|Number of Participants with Falls during follow-up, at 18 months|Change from Baseline in Functional Capacity at 18 months|Number of Participants Hospitalized during follow-up, at 18 months|Number of Participants Institutionalized during follow-up, at 18 months|Number of Participants included in Home Health care during follow-up, at 18 months",13-Nov-17,https://ClinicalTrials.gov/show/NCT01969526249,Methylene Blue for Cognitive Dysfunction in Bipolar Disorder,Completed,No Results Available,Bipolar Disorder,Drug: Methylene Blue,"Young Mania Rating Scale|Hamilton Depression Rating Scale (HAM-D), 17-item version Hamilton Rating Scale for Anxiety (HAM-A).|Clinical Global Impression Scale CGI-BP (41)|Affective Morbidity Index (42)|California Verbal Learning Task and a process dissociation task. Two tasks will focus on selective attention, negative priming and inhibition of return tasks.|A visual backward masking task that has been well studied in patients with BD will be used.|Trails B will be administered as a test of executive function.",01-Apr-08,https://ClinicalTrials.gov/show/NCT00214877250,"The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial",Completed,Has Results,Cognitive Impairment|Hypertension|Aging,"Drug: candesartan|Drug: lisinopril|Drug: hydrochlorothiazide|Drug: nifedipine, long acting|Drug: metoprolol, long-acting","Cognitive Assessment: Trail Making Test Part B|Cognitive Assessment: Hopkins Verbal Learning- Immediate Recall|Cognitive Assessment: Forward Digit Span Test|Blood Pressure Outcome: Systolic BP|Blood Flow Velocity, Sitting",15-Feb-13,https://ClinicalTrials.gov/show/NCT00605072251,Characterization of Factors Influencing the Cognitive Decline in Patients With Coronary Artery Disease,Completed,No Results Available,Coronary Artery Disease,Procedure: Cardiac surgery,"Compare cognitive disorders using the scale Dementia rating scale (DRS) of Mattis in 2 groups|Blood biomarkers: inflammation, coagulation, protein|Neuropsychological evaluation: global cognitive function using MMSE, memory, attention|Imaging parameters (MRI): abnormalities of white matter, ischemic lesions, hippocampus volume",09-Nov-16,https://ClinicalTrials.gov/show/NCT00946959252,Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects,Completed,Has Results,Cognitive Aging,Drug: Guanfacine|Drug: Placebo,Mean in the Prefrontal Executive Function Z-score (PEF6_6)|Alzheimer's Disease Cooperative StudyÛÓClinical Global Impression of Change (ADCS-CGIC)|Quality of Life (SF-36 MCS),13-Aug-14,https://ClinicalTrials.gov/show/NCT00935493253,Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa,Completed,No Results Available,HIV|Impaired Cognition,Drug: standard care|Drug: novel treatment,cognitive function|brain function,10-Jan-17,https://ClinicalTrials.gov/show/NCT01367236254,Evaluating the Risk of Cognitive Impairment After Surgical and Transcatheter Aortic Valve Replacement,Completed,No Results Available,Cardiovascular Disease|Aortic Valve Stenosis|Cognitive Assessments|Valve Surgery|Transcatheter Valve Replacement|Surgical Valve Replacement,Other: Observational/Cognitive Assessment,Montreal Cognitive Assessment|Trail Making,26-Mar-18,https://ClinicalTrials.gov/show/NCT02971020255,"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline",Completed,Has Results,Alzheimer Disease,Drug: Rivastigmine 5 cm^2|Drug: Rivastigmine 10 cm^2|Drug: Rivastigmine 15 cm^2|Drug: Placebo to 15 cm^2 patch|Drug: Placebo to 10 cm^2 patch,"Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) Subscale at Week 48 of Double Blind Period|Change in Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) Subscale Score From Baseline to Week 48 of Double Blind Period|Time to Functional Decline as Measured by Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) Subscale During the Double Blind Period|Change in Attention and Executive Function as Assessed by the Trail Making Test (Part A) at Week 48 of the Double Blind Period|Change in Attention and Executive Function as Assessed by the Trail Making Test (Part B) at Week 48 of Double Blind Period|Change From Baseline in Neuropsychiatric Inventory (NPI)-10 Score at Week 48 of Double Blind Period|Number of Patients With Adverse Events, Serious Adverse Events and Discontinuations Due to Adverse Events",19-Sep-12,https://ClinicalTrials.gov/show/NCT00506415256,Add On Treatment for Cognitive Deficits in Schizophrenia,Completed,No Results Available,Schizophrenia,Drug: PF 03654746|Other: Placebo,MATRICS Consensus Cognitive Battery|ASL perfusion and performance on neurocognitive measures|fMRI activation parameters and performance on neurocognitive measures.|ERP measures and performance on neurocognitive measures,02-May-11,https://ClinicalTrials.gov/show/NCT01346163257,Combined Cognitive and Physical Exercises Through Computer Games in Elderly: The LLM Project,Completed,No Results Available,Mild Cognitive Impairment|Mild Dementia|Healthy,Other: LLM training,overall cognition|physical fitness|Episodic memory|working memory|executive function|Quality of Life|Instrumental Activities of daily living|Depressive symptoms|Brain function,20-Oct-14,https://ClinicalTrials.gov/show/NCT02267499258,Memantine and Cognitive Dysfunction in Bipolar Disorder,Completed,Has Results,Bipolar Disorder,Drug: Memantine|Drug: Placebo,California Verbal Learning Test (CVLT) at Week 12|California Verbal Learning Test (CVLT) at Week 6|Rapid Visual Information Processing Task (RVP),06-Oct-17,https://ClinicalTrials.gov/show/NCT00586066259,"Anesthesia Depth Increases the Degree of Postoperative Dementia, Delirium, and Cognitive Dysfunction",Completed,No Results Available,Anesthesia|Delirium|Dementia|Bispectral Index Monitor,Device: Anesthesia depth monitor|Device: Sham control|Drug: propofol and sevoflurane,Postoperative cognition and mental capacity of elderlies following major surgery|Incidence of mental and other complications (serious adverse events),09-May-17,https://ClinicalTrials.gov/show/NCT02382445260,A Casefinding and Referral System for Older Veterans Within Primary Care,Completed,No Results Available,Depression|Incontinence|Cognitive Impairment,Behavioral: Casefinding and Referral System,,07-Apr-15,https://ClinicalTrials.gov/show/NCT00012740261,Effects of Tart Cherry Juice on the Body,Completed,No Results Available,Cardiovascular Risk Factors|Age-Related Cognitive Decline,Other: Tart cherry juice|Other: Placebo,Cognitive function|Cardiovascular risk factors|Oxidative stress markers|Inflammatory markers,04-Oct-16,https://ClinicalTrials.gov/show/NCT02922920262,The Impact of Family Financial Support on Cognition,Completed,No Results Available,Impaired Cognition,Behavioral: Financial Coaching|Behavioral: Access to Referrals to Social Services,Cognition,26-Oct-17,https://ClinicalTrials.gov/show/NCT02723318263,Mind-motor Exercise to Improve Cognition and Functional Fitness,Completed,No Results Available,Cognitive Decline,Behavioral: Square Stepping Exercise,Composite score from Cambridge Brain Sciences Cognitive Battery|Gait variability (stride time) under dual-task conditions|Gait variability (stride time) under single-task conditions|Gait velocity (speed) under dual-task conditions|Gait velocity (speed) under single-task conditions|Step length (average) under dual-task conditions|Step length (average) under single-task conditions|Memory composite score|Reasoning composite score|Concentration composite score|Planning (executive functioning) composite score|Short Performance Physical Battery - Balance|Neuropsychiatric Inventory Questionnaire,28-Sep-17,https://ClinicalTrials.gov/show/NCT02730013264,Impact of Physical Activity on Successful Aging,Completed,No Results Available,Alzheimer Disease|Cognitive Impairment|Physical Activity,Other: Physical activity (PA)|Other: cognitive treatment (CT),Mini Mental State Examination|Trail Making Test|Rivermead Behavioral Memory Test|Tower of London|Dual Task|Frontal Assessment Battery|Attention Matrix|Alzheimer's Disease Assessment Scale|6-Minute Walking Test|gait analysis by GAITRiteå¨ System|stabilometric assessments with Stability Line|Instrumental Activity in Daily Living Scale (IADL)|Neuropsychiatric Inventory Scale (NPI)|cerebral circulation|peripheral vascular function,30-Jan-17,https://ClinicalTrials.gov/show/NCT03034746265,Body Temperature in Persons With Tetraplegia When Exposed to Cold,Completed,Has Results,Tetraplegia|Hypothermia|Mild Cognitive Impairment,Drug: Midodrine hydrochloride,Visit 1: Percent Change in Core Body Temperature|Visit 2: Percent Change in Core Body Temperature With Midodrine|Visit 1: Percent Changes in Cognitive Performance - Stroop Interference|Visit 1: Percent Changes in Cognitive Performance - Delayed Recall,04-Mar-16,https://ClinicalTrials.gov/show/NCT01822535266,Deep Brain Stimulation (DBS) of the Nucleus Basalis Meynert (NBM) to Treat Cognitive Deficits in Light to Moderate Alzheimer's Disease,Completed,No Results Available,Alzheimer Disease,Other: Deep brain stimulation,cognitive improvement|determination of the optimal stimulation parameter,07-Jun-13,https://ClinicalTrials.gov/show/NCT01094145267,N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia,Completed,No Results Available,Schizophrenia,Drug: N-acetylcysteine (NAC)|Drug: Inactive placebo capsule,EEG: Change in Mismatch Negativity Amplitude|EEG: Change in P300 Amplitude|EEG: Change in Gamma Synchrony Evoked Power and Phase Synchronization|EEG: Change in Visual Cortical Plasticity|Change in MATRICS Consensus Cognitive Battery composite score|Change in Positive and Negative Syndrome Scale (PANSS) total score|Change in Clinical Assessment Interview for Negative Symptoms (CAINS) scores,04-Jun-15,https://ClinicalTrials.gov/show/NCT01885338268,Galantamine for Cognitive Deficits in Schizophrenia,Completed,No Results Available,Schizophrenia,Drug: Galantamine,"1. Change on selected cognitive deficits associated with schizophrenia (e.g., spatial working memory, sustained attention and prepulse inhibition.)",12-Dec-07,https://ClinicalTrials.gov/show/NCT00463879269,Angiotensin II Receptor Blockers (ARB) and ACE Inhibitors (ACEI) on Silent Brain Infarction and Cognitive Decline,Completed,No Results Available,Brain Infarction|Hypertension,Drug: Angiotensin II Receptor Antagonists|Drug: Angiotensin-converting Enzyme Inhibitors,Fatal and nonfatal stroke|Progression of silent brain infarction or white matter lesion on magnetic resonance imaging|Fatal and nonfatal acute coronary syndrome|Admission for heart failure|All cause mortality,30-Oct-13,https://ClinicalTrials.gov/show/NCT00126516270,Smart Autonomous Neuro-Rehabilitation System,Completed,No Results Available,Cognition Disorders|Cognitive Deficits,Behavioral: Cognitive rehabilitation training with RGS in the clinic|Behavioral: Passive/conventional cognitive training at home.,"Change in Digit Span Forward WAIS-IV from baseline to end of treatment and to follow-up|Change in Corsi block tapping test from baseline to end of treatment and to follow-up|Change in Trail Making Test, Part A from baseline to end of treatment and to follow-up|Change in Rey Auditory Verbal Learning Test from baseline to end of treatment and to follow-up|Change in Digit Span Backward WAIS-IV from baseline to end of treatment and to follow-up|Change in Corsi block-tapping test reversed from baseline to end of treatment and to follow-up|Change in Frontal Assessment Battery from baseline to end of treatment and to follow-up|Change in Trail Making Test, Part B from baseline to end of treatment and to follow-up|Change in Digit Symbol Coding in WAIS-IV from baseline to end of treatment and to follow-up|Change in Star Cancellation test from baseline to end of treatment and to follow-up|Change in Montreal Cognitive Assessment from baseline to end of treatment and to follow-up|Change in Mini-Mental State Examination from baseline to end of treatment and to follow-up|Change in Barthel Index from baseline to end of treatment and to follow-up|Change in Fugl-Meyer Assessment from baseline to end of treatment and to follow-up",23-May-18,https://ClinicalTrials.gov/show/NCT02816008271,Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors,Completed,Has Results,Schizophrenia|Cigarette Smoking,Drug: Varenicline|Drug: Placebo for varenicline,Cotinine Level|Change From Baseline in Cognitive Performance|Change From Baseline in Psychiatric Symptoms|Change From Basellne in Calgary Depression Scale Score,02-Dec-17,https://ClinicalTrials.gov/show/NCT00802919272,Dosage and Efficacy of Probucol-induced apoE to Negate Cognitive Deterioration,Completed,No Results Available,Dementia of the Alzheimer Type|Age-related Cognitive Decline|Mild Cognitive Impairment Due to Alzheimer Disease,Drug: Probucol,Plasma concentration of probucol following test dose|Apolipoprotein concentration in CSF before and after treatment with probucol at individualized dose,31-Jan-18,https://ClinicalTrials.gov/show/NCT02707458273,Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Placebo|Drug: Vortioxetine (Lu AA21004),Change From Baseline to Week 8 in DSST (Number of Correct Symbols) and RAVLT (Acquisition and Delayed Recall) Using the Composite Z-score Defined as the Weighted Sum of the Individual Patient Z-scores|Change From Baseline to Week 8 in DSST (Number of Correct Symbols)|Change From Baseline to Week 8 in RAVLT (Acquisition)|Change From Baseline to Week 8 in RAVLT (Delayed Recall)|Change From Baseline to Week 8 in the TMT A (Speed of Processing)|Change From Baseline to Week 8 in the TMT B (Executive Function)|Change From Baseline to Week 8 in Congruent STROOP Time to Complete (Executive Function)|Change From Baseline to Week 8 in Incongruent STROOP Time to Complete (Executive Function)|Change From Baseline to Week 8 in the SRT (Speed of Processing)|Change From Baseline to Week 8 in the CRT (Attention)|Change From Baseline to Week 8 in MADRS Total Score|Change From Baseline to Week 8 in CGI-S Score|Clinical Status Using CGI-I Score at Week 8|Proportion of Responders at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline|Proportion of Remitters at Week 8 (Remission is Defined as a MADRS Total Score <=10)|Change From Baseline to Week 1 Using the MADRS Total Score and the Composite Z-score|Change From Baseline to Week 8 Using the MADRS Total Score and the Composite Z-score|Risk of Suicidality Using C-SSRS Scores,05-Aug-14,https://ClinicalTrials.gov/show/NCT01422213274,Omega-3 and Blueberry Supplementation in Age-Related Cognitive Decline,Completed,No Results Available,Age-related Memory Disorders|Mood Disorders,Dietary Supplement: Omega-3 fatty acid|Dietary Supplement: Blueberry powder|Other: Placebo oil|Other: Placebo powder,Working Memory and Executive Ability|Mood Assessment|Daily Functioning Assessment|Long-term memory function,27-May-16,https://ClinicalTrials.gov/show/NCT01746303275,Post-operative Cognitive Dysfunction and the Change of Regional Cerebral Oxygen Saturation in Elderly Patients Undergoing Spinal Surgery,Completed,No Results Available,Elderly Patients Undergoing Spinal Surgery,Other: Neurologic and neuropsychologic tests,K-MMSE|visuomotor test(D-LOTCA battery)|Regional cerebral oxymetry monitoring,28-Jan-15,https://ClinicalTrials.gov/show/NCT01839227276,Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial,Completed,Has Results,Delirium|Postoperative Cognitive Dysfunction,Drug: Rivastigmine Patch|Other: Placebo Patch,Incidence of POD,09-Feb-15,https://ClinicalTrials.gov/show/NCT00835159277,The SOMNUS Study: Sedative Optimization Via Monitoring Neurological Status,Completed,No Results Available,Delirium|Cognitive Impairment|Critically Ill,"Other: Sedation,RASS Targeted plus BIS Monitoring|Other: Sedation, RASS Targeted","Number of ventilator free hours and days|Number of delirium and coma free days|Incidence of subacute cognitive dysfunction using RBANS- Repeatable Battery for the Assessment of Neuropsychological Status,|Incidence of subacute cognitive dysfunction using TRAILS A&B|Incidence of subacute cognitive dysfunction using SF-36 - Short Form Health Survey|Incidence of subacute cognitive dysfunction using MMSE - Mini Mental State Examination|Incidence of subacute cognitive dysfunction using IADLs - instrumental activities of daily living|Incidence of subacute cognitive dysfunction using AD8- ADL - activities of daily living|Incidence of subacute cognitive dysfunction using APACHE II - Acute Physiologic and Chronic Health Evaluation II score|ICU length of stay|Hospital length of stay|Six month mortality|Biomarkers for neurological injury and inflammation, Neuron-Specific Enolase (NSE)|Biomarkers for neurological injury and inflammation, S100|Biomarkers for neurological injury and inflammation, IL-6|Biomarkers for neurological injury and inflammation, C Reactive Protein (CRP)|sleep quality",08-Mar-18,https://ClinicalTrials.gov/show/NCT00469482278,Adderall XR and Processing Speed in Multiple Sclerosis (MS),Completed,No Results Available,Impaired Processing Speed|Cognitive Impairment|Multiple Sclerosis,Drug: Adderall XR 5mg|Drug: Adderall XR 10 mg|Drug: Placebo,Change in score of Paced Auditory Serial Addition Test (PASAT)|Change in Score of Symbol Digit Modalities Test (SDMT),12-May-15,https://ClinicalTrials.gov/show/NCT01667484279,Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors,Completed,No Results Available,"Brain Neoplasms, Malignant|Brain Neoplasms, Benign|Malignant Meningioma|Glioblastoma Multiforme|Anaplastic Astrocytoma",Drug: pioglitazone|Drug: Pioglitazone,Best tolerated dose of 2 different doses of orally administered pioglitazone|Toxicities associated with both dose levels|To evaluate the effect of pioglitazone on glycemic levels and hemoglobin A1c values when pioglitazone is used as a cytoprotective agent concurrent with radiotherapy in normoglycemic patients.,30-May-17,https://ClinicalTrials.gov/show/NCT01151670280,Targeting Circadian and Cognitive Dysfunction in Bipolar Disorder With Modafinil,Completed,No Results Available,Bipolar Disorder,Drug: Modafinil|Drug: Placebo,safety of adjunctive modafinil|MCCB|sleep quality|UPSA|QoL|Vital signs|Electrocardiogram|liver function tests|chemistry panel|Complete blood count|urinalysis|Suicide risk scale|Medication log,21-Mar-18,https://ClinicalTrials.gov/show/NCT01965925281,Cognitive/Physical Computer-Game Blended Training of Elderly: Neuroscientific LLM Studies,Completed,No Results Available,"Mild Cognitive Impairment, So Stated|Mild Dementia|Healthy",Other: LLM|Other: FFA|Other: Brain Fitness|Other: VideoGrade,overall cognition|physical fitness|Episodic memory|working memory|executive function|Quality of Life|Instrumental Activities of daily living|Depressive symptoms|Brain function,11-Dec-14,https://ClinicalTrials.gov/show/NCT02313935282,Preventing Cognitive Decline With Alternative Therapies,Completed,No Results Available,Dementia|Memory Disorders,Drug: Ginkgo Biloba Extract,,18-Aug-06,https://ClinicalTrials.gov/show/NCT00010920283,A Study of rTMS for Cognitive Deficits in Chronic Patients With Schizophrenia,Completed,No Results Available,Schizophrenia,Device: repetitive TMS|Device: Sham rTMS,Scale for the Assessment of Negative Symptoms (SANS)|Positive and Negative symptom scale (PANSS)|CANTAB,06-Sep-17,https://ClinicalTrials.gov/show/NCT03273439284,Placebo Controlled Study of Atomoxetine in the Treatment of Mild to Moderate Cognitive Difficulties in Menopausal Women,Completed,Has Results,Menopause|Cognitive Disturbances,Drug: atomoxetine|Drug: placebo,Brown Attention Deficit Disorder Scale|BADDS Total Score|Blood Pressure|Heart Rate|Weight,17-Apr-17,https://ClinicalTrials.gov/show/NCT00611533285,A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I,Completed,No Results Available,Cognitive Decline|Mucopolysaccharidosis I|Hurler-Scheie Syndrome|Scheie Syndrome|Lysosomal Storage Disease,Drug: laronidase,The objective of this study is to assess the ability of intrathecal ë±-L-iduronidase to be administered safely|The objective of this study is to assess the ability of intrathecal ë±-L-iduronidase to stabilize or reverse cognitive decline.,26-Jan-16,https://ClinicalTrials.gov/show/NCT00852358286,Randomized Trial of Exercise and Social Interaction in a Community-Based Sample of Non-Demented Chinese Elders,Completed,No Results Available,Cognitive Impairment|Dementia|Mild Cognitive Impairment|Alzheimer Disease,Other: Fast walking|Other: Tai Chi|Other: Intellectual stimulation|Other: Contact and testing only,Change in cognitive performance on battery of neuropsychological tests|Change in whole brain volume,28-Sep-12,https://ClinicalTrials.gov/show/NCT01696019287,Septic Encephalopathy and Late Cognitive Dysfunction,Completed,No Results Available,Sepsis|Severe Sepsis,Drug: n-3 fatty acids,,10-Mar-15,https://ClinicalTrials.gov/show/NCT00772096288,Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia,Completed,Has Results,Schizophrenia|Schizoaffective Disorder,Drug: Cannabidiol|Drug: Placebo,Verbal Short Term Memory|Overall Cognition as Measured on the MATRICS Battery,08-Jun-17,https://ClinicalTrials.gov/show/NCT00588731289,Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic,Completed,Has Results,Schizophrenia|Cognition|Cigarette Smoking,Device: tDCS,Change From Baseline in Cigarette Craving|Change From Baseline in Cognitive Performance,30-Aug-17,https://ClinicalTrials.gov/show/NCT02128919290,Cardiac Surgery Neuroprotection Study in Elders,Completed,No Results Available,Post-operative Cognitive Decline|Post-operative Delirium,Drug: Aspart insulin|Drug: Placebo,Change from baseline cognitive function|Delirium and Coma Free Days|Association between post-operative delirium and post-operative cognitive decline|Hypoglycemia|Nasal irritation|Survival|ICU length of stay|Hospital length of stay,14-Jan-15,https://ClinicalTrials.gov/show/NCT01561378291,Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia,Completed,Has Results,Schizophrenia|Schizoaffective Disorder,Drug: modafinil|Drug: Placebos,"Percent Change in Accuracy on High-control (i.e., Difficult) Condition of Preparing to Overcome Prepotency Task|Control-related BOLD Signal Change in Locus Coeruleus|Gamma Power Change in Count of Clusters|Change in Positive Symptoms|Change in Negative Symptoms",29-Sep-17,https://ClinicalTrials.gov/show/NCT00423943292,Exercise as a Strategy to Treat Cognitive Dysfunction in Persons With Multiple Sclerosis,Completed,No Results Available,Multiple Sclerosis,Behavioral: exercise|Behavioral: stretching,Paced Auditory Serial Addition Test (PASAT)|Symbol Digit Modalities Test (SDMT)|VO2 max|Long latency cognitive event related potentials ( LLCERP),09-Dec-14,https://ClinicalTrials.gov/show/NCT01219647293,Methylphenidate Treatment of Attention Deficits in Epilepsy,Completed,Has Results,Epilepsy|Cognitive Deficits|Attention Deficits,Drug: Methylphenidate,"Conners' Continuous Performance Test (CPT) (Double-blind Portion, Primary Variables)|Symbol-digit Matching Test (Double-blind Portion)|MCG Paragraph Memory Test (Double-blind Portion)|Conners CPT Outcomes (Primary Variables) (Open-Label Portion)|Symbol-digit Matching Test (Open Label Phase)|MCG (Open-label Portion)|Seizure Frequency (Open-label Portion)|QOLIE-89 Aggregate Score|CPT Scores (Double-blind Portion) (Secondary Variables)|Seizure Frequency/Severity (Double-blind Portion)|QOLIE-89 Selected Cognitive Subscales (Open-label)|CPT Outcomes (Secondary Variables) (Open-label Portion)",30-May-17,https://ClinicalTrials.gov/show/NCT02178995294,A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia,Completed,No Results Available,Schizophrenia,Drug: ABT-126|Drug: Placebo,Cognition: MCCB (MATRICS Consensus Cognitive Battery) change from baseline to week 12|Functioning: UPSA-2 (University of California San Diego Performance-based Skills Assessment-2)|Symptom Severity: PANSS (Positive and Negative Syndrome Scale)|Symptom Severity: NSA-16 (16-item version of the Negative Symptom Assessment Scale),24-Mar-15,https://ClinicalTrials.gov/show/NCT01678755295,A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia,Completed,No Results Available,Schizophrenia,Drug: ABT-126|Drug: Placebo,Cognition: MCCB (MATRICS Consensus Cognitive Battery)|Functioning: UPSA-2 (University of California San Diego Performance-based Skills Assessment-2)|Symptom Severity: PANSS (Positive and Negative Symptom Scale)|Symptom Severity: NSA-16 (16-item version of the Negative Symptom Assessment Scale),15-May-15,https://ClinicalTrials.gov/show/NCT01655680296,Long-Term Cognitive Decline After Coronary Artery Bypass Grafting: is Off-Pump Surgery Beneficial?,Completed,No Results Available,Coronary Artery Disease|Cardiopulmonary Bypass|Cognition Disorders,Device: cardiac stabilizer instead of cardiopulmonary bypass,"cognitive decline 5 year after the index treatment|-freedom from cardiovascular events (i.e. mortality, stroke, myocardial infarction, re-CABG, or PTCA|-recurrence of angina|-use of anti-anginal drugs|-quality of life (SF-36 and EuroQuol",04-Dec-07,https://ClinicalTrials.gov/show/NCT00189215297,Computer-Based Training for Mild Alzheimer's Disease,Completed,No Results Available,Alzheimer's Disease,Procedure: Computer-based Cognitive Training,The primary objective of this trial will be to assess the feasibility of using computer-based|cognitive training in an a population with early Alzheimer's Disease.|A standardized set of neuropsychological assessments will be conducted pre- and post-|compuer-based training.,15-May-13,https://ClinicalTrials.gov/show/NCT00319891298,Memory Improvement With Docosahexaenoic Acid Study (MIDAS),Completed,No Results Available,Age-Related Cognitive Decline|Age-Related Memory Disorders,Dietary Supplement: DHA (nutritional supplement) or placebo,"Determine the effects of DHA, a nutritional supplement (900 mg/d) on improving cognitive functions (i.e. working memory, memory retention, attention, and executive function) in healthy elderly subjects at 24 weeks|Effects of DHA on visual acuity, levels of plasma phospholipids, and evaluating the safety and tolerability of the DHA dose administered|The study will include a screening period, baseline, and 24 week treatment period.",19-May-14,https://ClinicalTrials.gov/show/NCT00278135299,Prevention of Depression in Spouses of People With Cognitive Impairment,Completed,Has Results,Depression,Behavioral: PST-MCI/AD Caregiving|Behavioral: NT-MCI/AD Caregiving,Depressive Symptoms,03-Apr-18,https://ClinicalTrials.gov/show/NCT00321971300,Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy,Completed,No Results Available,Schizophrenia|Impaired Cognition,Drug: EVP-6124|Drug: Placebo,Change from Baseline in the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) to Day 182|Change from Baseline in the Schizophrenia Cognition Rating Scale (SCoRs) to Day 182|Safety and Tolerability of EVP-6124 or Placebo in Subjects with Schizophrenia|Change from Baseline in the Positive and Negative Symptom Scale (PANSS) to Day 182|Change from Baseline in the Clinical Global Impression-Severity (CGI-S) to Day 182|Change from Baseline in the Clinical Global Impression Change Scale (CGI-C) to Day 182|Change from Baseline in the EuroQOL-5D (EQ-5D) to Day 182,03-May-16,https://ClinicalTrials.gov/show/NCT01716975301,Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy,Completed,No Results Available,Schizophrenia|Impaired Cognition,Drug: EVP-6124|Drug: Placebo,Change from Baseline in the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) to Day 182|Change from Baseline in the Schizophrenia Cognition Rating Scale (SCoRs) to Day 182|Safety and Tolerability of EVP-6124 or Placebo in Subjects with Schizophrenia|Change from Baseline in the Positive and Negative Symptom Scale (PANSS) to Day 182|Change from Baseline in the Clinical Global Impression-Severity (CGI-S) to Day 182|Change from Baseline in the Clinical Global Impression Change Scale (CGI-C) to Day 182|Change from Baseline in the EuroQOL-5D (EQ-5D) to Day 182,03-May-16,https://ClinicalTrials.gov/show/NCT01714661302,A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy,Completed,No Results Available,Schizophrenia|Impaired Cognition,Drug: EVP-6124,Safety and Tolerability of EVP-6124 or Placebo in Subjects with Schizophrenia|Change from Baseline in the Clinical Global Impression (CGI) - Severity (CGI-S) to Day 182|Change from Baseline in the Clinical Global Impression (CGI) - Change (CGI-C) to Day 182|Change from Baseline in the EuroQol-5D (EQ-5D-5L) to Day 182|Change from Baseline in the Columbia Suicide Severity Rating Scale (C-SSRS) to Day 182|Change from Baseline in the Client Socio-Demographic and Service Receipt Inventory-European Version (CSSRI-EU) to Day 182,03-May-16,https://ClinicalTrials.gov/show/NCT01714713303,A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia,Completed,No Results Available,Schizophrenia,Drug: PF-3463275|Drug: Placebo,"Change from baseline in the CNS Vital Signs Cognition Battery composite score|Safety Endpoints: tolerability, laboratory tests, vital signs, and ECG's.|Pharmacokinetics of PF-3463275|Positive and Negative Syndrome Scale (PANSS)|Change from baseline in the CNS Vital Signs Cognition Battery domain scores",02-Oct-08,https://ClinicalTrials.gov/show/NCT00567203304,A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder,Completed,No Results Available,Schizophrenia,Drug: Placebo|Drug: RO4917838|Drug: Standard Antipsychotic Therapy,"Change From Baseline in Cognitive Dysfunction Biomarker (Mismatch Negativity) at Week 6, as Measured Using Electroencephalography (EEG)|Change From Baseline in Cognitive Dysfunction Biomarker (Visual Event-Related Potential [ERP]) at Week 6, as Measured Using EEG|Change From Baseline in Cognitive Dysfunction Biomarker (N1 Refractoriness) at Week 6, as Measured Using EEG|Change From Baseline in Cognitive Dysfunction Biomarker (P3 Component) at Week 6, as Measured Using EEG|Change From Baseline in Cognitive Dysfunction Biomarker (Visual Evoked Potential [VEP]) at Week 6, as Measured Using EEG|Change From Baseline in Cognitive Dysfunction Biomarker (Mismatch Negativity) at Week 1, as Measured Using EEG|Change From Baseline in Cognitive Dysfunction Biomarker (Visual Event-Related Potential [ERP]) at Week 1, as Measured Using EEG|Change From Baseline in Cognitive Dysfunction Biomarker (N1 Refractoriness) at Week 1, as Measured Using EEG|Change From Baseline in Cognitive Dysfunction Biomarker (P3 Component) at Week 1, as Measured Using EEG|Positive Predictive Value of Cognitive Dysfunction Biomarkers (Mismatch Negativity, ERP, N1 Refractoriness, P3 Component, and VEP) Change at Week 1 to Predict the Presence of Biomarker Response at Week 6, as Measured Using EEG|Positive Predictive Value of Cognitive Dysfunction Biomarkers (Mismatch Negativity, ERP, N1 Refractoriness, P3 Component, and VEP) Change at Week 1 to Predict the Change in Symptoms at Week 6, as Measured Using EEG|Change From Baseline in Positive and Negative Syndrome Scale Score|Change From Baseline in Negative Symptom Assessment Score|Change From Baseline in Clinical Global Impression Scale|Change From Baseline in Calgary Depression Scale Score|Change From Baseline in Global Assessment of Functioning Score|Change From Baseline in Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Cognition Battery Score|Change From Baseline in Cognitive Dysfunction Biomarker (Visual Evoked Potential [VEP]) at Week 1, as Measured Using EEG",02-Nov-16,https://ClinicalTrials.gov/show/NCT01116830305,NIV Reduces CBF in COPD Patients Without Cognitive Function,Completed,No Results Available,COPD|Non-invasive Ventilation|Cognitive Impairment|Cerebral Blood Flow,Other: Non-invasive ventilation,Cognitive Function|Cerebral blood flow,11-May-17,https://ClinicalTrials.gov/show/NCT03149835306,"A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder",Completed,No Results Available,Bipolar Disorder,Drug: Galantamine|Drug: Placebos,Cognitive Function,18-Apr-17,https://ClinicalTrials.gov/show/NCT00195845307,Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia,Completed,No Results Available,Schizophrenia,Drug: Atomoxetine,"Is adjunctive atomoxetine is more effective than placebo for neuropsychological measures of reaction time, motor speed, psychomotor speed, sustained attention, learning and memory, working memory, and executive function.|Examine whether adjunctive atomoxetine is more effective than placebo for positive symptoms and negative symptom measures.",05-Mar-15,https://ClinicalTrials.gov/show/NCT00161031308,Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits,Completed,Has Results,Schizophrenia,Drug: armodafinil|Drug: placebo,Mean Change From Baseline to Last Observation After Baseline in Composite Score on the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery|Change From Baseline to Week 4 in Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery Composite Score|Change From Baseline to Week 4 or Last Observation After Baseline in the Speed of Processing Domain of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery|Change From Baseline to Week 4 or Last Observation After Baseline in the Attention/Vigilance Domain of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery|Change From Baseline to Week 4 or Last Observation After Baseline in the Working Memory Domain of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery|Change From Baseline to Week 4 or Last Observation After Baseline in the Verbal Learning Domain of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery|Change From Baseline to Week 4 or Last Observation After Baseline in the Visual Learning Domain of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery|Change From Baseline to Week 4 or Last Observation After Baseline in the Reasoning and Problem Solving Domain of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery|Change From Baseline to Week 4 or Last Observation After Baseline in the Social Cognition Domain of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery|Change From Baseline to Week 4 or Last Observation After Baseline in the Trail Making Test of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery|Change From Baseline to Week 4 or Last Observation After Baseline in the Brief Assessment of Cognition in Schizophrenia: Symbol Coding (BASC SC) Test of the MATRICS Consensus Cognitive Battery|Change From Baseline to Week 4 or Last Observation After Baseline in the Fluency Test of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery|Change From Baseline to Week 4 or Last Observation After Baseline in the Wechsler Memory Scale: Spatial Span (WMS-III SS) Test of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery|Change From Baseline to Week 4 or Last Observation After Baseline in the Letter-Number Span (LNS) Test of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery|Change From Baseline to Week 4 or Last Observation After Baseline in the Wisconsin Card Sort Test (WCST) - Number of Perseverative Errors|Change From Baseline to Week 4 or Last Observation After Baseline in the Wisconsin Card Sort Test (WCST) - Consecutive Responses on the Final Category|Change From Baseline to Week 4 or Last Observation After Baseline in the Wisconsin Card Sort Test (WCST) - Categories Completed|Change From Baseline to Week 4 or Last Observation After Baseline in the Trails B Test|Change From Baseline to Endpoint (Week 4 or Last Observation After Baseline) in the Median Value for Actigraphy Data of Average Activity|Change From Baseline to Week 1 in the Median Value for Actigraphy Data of Average Activity|Change From Baseline to Week 2 in the Median Value for Actigraphy Data of Average Activity|Change From Baseline to Week 3 in the Median Value for Actigraphy Data of Average Activity|Change From Baseline to Week 4 in the Median Value for Actigraphy Data of Average Activity|Change From Baseline to Endpoint (Week 4 or Last Observation After Baseline) in the Median Value for Actigraphy Data of Maximum Activity|Change From Baseline to Week 1 in the Median Value for Actigraphy Data of Maximum Activity|Change From Baseline to Week 2 in the Median Value for Actigraphy Data of Maximum Activity|Change From Baseline to Week 3 in the Median Value for Actigraphy Data of Maximum Activity|Change From Baseline to Week 4 in the Median Value for Actigraphy Data of Maximum Activity|Change From Baseline to Endpoint (Week 4 or Last Observation After Baseline) in the Median Value for Actigraphy Data of Standard Deviation of Activity|Change From Baseline to Week 1 in the Median Value for Actigraphy Data of Standard Deviation of Activity|Change From Baseline to Week 2 in the Median Value for Actigraphy Data of Standard Deviation of Activity|Change From Baseline to Week 3 in the Median Value for Actigraphy Data of Standard Deviation of Activity|Change From Baseline to Week 4 in the Median Value for Actigraphy Data of Standard Deviation of Activity|Change From Baseline to Endpoint (Week 4 or Last Observation After Baseline) in the Median Value for Actigraphy Data of Total Activity|Change From Baseline to Week 1 in the Median Value for Actigraphy Data of Total Activity|Change From Baseline to Week 2 in the Median Value for Actigraphy Data of Total Activity|Change From Baseline to Week 3 in the Median Value for Actigraphy Data of Total Activity|Change From Baseline to Week 4 in the Median Value for Actigraphy Data of Total Activity|Change From Baseline to Endpoint (Week 4 or Last Observation After Baseline) in the Minimum Value for Actigraphy Data of Total Activity|Change From Baseline to Week 1 in the Minimum Value for Actigraphy Data of Total Activity|Change From Baseline to Week 2 in the Minimum Value for Actigraphy Data of Total Activity|Change From Baseline to Week 3 in the Minimum Value for Actigraphy Data of Total Activity|Change From Baseline to Week 4 in the Minimum Value for Actigraphy Data of Total Activity|Change From Baseline to Endpoint (Week 4 or Last Observation After Baseline) in the Maximum Value for Actigraphy Data of Total Activity|Change From Baseline to Week 1 in the Maximum Value for Actigraphy Data of Total Activity|Change From Baseline to Week 2 in the Maximum Value for Actigraphy Data of Total Activity|Change From Baseline to Week 3 in the Maximum Value for Actigraphy Data of Total Activity|Change From Baseline to Week 4 in the Maximum Value for Actigraphy Data of Total Activity|Change From Baseline to Endpoint (Week 4 or Last Observation After Baseline) in the Schizophrenia Cognition Rating Scale (SCoRS) Interviewer Total Scores|Change From Baseline to Week 2 in the Schizophrenia Cognition Rating Scale (SCoRS) Interviewer Total Scores|Change From Baseline to Week 4 in the Schizophrenia Cognition Rating Scale (SCoRS) Interviewer Total Scores|Change From Baseline to Week 4 or Last Observation After Baseline in the Schizophrenia Cognition Rating Scale (SCoRS) Interviewer Global Rating|Change From Baseline to Week 2 in the Schizophrenia Cognition Rating Scale (SCoRS) Interviewer Global Rating|Change From Baseline to Week 4 in the Schizophrenia Cognition Rating Scale (SCoRS) Interviewer Global Rating|Clinical Global Impression of Severity of Illness (CGI-S) Ratings at Week 4 or Last Observation Following Baseline|Patient Global Impression of Change (PGIC) at Week 4 or Last Observation Following Baseline|Change From Baseline to Week 4 or Last Observation After Baseline in Scale for the Assessment of Negative Symptoms (SANS) Total Scores|Change From Baseline to Week 1 in Scale for the Assessment of Negative Symptoms (SANS) Total Scores|Change From Baseline to Week 2 in Scale for the Assessment of Negative Symptoms (SANS) Total Scores|Change From Baseline to Week 4 in Scale for the Assessment of Negative Symptoms (SANS) Total Scores|Change From Baseline to Week 4 or Last Observation After Baseline in the Positive and Negative Symptom Scale for Schizophrenia (PANSS) Negative Scale Score|Change From Baseline to Week 1 in the Positive and Negative Symptom Scale for Schizophrenia (PANSS) Negative Scale Score|Change From Baseline to Week 2 in the Positive and Negative Symptom Scale for Schizophrenia (PANSS) Negative Scale Score|Change From Baseline to Week 4 in the Positive and Negative Symptom Scale for Schizophrenia (PANSS) Negative Scale Score|Change From Baseline to Week 4 or Last Observation Following Baseline in the Positive and Negative Symptom Scale for Schizophrenia (PANSS) Total Score|Change From Baseline to Week 1 in the Positive and Negative Symptom Scale for Schizophrenia (PANSS) Total Score|Change From Baseline to Week 2 in the Positive and Negative Symptom Scale for Schizophrenia (PANSS) Total Score|Change From Baseline to Week 4 in the Positive and Negative Symptom Scale for Schizophrenia (PANSS) Total Score|Change From Baseline to Week 4 or Last Observation Following Baseline in Epworth Sleepiness Scale (ESS) Total Scores|Change From Baseline to Week 1 in Epworth Sleepiness Scale (ESS) Total Scores|Change From Baseline to Week 2 in Epworth Sleepiness Scale (ESS) Total Scores|Change From Baseline to Week 4 in Epworth Sleepiness Scale (ESS) Total Scores|Clinical Global Impression of Severity of Illness (CGI-S) Ratings at Week 1|Clinical Global Impression of Severity of Illness (CGI-S) Ratings at Week 2|Clinical Global Impression of Severity of Illness (CGI-S) Ratings at Week 4|Patient Global Impression of Change (PGIC) at Week 1|Patient Global Impression of Change (PGIC) at Week 2|Patient Global Impression of Change (PGIC) at Week 4|Clinical Global Impression of Severity of Illness (CGI-S) Ratings at Baseline,19-Jul-13,https://ClinicalTrials.gov/show/NCT00487942309,The Effect of Retrobulbar Block for Eye Surgery on Brain Oxygenation and Cognitive Functions in Elderly Patients,Completed,No Results Available,Vitreoretinal Surgery|Cognitive Function Abnormal|Intraoperative Monitoring,Drug: 2% lidocaine hydrochloride|Drug: 0.5% levobupivacaine,Cerebral oxygen saturation changes (rSO2)|Cognitive function measurement|Sensory block onset time by the conjunctival feeling score using the cotton contact test.|Sensory block end time by the conjunctival feeling score using the cotton contact test.|Motor block onset time by eye movements score.|Motor block end time by eye movements score.|The akinesia score measurement|The mean arterial pressure (MAP) measurement|The heart rate (HR) measurement|The oxygen saturation (SpO2) measurement|Surgeon satisfaction|Patient satisfaction,16-Jun-17,https://ClinicalTrials.gov/show/NCT03189329310,"Effect of VSL#3 (Original De Simone Formulation) on Cognitive Function, Risk of Falls and Quality of Life in Patients With Cirrhosis",Completed,No Results Available,Cirrhosis|Cognitive Dysfunction,Dietary Supplement: VSL#3 (Original De Simone formulation)|Other: Placebo,To assess the effect of VSL#3 (Original De Simone formulation) on cognitive function in patients with cirrhosis,19-May-16,https://ClinicalTrials.gov/show/NCT01686698311,"Cognitive Deficits in Major Depressive Disorder and Bipolar Disorder, Depressed Type: Prevalence and Improvement With Treatment of Depressive Symptoms",Completed,No Results Available,Major Depression|Bipolar Disorder,Other: Prevalence,To examine the relationship between severity and type of depression with cognitive deficits,18-Nov-13,https://ClinicalTrials.gov/show/NCT00844974312,Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia,Completed,No Results Available,Schizophrenia|Cognition|Psychosis,Drug: Curcumin|Drug: Placebo,MATRICS Consensus Cognitive Battery (MCCB)|Empathic Accuracy Assessment|EEG Mismatch Negativity Paradigm (MMN)|EEG Visual Cortical Plasticity Paradigm|Brain Derived Neurotrophic Factor|Brief Psychiatric Rating Scale (BPRS)|The Clinical Assessment Interview for Negative Symptoms|Columbia-Suicide Severity Rating Scale (C-SSRS)|Udvalg for Kliniske UndersÌügelser (UKU) Side Effects Rating Scale,23-Oct-17,https://ClinicalTrials.gov/show/NCT02104752313,Activity & Cognition After Treatment for Breast Cancer,Completed,No Results Available,Breast Cancer|Mild Cognitive Impairment|Physical Activity,Behavioral: Walking,Change from baseline in cognitive function in breast cancer survivors immediately and one hour after an acute bout of exercise as assessed by a battery of cognitive functioning measures.|Change in relationship between exercise and cognitive function in breast cancer survivors as assessed by physical activity and fitness levels.|Physical activity guidelines in breast cancer survivors as assessed by graded exercise test.|Change from baseline in anxiety levels after one bout of exercise as assessed by HADS questionnaire.|Change in relationship between exercise and cognitive function in breast cancer survivors as assessed by psychosocial questionnaires.,24-Feb-17,https://ClinicalTrials.gov/show/NCT02592070314,Matching Cognitive Remediation to Cognitive Deficits in Substance-Abusing Inmates,Completed,No Results Available,Psychopathy|Personality Disorders,Other: Cognitive Remediation,Psychophysiological change from pre-treatment to post-treatment|Frequency of Conduct Reports,02-Jun-15,https://ClinicalTrials.gov/show/NCT01428349315,Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elapraseå¨ in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment,Completed,No Results Available,Hunter Syndrome,Biological: idursulfase-IT|Other: No IT treatment,"Change from baseline in the GCA score after 12 months of treatment at visit week 52, as obtained by DAS-II testing|Change from baseline in the adaptive behavior composite (ABC) score after 12 months of treatment at visit week 52, as obtained by VABS-II testing|Change from baseline in the GCA score at visit weeks 16, 28 and 40 as obtained by DAS-II testing|Change from baseline in the ABC score at visit weeks 16, 28 and 40 as obtained by VABS-II testing|Change from baseline in standard scores at visit weeks 16, 28, 40 and 52 in cluster areas of the DAS-II|Change from baseline in standard scores at visit weeks 16, 28, 40 and 52 of VABS-II domains|Change from baseline in age equivalents at visit weeks 16, 28, 40 and 52 developmental quotients, and T-scores for the subtests of the DAS-II|Change from baseline to visit weeks 16, 28, 40 and 52 in age equivalents, developmental quotients, and V-scale scores of the VABS-II subdomains|Change from baseline to visit weeks 16, 28, 40 and 52 in the V-scale scores and observed maladaptive levels of the VABS-II Maladaptive Behavior Index and its subscales",08-Nov-17,https://ClinicalTrials.gov/show/NCT02055118316,Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans,Completed,Has Results,Alzheimer Disease|Mild Cognitive Impairment|Neurodegenerative Diseases,Drug: florbetapir F 18,Inter-rater Reliability|Sensitivity of Florbetapir-PET to Detect Moderate to Frequent Beta-amyloid Neuritic Plaques (Probable/Definite Alzheimer's Disease)|Specificity of Florbetapir-PET to Detect no or Sparse Beta-amyloid Neuritic Plaques (Probable/Definite Alzheimer's Disease),07-Jun-12,https://ClinicalTrials.gov/show/NCT01550549317,Clinical Evaluation of Florbetapir F 18 (18F-AV-45),Completed,No Results Available,Alzheimer Disease|Mild Cognitive Impairment|Neurodegenerative Diseases,Drug: Florbetapir F 18,Safety assessment|Florbetapir F 18 tracer uptake as determined by SUVR,12-Jun-17,https://ClinicalTrials.gov/show/NCT01518374318,Treatment Study for Cognitive Deficits in Schizophrenia,Completed,Has Results,Schizophrenia,Drug: MK-0777|Drug: placebo,Composite MATRICS Consensus Cognitive Battery Score|UPSA(UCSD Performance-Based Skills Assessment) Summary Score|Schizophrenia Cognition Rating Scale (SCoRS) Score,31-Oct-14,https://ClinicalTrials.gov/show/NCT00505076319,An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016),Completed,No Results Available,Amnestic Mild Cognitive Impairment|Alzheimer's Disease|Prodromal Alzheimer's Disease,Drug: MK-8931,Area under the concentration versus time curve of MK-8931 from 0 to infinity (AUC0-ö_)|Maximum observed plasma concentration of MK-8931 (Cmax)|Area under the concentration versus time curve of MK-8931 from 0 to the time of the last quantifiable (above LLOQ) sample (AUCO-last)|Area under the concentration versus time curve of MK-8931 from 0 to 24 hours (AUC0-24)|Plasma concentration of MK-8931 at 24 hours(C24hr)|Apparent clearance of MK-8931 after extravascular administration (CL/F)|Time to maximum observed MK-8931 plasma drug concentration (Tmax)|Apparent terminal half-life of MK-8931 (t1/2)|Apparent volume of distribution of MK-8931 during the terminal phase after extravascular administration (Vz/F),28-Jul-17,https://ClinicalTrials.gov/show/NCT02910739320,Study of Donepezil in Female Breast Cancer Survivors With Cognitive Dysfunction,Completed,Has Results,Anxiety Disorder|Breast Cancer|Cognition Disorders|Depression|Fatigue|Sleep Disorders,Drug: donepezil hydrochloride|Drug: Placebo,Retention|Compliance|HVLT-IR|Fatigue,28-Aug-17,https://ClinicalTrials.gov/show/NCT01466270321,Oral Vitamin B12 Supplementation and Cognitive Performance in Elderly People,Completed,No Results Available,Cognitive Decline|Cognitive Symptoms,Behavioral: vitamin B12 supplementation|Behavioral: vitamin B12 + folic acid combined supplementation,"Cognitive performance in the domains of attention, concentration, memory, executive function, speed|Blood biochemistry including vitamin B12, methylmalonic acid, holotranscobalamin, homocysteine, and red blood cell folate",24-Jun-05,https://ClinicalTrials.gov/show/NCT00111267322,Effects of Strengthening Exercise on the Brain for Early Dementia and Normative Older Adults,Completed,Has Results,Cognitive Decline|Dementia|Alzheimer's Disease|Mild Cognitive Impairment,Behavioral: Strengthening exercise,Stroop Test Performance From Pre- to Post-intervention|Digits Backwards Test Performance From Pre- to Post-intervention|Color Trails Test Performance From Pre- to Post-intervention|Fuld Test Performance From Pre- to Post-intervention|Figure Copy & Delayed Test Performance From Pre- to Post-intervention|Neurophysiological Function Pre- & Post- Intervention,11-Mar-15,https://ClinicalTrials.gov/show/NCT01264614323,Examining the Effects of (MiM) Treatment on Emotional and Cognitive Functioning of Residents in Long-term Care,Completed,No Results Available,Emotion|Impaired Cognition,"Behavioral: Music, Imagery, Movement|Behavioral: Social Control",emotional functioning|cognitive functioning,21-Jun-16,https://ClinicalTrials.gov/show/NCT02219620324,The Influence of GINkGo Biloba on the Pharmacokinetics of the UGT Substrate raltEgraviR (GINGER),Completed,No Results Available,HIV Infections|Depression|Mild Cognitive Impairment,Drug: raltegravir single dose|Drug: ginkgo biloba multiple dose,raltegravir concentrations|adverse events,27-Nov-12,https://ClinicalTrials.gov/show/NCT01246804325,D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia,Completed,Has Results,Schizophrenia|Schizoaffective Disorder,Drug: D-serine|Behavioral: Cognitive Retraining (CRT)|Drug: Placebo|Behavioral: Cognitive Retraining Placebo,Wisconsin Card Sorting Test (WCST)|Hopkins Verbal Learning Test|Spatial Span- Total Score|Positive and Negative Syndrome Scale (PANSS)|Heinrichs-Carpenter Quality of Life Scale|Simpson-Angus Neurological Rating Scale|UCSD Performance-Based Skills Assessment (UPSA),10-May-17,https://ClinicalTrials.gov/show/NCT00237809326,Silent Cerebrovascular Lesion and Cognitive Decline Prevention by Cholesterol Lowering in Elderly AF Patients,Completed,No Results Available,Atrial Fibrillation|Neuropsychology|Magnetic Resonance Imaging|Inflammation|Hemostasis,Drug: Atorvastatin|Drug: ezetimibe,Neurocognitive function|Cerebrovascular lesions on MRI|Level of inflammatory markers|Level of hemostatic markers,20-Mar-07,https://ClinicalTrials.gov/show/NCT00449410327,New Approach for Treatment of Behavioral Disorders in Alzheimer's Disease (Alzheimer's Behavioral and Cognitive Disorders),Completed,Has Results,Alzheimer Disease|Behavioral Disorders|Cognitive Impairment,Other: Ecological Environmental therapy,Evaluations of Behavioral Disorders|Evaluation of Cognitive Status (Score 0-30)|Body Composition (Kilograms of Fat Free Mass)|Systolic Blood Pressure (mmHg)|Diastolic Blood Pressure (mmHg)|Blood Glucose (mg/dl)|Blood Cholesterol HDL (mg/dl)|Blood Cholesterol LDL (mg/dl)|Daily Energy Expenditure (Kcal/Day)|Evaluation of Activity of Daily Life|Salivary Cortisol (Nmol/l)|Number of Medications|Number of Patients Treated With Quetiapine|Number of Patients Treated With Citalopram|Number of Patients Treated With Donepezil|Number of Patients Treated With Memantine|Number of Patients Treated With Ticlopidin,29-Feb-16,https://ClinicalTrials.gov/show/NCT02462291328,Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists,Completed,No Results Available,Bipolar Disorder|Major Depressive Disorder,Biological: Liraglutide,Executive function|Resting-state functional network connectivity,13-May-16,https://ClinicalTrials.gov/show/NCT02423824329,Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder,Completed,No Results Available,Major Depressive Disorder,Drug: Vortioxetine 10 mg|Drug: Paroxetine 20 mg|Drug: Placebo,Change in Digit Symbol Substitution Test (DSST): number of correct symbols|Change in Trail Making Test (TMT) score: TMT-A; speed of processing|Change in TMT-B; executive functioning|Change in reaction time score: Choice Reaction Time (CRT); attention|Change in reaction time score: Simple Reaction Time (SRT); psychomotor speed)|Change in Stroop Colour Naming Test (STROOP): incongruent score; executive functioning|Change in STROOP: congruent score; speed of processing|Change in Perceived Deficits Questionnaire - Depression (PDQ-D) total score|Change in Montgomery and Asberg Depression Rating Scale (MADRS) total score|Change in Clinical Global Impression - Severity of Illness (CGI-S)|Clinical Global Impression - Global Improvement (CGI-I) score|Change in the Functioning Assessment Short Test (FAST) total score|Change in University of San Diego Performance-based Skills Assessment - Brief (UPSA-B) total score,28-Feb-17,https://ClinicalTrials.gov/show/NCT02279966330,Citocoline for Treatment of FXTAS,Completed,No Results Available,Balance and Cognitive Deficits in Fragile X-associated Tremor Ataxia Syndrome,Drug: citocoline,FXTAS Rating Scale Score,30-Aug-17,https://ClinicalTrials.gov/show/NCT02197104331,Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder,Completed,No Results Available,Major Depressive Disorder,Drug: Vortioxetine 10-20 mg|Drug: Placebo|Drug: SSRI,"Change in Digit Symbol Substitution Test (DSST): number of correct symbols|Change in Rey Auditory Verbal Learning Test (RAVLT) score: memory (delayed recall) and learning [acquisition])|Change in Trail Making Test (TMT) score: TMT-A; speed of processing|Change in TMT score: TMT-B; executive functioning|Change in reaction time score: Choice Reaction Time (CRT); attention|Change in reaction time score: Simple Reaction Time (SRT); psychomotor speed|Change in Stroop Colour Naming Test (STROOP): incongruent score; executive functioning|Change in STROOP: congruent score; speed of processing|Change in Perceived Deficits Questionnaire - Depression (PDQ-D) total score|Change in Hamilton Depression Rating Scale-17 (HAMD-17) total score|Change in Clinical Global Impression - Severity of Illness (CGI-S)|Clinical Global Impression - Global Improvement (CGI-I) score|Change in University of San Diego Performance-based Skills Assessment - Brief (UPSA-B) total score|Number of adverse events|Columbia Suicide Severity Rating Scale (C-SSRS) categorisation based on Columbia Classification Algorithm of Suicide Assessment (C-CASA) definitions (1, 2, 3, 4 and 7)",24-May-17,https://ClinicalTrials.gov/show/NCT02279953332,Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder,Completed,Has Results,"Depressive Disorder, Major",Drug: vortioxetine (Lu AA21004)|Drug: Duloxetine|Drug: Placebo,Change From Baseline to Week 8 in the Digit Symbol Substitution Test (DSST)|Change From Baseline to Week 8 in the Perceived Deficits Questionnaire (PDQ) Attention/Concentration and Planning/Organization Subscore|Clinical Global Impressions-Improvement (CGI-I) Score at Week 8|Change From Baseline to Week 8 in the Trail Making Test (TMT-A)|Change From Baseline to Week 8 in the Trail Making Test B (TMT-B)|Change in Time From Baseline to Week 8 in the Stroop Test|Change From Baseline to Week 8 in the Groton Maze Learning Test (GMLT)|Change From Baseline to Week 8 in the Detection Task (DT)|Change From Baseline to Week 8 in the Identification Task (IT)|Change From Baseline to Week 8 in the One-Back Task|Proportion of Cognitive Dysfunction Improvement Due to Improvement of Depression|Change From Baseline to Week 8 in the MADRS Total Score|Percentage of Participants With MADRS Response at Week 8|Percentage of Participants in MADRS Remission at Week 8|Change From Baseline to Week 8 in the Clinical Global Impressions-Severity (CGI-S) Score,05-Feb-15,https://ClinicalTrials.gov/show/NCT01564862333,Effectiveness of a Brain-Computer Interface Based System for Cognitive Enhancement in the Normal Elderly,Completed,No Results Available,Alzheimer's Disease|Mild Cognitive Impairment|Age-Related Cognitive Decline|Dementia,Device: BrainPalTM,Total Score on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|Number of Adverse Events reported by participants on the Safety Measurement Form|Usability Measurement,25-Jul-14,https://ClinicalTrials.gov/show/NCT01661894334,Postoperative Neuroinflammation and Cognitive Dysfunction After Abdominal Surgery,Completed,No Results Available,Anesthesia|Surgery|Neurogenic Inflammation|Cognitive Disorders,Radiation: Positron emission tomography (PET) using [11C]PBR28,Binding of the PET probe [11C]PBR28|Cognitive testing|Inflammatory biomarkers,11-Jan-17,https://ClinicalTrials.gov/show/NCT01881646335,Omega-3 Fatty Acids and/or Multi-domain Intervention in the Prevention of Age-related Cognitive Decline,Completed,No Results Available,Frail Elderly Subjects,Dietary Supplement: omega-3|Behavioral: multi-domain intervention|Drug: Placebo,"Change in cognitive function at 36 months determined by a composite score (sum of Z-score of 4 tests: FCRST test (free recall + total recall) score, MMSE orientation score, Wais-R score (Digit Substitution Symbol test), and the Category Naming Test score|Changes in other cognitive functions. Changes in functional capacities. To study the long-term safety and tolerability of V0137 CA treatment. To study compliance and adhesion to the ""multi-domain"" intervention program.",17-Apr-15,https://ClinicalTrials.gov/show/NCT00672685336,Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women,Completed,No Results Available,Cognitive Impairment|Executive Dysfunction|Endothelial Dysfunction|Cardiovascular Disease,Drug: Leuprolide acetate|Drug: Estradiol|Drug: Medroxyprogesterone|Drug: Placebo,Changes in Prefrontal cortex brain activation|Changes in Endothelial function|Changes in artery compliance|Changes in Executive cognitive function,29-Nov-17,https://ClinicalTrials.gov/show/NCT02122198337,Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.,Completed,Has Results,Major Depressive Disorder,Drug: Lisdexamfetamine Dimesylate (Vyvanse)|Drug: Placebo,Change From Baseline in the Dysphoric Apathy/Retardation Sub-factor (MDAR) of Montgomery-Asberg Depression Rating Scale (MADRS) at 4 Weeks.,23-May-17,https://ClinicalTrials.gov/show/NCT01148979338,Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects,Completed,No Results Available,Alzheimer's Disease,Drug: GSK2981710|Drug: Placebo,Part 1: Plasma BHB elevation time course of GSK2981710|Part 1: Area under the time concentration curve (AUC) of GSK2981710|Part 1: Maximum concentration (Cmax) of GSK2981710|Part 2: Change from Baseline in performance on CANTAB Paired Associates Learning task|Part 2: Change from Baseline in performance on CANTAB Verbal Recognition Memory task|Part 2: Change from Baseline in performance on CANTAB Spatial Working Memory (SWM) task|Part 2: Change from Baseline in performance on CANTAB Rapid Visual Processing task|Part 2: Change from Baseline in performance on CANTAB Reaction Time task|Part 2: Change from Baseline in performance on Source Memory Task|Part 1 and 2: Safety and tolerability of GSK2981710 as assessed by number of subjects with adverse events (AE)s|Part 1 and 2: Safety and tolerability of GSK2981710 as assessed by change from Baseline in ECG readings|Part 1 and 2: Safety and tolerability of GSK2981710 as assessed by change from Baseline in laboratory values|Part 1 and 2: Safety and tolerability of GSK2981710 as assessed by change from Baseline in vital signs|Part 1 and 2: Safety and tolerability of GSK2981710 as assessed by Gastrointestinal (GI) Symptom and stool diary|Part 1 and 2: Safety and tolerability of GSK2981710 as assessed by Liking Assessment|Part 2: Change from Baseline in P300 EEG measurement|Part 2: Resting EEG measurement|Part 2: EEG measurement during Source Memory Task|Part 2: Correlation between systemic exposure of BHB and selected PD measurements,09-May-17,https://ClinicalTrials.gov/show/NCT01702480339,Insulin Resistance and Cognitive Dysfunction in Obese Adolescents: Pilot Study,Completed,No Results Available,Obesity,Other: Exercise Program,Formal exercise intervention and cognitive dysfunction in obeses adolescents|Systemic and Cognitive effects of adding exercise program to obese adolescent's lifestyle.,10-Jan-17,https://ClinicalTrials.gov/show/NCT01737658340,Feasibility Aquatic Physical Exercise to Reduce Falls in Institutionalized Elderly,Completed,No Results Available,Age Problems|Cognitive Impairment|Elderly|Postural Balance|Strength,Other: Exercise,"Change from baseline Number of Falls at 3 months, 6 months and 9 months|Balance measured with Performance Oriented Mobility Assessment|Pain measured with Visual Analogue Scale|Mobility measured with Timed Up & Go Test|Daily living activities measured with Barthel Test|Muscle strength measured with Five Sit to Stand test and Handgrip Test|Intervention Perception measured with Qualitative interview",05-May-17,https://ClinicalTrials.gov/show/NCT03019211341,Effect of Lidocaine in Antiarrhythmic Dosage on Postoperative Cognitive Dysfunction in Supratentorial Craniotomy Dysfunction in Supratentorial Craniotomy,Completed,No Results Available,Supratentorial Craniotomy Dysfunction,Drug: lidocaine|Drug: saline,Mini-Mental State Examination (MMSE)|Montreal Cognitive Assessment (MoCA)|Hamilton Depression Scale (HAMD)|Clinical Dementia Rating (CDR)|Confusion Assessment Method for the Diagnosis of Delirium in the Intensive Care unit (ICU) (CAM-ICU)|AjDO2 (Arterial Jugular Difference)|AjDGlc|AjDGlutamate|AjDLct|S100|Amyloid-ë_ protein(Aë_),22-May-13,https://ClinicalTrials.gov/show/NCT00975910342,Impact of Anesthesia Maintenance Methods on Incidence of Postoperative Delirium,Completed,No Results Available,Delirium|Postoperative Complications|Postoperative Cognitive Dysfunction,Drug: Sevoflurane|Drug: Propofol,Incidence of delirium|Length of stay in hospital after surgery|Incidence of non-delirium complications|Cognitive function at 30 days after surgery|All-cause 30-day mortality,03-Jan-18,https://ClinicalTrials.gov/show/NCT02662257343,A Treadmill Training Program Augmented by Virtual Reality to Decrease Fall Risk in Older Adults,Completed,No Results Available,Elderly Adults|Parkinson|Mild Cognitive Disorder,Other: TT+VR|Other: TT alone,Falls rate|Gait|Cognitive function|Balance and mobility|Quality of life,19-Apr-16,https://ClinicalTrials.gov/show/NCT01732653344,Effects of Propofol and Sevoflurane on Early POCD in Elderly Patients With Metabolic Syndrome,Completed,No Results Available,Postoperative Complications,Other: metabolic syndrome,Number of participants with Postoperative cognitive dysfunction (POCD) as assessed by Mini-Mental State Examination (MMSE) score in propofol group and sevoflurane group,30-Jun-16,https://ClinicalTrials.gov/show/NCT02766062345,Efficacy and Safety of Two Pharmacologic Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE Study,Completed,No Results Available,Neurocognitive Disturbance|HIV Infection,Drug: Lithium|Drug: Rivastigmine,Percentage of persons with neurocognitive impairment in the different study groups|Adverse events associated with the initiation of therapy and toxicity parameters|Emotional variables|Functional variables|Quality of life variables|Demographics,01-Apr-14,https://ClinicalTrials.gov/show/NCT01348282346,"Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia",Completed,No Results Available,Schizophrenia|Negative Symptoms|Cognitive Dysfunction,Drug: TC-5619|Drug: Placebo,"Change from baseline in the Scale for Assessment of Negative Symptoms (SANS)|Change from baseline in the Cogstate Schizophrenia Battery (CSB)|Change from baseline in UCSD Performance Based Skills Assessment, brief version (UPSA-Brief)",03-Jun-15,https://ClinicalTrials.gov/show/NCT01488929347,Skeletal Muscle as a Mediator of Exercise Induced Effects on Metabolism & Cognitive Function: Role for Myokines & miRNAs,Completed,No Results Available,Mild Cognitive Impairment|Alzheimer Disease|Parkinson Disease|Healthy Volunteers,Behavioral: 3 months exercise intervention program,muscle microRNAs and myokines|whole body energy metabolism|cognitive function|motoric function|Muscle functional tests,17-Apr-18,https://ClinicalTrials.gov/show/NCT02253732348,"Dopaminergic, Functional, Structural, and Cognitive Disturbances in First-episode Schizophrenia",Completed,No Results Available,Schizophrenia,Drug: zuclopenthixol|Drug: risperidone,"All examinations are done at baseline (patients and controls). In the patient group, they are repeated after 3 months of treatment|PANSS|SANS|SAPS|MRI|fMRI|startle response|PrePulse Inhibition of the startle response (PPI)|Cognition|The cognitive test battery comprised tests from the Cambridge Neuropsychological Test Automated Battery (CANTAB) as well as paper-and-pencil cognitive tests.",19-Sep-11,https://ClinicalTrials.gov/show/NCT00206960349,Cognitive and Emotional Impairment After Stroke,Completed,No Results Available,Stroke|Cognitive Impairment|Vascular Dementia,Other: Multifactorial vascular-risk-factor-intervention,"Effects of vascular risk-factor-intervention on changes in TMTA, ten-words-test and HAD|Prevalence of dementia and depression after stroke",21-Sep-09,https://ClinicalTrials.gov/show/NCT00506818350,Reducing Disabilities in Alzheimer's Disease (RDAD) Translation in Area Agencies on Aging (AAAs),Completed,No Results Available,Alzheimer's Disease|Dementia|Memory Impairment|Cognitive Impairment,Behavioral: RDAD,Minutes of exercise per week|Restricted Activity Days|Restricted Days of Activity|Independence/Residential Status|Revised Memory and Behavior Problem Checklist (RMBPC)|Quality of Life-AD|CES-D,15-Sep-17,https://ClinicalTrials.gov/show/NCT01708304351,Gabapentin Treatment of Cannabis Dependence,Completed,Has Results,Cannabis Dependence|Cannabis Withdrawal|Cognitive Deficits,Drug: gabapentin 1200mg/day|Drug: Placebo|Behavioral: Manual-guided behavioral counseling,Percentage of Negative Urinary Drug Screens (UDS) for Cannabis at 12 Weeks Following Administration of Gabapentin or Placebo During the Double Blind Period,06-Jun-17,https://ClinicalTrials.gov/show/NCT00974376352,A Rehabilitation Program in Children With Sickle Cell Disease and Cognitive Deficits: a Pilot Study,Completed,No Results Available,Sickle Cell Disease,Behavioral: General Tutoring|Behavioral: Memory Training,The proportion of children who complete the trial|Measure of working memory|Measure of academic achievement,12-Dec-14,https://ClinicalTrials.gov/show/NCT00895154353,Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia,Completed,Has Results,Diabetes|Schizophrenia|Insulin Resistance|Cognitive Impairment,Drug: Pioglitazone|Behavioral: Life style diet group|Other: Placebo,Change From Baseline in Serum Triglycerides at 3 Months ( 3 Months-baseline) US Sample|Change From Baseline in Serum HDL at 3 Months (3 Months-baseline) US Sample|Change From Baseline in Serum Glucose at 3 Months (3 Months-baseline) US Sample|2 Hour Glucose From Glucose Tolerance Test US Sample|Change in RBANS List Recognition Scores at 3 Months (3 Months-baseline) US Sample|Change From Baseline in Serum Glucose at 3 Months ( 3 Months -Baseline) China Sample|Change From Baseline in Serum Triglycerides at 3 Months (3 Months-baseline) China Sample|2 Hour Glucose From Glucose Tolerance Test China Sample|Change From Baseline in Serum HDL at 3 Months (3 Months-baseline) China Site,11-Dec-17,https://ClinicalTrials.gov/show/NCT00231894354,Remediation of Cognitive Dysfunction in Euthymic Bipolar Disorder Patients Using Transcranial Direct Current Stimulation (tDCS),Completed,No Results Available,Bipolar Disorder,Device: Transcranial direct current stimulation (Eldith DC Stimulator),Total correct responses.,03-Nov-15,https://ClinicalTrials.gov/show/NCT01339598355,"Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems",Completed,No Results Available,"Memory Disorder|Retention Disorder, Cognitive|Subjective Cognitive Impairment|Memory, Concentration or Attention Problems",Drug: Memantine|Drug: Placebo,"""Patient Global Impression of Change"" (PGI-C) at visit 4|Change from baseline to visit 3 and 5 of Patient Global Impression of Change (PGI-C)|Change from baseline to visit 4 in ""Everyday Cognition 39"" (ECog 39) total score|Change from baseline to visit 4 in ""Hospital Anxiety and Depression Scale"" (HADS) Score|Change from baseline to visit 3, 4, 5 of ""Computer-based Neuropsychological Test Battery (C-NTB) by CogState Ltd.",27-Nov-13,https://ClinicalTrials.gov/show/NCT01261741356,Galantamine-CR and Cognitive Dysfunction in Bipolar Disorder,Completed,No Results Available,Bipolar Disorder,Drug: Galantamine-CR,neurocognitive testing at last study visit (18 weeks),24-Apr-07,https://ClinicalTrials.gov/show/NCT00181636357,ABC Trial: Awakening and Breathing Controlled,Completed,No Results Available,"Aging|Respiration, Artificial",Procedure: SAT: Spontaneous Awakening Trial|Procedure: SBT: Spontaneous Breathing Trial,Ventilator free days|Length of stay in the ICU and hospital|28-day and 1-year survival|Duration of coma and delirium|Cognitive function|Psychological status|Functional status|Quality of life,11-Dec-09,https://ClinicalTrials.gov/show/NCT00097630358,Effectiveness of a Psycho-educational Group (PEG) Intervention on Supportive Care and Survivorship Issues in Early-stage Breast Cancer Survivors Who Have Received Systemic Treatment,Completed,No Results Available,Breast Cancer|Cancer|Anxiety|Cognitive Dysfunction,Behavioral: Psychoeducation group|Behavioral: Usual Care,"Severity of anxiety, as measured using Beck Anxiety Inventory|Quality of life|Severity of cognitive dysfunction, as measured using FACT-Cog|Severity of symptom burden, as measured using Rotterdam Symptom Checklist",22-Sep-16,https://ClinicalTrials.gov/show/NCT02600299359,"Egcg, a dyrk1a Inhibitor as Therapeutic Tool for Reversing Cognitive Deficits in Down Syndrome Individuals.",Completed,No Results Available,Down Syndrome,Dietary Supplement: Epigallocatechin-3-gallate (EGCG)|Drug: Placebo,Memory|DYRK1A activity biomarkers|Psychomotor speed|Attention|Executive functions|Visuomotor coordination|Functional outcome in daily living and adaptative behaviour|Quality of life|Qualitative data on treatment effects,13-Mar-13,https://ClinicalTrials.gov/show/NCT01394796360,Computerized Exercise Training for Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya,Completed,No Results Available,Multiple Sclerosis|Cognitive Deficits|Gilenya Modifying Therapy for MS,Other: plasticity-based computerized cognitive remediation program|Drug: Gileyna,Change from Baseline in Neuropsychological Test Results at 12weeks|Evaluate the feasibility of PACR for adults with MS on Gilenya therapy who have cognitive impairment based on Participant Adherence to Study Protocol,10-May-16,https://ClinicalTrials.gov/show/NCT02141022361,Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease,Completed,No Results Available,Alzheimer's Disease|Dementia|Memory Loss|Cognitive Impairment,Drug: ladostigil hemitartrate,ADAS-Cog: Alzheimer's Disease Assessment Scale-Cognitive Subscale|Safety Evaluation|Neuropsychiatric Inventory (NPI)|Cornell Scale for Depression in Dementia (CSDD)|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|Mini-Mental State Examination (MMSE)|ADAS-Cog: Alzheimer's Disease Assessment Scale - Cognitive Subscale,23-Jul-13,https://ClinicalTrials.gov/show/NCT01354691362,Cognitive Rehabilitation in Patients With Spina Bifida,Completed,No Results Available,Executive Dysfunction|Cognitive Deficits|Spina Bifida,Behavioral: Goal management training (GMT),Self and informant report of cognitive difficulties|self report of cognitive failures|self report of psychological problems|self report of quality of life|Self report of coping strategies|Cognitive functions measured by neuropsychological tests,22-Jan-14,https://ClinicalTrials.gov/show/NCT01302314363,Trial of a Medical and Mental Health Unit for Older People,Completed,No Results Available,Dementia|Confusion|Cognitive Impairment|Delirium,Behavioral: A medical and mental health unit,Number of days at home in the 3 months after randomisation|Quality of life|Behavioural disability|Mortality|Personal activities of daily living|Participant / generic disability|Cognition|Carer satisfaction with hospital care|Carer strain and general health|Service Outcomes|Quality of care and patient experience on the ward|Health and social care costs,03-Dec-15,https://ClinicalTrials.gov/show/NCT01136148364,Perioperative Cognitive Function - Dexmedetomidine and Cognitive Reserve,Completed,Has Results,Postoperative Delirium|PD|Postoperative Cognitive Dysfunction|POCD,Drug: Precedex (Dexmedetomidine)|Drug: Placebo,Delirium Battery|Neuropsychological Testing|Intraoperative Bradycardia|Intraoperative Hypotension|Intraoperative Hypertension|Length of Stay,23-Apr-18,https://ClinicalTrials.gov/show/NCT00561678365,Cerebral Oximetry and Neurocognitive Functions in Cardiosurgical Patients,Completed,Has Results,Coronary Artery Disease|Postoperative Cognitive Dysfunction|Neurological Impairment,Device: INVOS,"Difference in Incidence of Cognitive Impairment Between Groups. Change Between Preoperative and Postoperative Cognitive Function Was Assessed by Performing Standardized Neurocognitive Tests.|Evidence of Coma, Stupor, Cerebral Insult, Delirium, Ventilation Longer Than 24 Hours, Myocardial Infarction, Atrial Fibrillation, Dialysis, Reoperation for Bleeding, Infection, Hospital Stay > 7 Days",08-Jul-15,https://ClinicalTrials.gov/show/NCT00917124366,Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn,Completed,No Results Available,Depressive Symptoms|Parkinson's Disease,Drug: Rasagiline|Drug: Placebo,"Change from baseline in BDI-IA total score|Evaluate if rasagiline compared to placebo improves cognitive function, over a treatment period of 12 weeks in idiopathic Parkinsonå«s Disease, using a formal neuropsychiatric cognitive test battery; quality of life (PDQ 39); apathy; ADL, motor function|Change in quality of life using the PDQ-39 scale|Change in apathy using the Apathy Scale|Change in ADL and motor function using UPDRS scales part II and III, respectively",06-Jan-17,https://ClinicalTrials.gov/show/NCT01055379367,Clinical Trial of Brain-Penetrating HIV Drugs to Prevent Cognitive Impairment in China,Completed,No Results Available,HIV Infections|Central Nervous System Diseases|Dementia,Drug: zidovudine-lamivudine-nevirapine|Drug: tenofovir-lamivudine-efavirenz,Decline in neuropsychological performance at 96 weeks,04-Apr-16,https://ClinicalTrials.gov/show/NCT01340950368,"Phase I, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of an M1 Agonist to Treat Cognitive Impairment",Completed,No Results Available,Alzheimer's Disease,Drug: HTL0009936|Drug: HTL0009936 placebo,"Number of participants with Adverse Events, as a measure of safety and tolerability|Changes in Safety Lab parameters as a measure of safety and tolerability|Changes in vital signs as a measure of safety and tolerability|Changes in 12-lead electrocardiograms as a measure of safety and tolerability|Pharmacokinetic measures in plasma as measured by Peak plasma concentration (Cmax)|Pharmacokinetic measures in cerebro spinal fluid (CSF) in young males as measured by max observed CSF (Cmax CSF)|Pharmacokinetic measures to assess the food effect as measured by ANOVA|Pharmacodynamic response as measured by pupillometry|Pharmacokinetic measures in urine in young males and elderly male and female subjects as measured by amount of urine excreted at collection intervals|Pharmacodynamic response as measured by Bond and Lader visual analogue scale|Pharmacodynamic response as measured by changes in qEEG and Event Related Potentials (ERP)",20-Jun-17,https://ClinicalTrials.gov/show/NCT02291783369,Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple Sclerosis,Completed,No Results Available,Multiple Sclerosis,Drug: lisdexamfetamine sulfate|Drug: placebo,Symbol Digit Modalities Test SDMT) and Paced Auditory Serial Addition Test|California Verbal Learning Test - 2nd edition|Brief Visuospatial Memory Test - Revised|vitals,11-Jun-12,https://ClinicalTrials.gov/show/NCT01615887370,Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI),Completed,Has Results,Alzheimer's Disease,Drug: florbetapir F 18,Inter-reader Agreement - Median Kappa Statistic|Overall Inter-reader Agreement - Fleiss' Kappa,27-Jun-12,https://ClinicalTrials.gov/show/NCT01565382371,Cognitive Remediation Therapy Within a Secure Forensic Setting,Completed,No Results Available,Schizophrenia|Schizoaffective Disorder|Cognitive Deficits,Behavioral: Cognitive Remediation Therapy|Other: Treatment as usual,The MATRICS Consensus Cognitive Battery (MCCB)|Social and Occupational Functioning Assessment Scale (SOFAS)|Positive and Negative Syndrome Scale (negative and disorganized factors)|Clinical Assessment Interview for Negative Symptoms (CAINS),25-Jul-17,https://ClinicalTrials.gov/show/NCT02360813372,Clinical Trial of Lamotrigine to Reverse Cognitive Impairment in Chronic Corticosteroid-Treated Patients,Completed,No Results Available,Memory Impairment Due to Corticosteroid Use.|Hypomania Due to Corticosteroid Use.|Hippocampal Atrophy Due to Corticosteroid.,Drug: Lamotrigine (Drug),,03-Aug-11,https://ClinicalTrials.gov/show/NCT00223262373,"Remifentanil/Sufentanil for CABG+/-AVR Evaluated by Recovery, Cognitive Function, Haemodynamics and Biochemical Markers.",Completed,No Results Available,Ischaemic Heart Disease|Aortic Stenosis,Drug: Remifentanil|Drug: Sufentanil,Cognitive function score|Fast-track potential|Eligible time to discharge from ICU|Postoperative cognitive dysfunction,13-Aug-15,https://ClinicalTrials.gov/show/NCT02053818374,A Study of Decreased Mental Function Associated With HIV,Completed,No Results Available,Cognitive Disorders|HIV Infections,Drug: Selegiline hydrochloride,,16-Jan-15,https://ClinicalTrials.gov/show/NCT00027040375,Therapy of Alzheimer's Disease With Neurofeedback,Completed,No Results Available,Alzheimer Dementia (AD)|Elderly,Other: rtfMRI neurofeedback training|Device: 3T MRI,Visual and Verbal Memory Test (VVM)|Montreal Cognitive Assessment (MoCA)|Wechsler Memory Scale Revised (WMS-R)|Trail Making Test (TMT)|Visual Patterns Test (VPT)|Parahippocampal activation|Memory-related functional connectivity using Granger Causality Analysis (GCA)|Change of brain structure|Change of brain function,06-Mar-17,https://ClinicalTrials.gov/show/NCT03070821376,A New Rehabilitation Treatment Following Stroke,Completed,No Results Available,Stroke,Behavioral: A New Rehabilitation Treatment following Stroke,The efficacy of multisensory vs. unisensory rehabilitation program for stroke participants with perceptual impairments at the acute vs. chronic stage of the disorder.|Changes in brain networks related to the recovery of perceptual and cognitive functions.,17-Nov-17,https://ClinicalTrials.gov/show/NCT02482688377,Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient,Completed,No Results Available,Alzheimer's Disease,Biological: GSK933776,"The temporal changes of amyloid beta levels in CSF after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment|The temporal changes of total and free amyloid beta levels in plasma after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment|The temporal changes of Tau and phosphor Tau - 181 levels in CSF after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment|Estimated pharmacokinetic parameters of AUC, Cmax and Tmax in CSF and plasma at multiple time points with various intervals.|To assess the safety and tolerability after single dose of GSK933776 administration.",14-Jun-17,https://ClinicalTrials.gov/show/NCT01424436378,Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients,Completed,Has Results,Parkinson's Disease,Drug: florbetapir F 18,Mean Cortical Amyloid Burden|Correlation Between Global Amyloid Burden and Clinical Measures of Cognitive Decline.|Correlation of Florbetapir SUVR With CSF Biomarker Values,11-Mar-13,https://ClinicalTrials.gov/show/NCT00857532379,Dietary Intake of Alpha-linolenic Acid in Elderly,Completed,No Results Available,"Cardiovascular Diseases|Inflammation|Metabolism Disorder, Lipid",Dietary Supplement: Rapeseed oil|Dietary Supplement: Sunflower oil,"Effects of diet supplementation on fatty acid composition in serum and red cell membrane phospholipids, at the end of dietary period|Pulse wave velocity (PWV)|Others",19-Jan-17,https://ClinicalTrials.gov/show/NCT03025620380,A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac),Completed,Has Results,Human Immunodeficiency Virus (HIV)|HIV Associated Neurocognitive Disorders (HAND),Drug: Maraviroc,Change in Neurocognitive Functioning|Change in CSF Neopterin Concentration|Change in MRS Cerebral Metabolite Ratios in Basal Ganglia|Change in MRS Cerebral Metabolite Ratios in Frontal White Matter,20-May-16,https://ClinicalTrials.gov/show/NCT01449006381,"Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI and AD Subjects",Completed,No Results Available,Alzheimer's Disease,Drug: florbetapir F 18|Drug: 18F-AV-1451,Cross-sectional 18F-AV-1451 Imaging Results|Change in tau deposition over time|18F-AV-1451 imaging in healthy individuals,24-Aug-17,https://ClinicalTrials.gov/show/NCT02016560382,"Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy",Completed,Has Results,Delirium|Cognitive Impairment|Post-traumatic Stress Disorder|Depression|Anxiety,Drug: Haloperidol|Drug: Placebo,Efficacy of Low-dose Haloperidol in Reducing Delirium Incidence|Efficacy of Low-dose Haloperidol in Reducing Days With Delirium|Efficacy of Low-dose Haloperidol in Reducing ICU and Hospital Length of Stay|Efficacy of Low-dose Haloperidol in Reducing Cognitive Impairment at Post-operative Follow-up,13-Apr-17,https://ClinicalTrials.gov/show/NCT02213900383,Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease,Completed,No Results Available,Alzheimer's Disease,Drug: R-pramipexole,Number of Patients with Adverse Events|Reduction of Oxidative Stress|Changes in cerebral glucose metabolism|Effects on Cognitive Performance,25-Apr-16,https://ClinicalTrials.gov/show/NCT01388478384,Comparison of Tianeptine Versus Escitalopram Patients Major Depressive Disorder,Completed,No Results Available,Major Depressive Disorder,Drug: Tianeptine|Drug: Escitalopram,Changes in Hamilton Rating Scale for Depression(HAM-D)score from baseline|Changes in Korean version-California Verbal Learnign Test(K-CVLT) total score from baseline|Changes in Visual Continuous Performance Test(CPT) total score from baseline|Changes in Raven Progressive Matrices(RPM) total score from baseline|Changes in Hamilton Rating Scale for Anxiety(HAM-A) score from baseline|Changes in Clinical Clinical Global Impression- improvement(CGI-I)|Change in Response Rate from baseline|Change in Mini-Mental status examination(MMSE) total score from baseline|Change in Sexual Function Scale|Change in Clinical Global Impression- severity(CGI-S)|Change in Remission Rate from baseline,25-Jan-13,https://ClinicalTrials.gov/show/NCT01309776385,Trial of Ginkgo as a Treatment for Cognitive Problems in Multiple Sclerosis,Completed,Has Results,"Multiple Sclerosis|Cognitive Ability, General",Drug: Ginkgo biloba|Drug: Placebo,"Primary Outcome is Performance on the Interference Condition of the Stroop, the Long Delay Free Recall Portion of the California Verbal Learning Test II, the 2 Second Paced Auditory Serial Addition Test and the Controlled Oral Word Association Test.|Secondary Outcome: Measures of Self-report as Well as Family Reports of Subject's Cognitive Deficits and Assessment of Social Integration.",06-Jun-14,https://ClinicalTrials.gov/show/NCT00841321386,Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074,Completed,Has Results,Alzheimer's Disease,Drug: CHF 5074 1x|Drug: CHF 5074 2x|Drug: CHF 5074 3x|Drug: Placebo,Differences in ö sCD40L Levels Between CHF 5074 Doses and Placebo at Any Specific Time Point|Measurement of Trough CHF 5074 Plasma Levels|Changes in Plasma ëÓTNFë± Concentrations,11-Jan-16,https://ClinicalTrials.gov/show/NCT01303744387,A Study of LY3002813 in Participants With Alzheimer's Disease,Completed,No Results Available,Alzheimer Disease,Biological: LY3002813-IV|Biological: LY3002183-SC|Drug: Placebo-IV,Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics: Maximum Concentration (Cmax) of LY3002813|Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY3002813,26-Dec-17,https://ClinicalTrials.gov/show/NCT01837641388,A Safety Study of TTP4000 in Subjects With Alzheimer's Disease,Completed,No Results Available,Alzheimer's Disease,Drug: TTP4000|Drug: Placebo,Number of participant with adverse events|Evaluation of participant plasma TTP4000 concentrations,12-Feb-15,https://ClinicalTrials.gov/show/NCT01548430389,"Safety and Effectiveness of the Selegiline ""Patch"" for Decreased Mental Function in HIV Patients",Completed,No Results Available,Cognition Disorders|HIV Infections,Drug: Selegiline hydrochloride,"Change in cognitive performance Week 24 from screening|frequencies of adverse experiences, abnormal results on laboratory tests, changes over time in laboratory tests and vital signs|Clinical global impression by the investigator comparing selegiline-treated arms with the placebo arm|clinical global impression by the subject comparing selegiline-treated arms with the placebo arm|cognitive domain-specific scores compared between selegiline-treated arms and the placebo arm|neuropsychologic function tests (NPZ-8)|fatigue scale (quality of life)|markers of immune activation and oxidative stress/apoptosis|comparison of selegiline and active metabolite steady-state concentrations at Weeks 4, 12, and 24 to cognitive performance|comparison of selegiline and active metabolite steady-state concentrations at Weeks 4, 12, and 24 to historical data in normal volunteers after 7 days of transdermal selegiline administration|comparison of selegiline and active metabolite steady-state concentrations at Week 4 in subjects on ritonavir-containing protease inhibitor (PI) antiviral regimens, subjects on other PI regimens, and subjects on non-PI-containing antiviral regimens",21-May-12,https://ClinicalTrials.gov/show/NCT00013585390,Treating Cancer-Related Fatigue Through Systematic Light Exposure,Completed,No Results Available,Hematopoietic Stem Cell Transplantation|Breast Cancer|Fatigue|Mild Cognitive Impairment|Light|Quality of Life|Sleep,Device: Bright white light|Device: Dim red light,FACIT-Fatigue Scale|The Pittsburgh Sleep Quality Index|SF-36 Scale|CNS-Vital Signs|The Cognitive Failures Questionnaire|Brief Symptom Inventory-18|Actiwatch Spectrum,11-Apr-17,https://ClinicalTrials.gov/show/NCT01873794391,Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia,Completed,No Results Available,Schizophrenia,Drug: AZD3480,"Domain scores for Attention/Vigilance, Working Memory, Verbal Learning, Speed of Processing and Verbal Fluency as measured on the IntegNeuro computerized test battery of cognitive function|UCSD Performance Based Skills Assessment (UPSA2) and on the Social Functioning Scale (SFS)",25-Nov-08,https://ClinicalTrials.gov/show/NCT00528905392,"A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI",Completed,No Results Available,Alzheimer's Disease,Drug: donezepil (Aricept),"Neuropsychologic test scores: GMLT, DSST, Cog State TM including PAL test, RAVLT, ADAS-cog at baseline (pre-dose) 5 and 8 hours after the first dose and 2 and 6 weeks. (Continues in next bullet.)|MRS (Magnetic Resonance Spectroscopy) profile including but not limited to NAA (N-acetyl-aspartate), NAA/Cr (N-acetyl-aspartate/creatinine ratio), MI (Myoinositol) and MI/Cr (Myoinositol/creatinine ratio).",05-Feb-08,https://ClinicalTrials.gov/show/NCT00483028393,Exercise Periodization and Older Adults,Completed,No Results Available,Aging|Physical Activity|Sarcopenia|Cognitive Decline|Blood Pressure|Physical Disability,Other: Physical exercise,Changes in transfer capacity in seconds|Changes in fat-free mass in kg|Changes in overall cognitive capacity in points|Changes in blood pressure in mmHg|Changes in shor-term memory in points,23-Feb-18,https://ClinicalTrials.gov/show/NCT03443375394,Study of the Effects of Cerefolin NAC on Inflammation Blood Markers in Older Individuals With Memory Complaints,Completed,Has Results,Subjective Memory Loss in Older Persons,Other: Cerefolin NAC (a medical food)|Other: Cerefolin NAC placebo,"Six Month Blood Levels of Homocysteine, Glutathione, and the Ratio of Aë_42 to Aë_40 (as a Percent of Baseline Levels) After Daily Intake of Cerefolin NAC Plus a Multivitamin Versus a Multivitamin Only|Tolerability of Cerefolin NAC and a Multivitamin Versus a Multivitamin Only|Six Month Levels of Inflammation and Oxidative Stress Markers(as a Percent of Baseline Levels) After Daily Treatment With Cerefolin NAC and a Multivitamin or a Multivitamin Only",23-May-13,https://ClinicalTrials.gov/show/NCT00597376395,Research Study of Bipolar Mood Symptoms and Cognitive Problems,Completed,Has Results,Bipolar Disorder,Drug: Valacyclovir|Drug: Placebo,Percent Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status at 16 Weeks|Change From Baseline in Montgomery Asberg Depression Score at 16 Weeks,11-Apr-17,https://ClinicalTrials.gov/show/NCT00428298396,Functional Magnetic Resonance Imaging (fMRI) Investigation of Nicotine Withdrawal Symptoms,Completed,Has Results,Smoking,Drug: Nicotine|Drug: Placebo,Percent Mean Change in Blood Oxygen-level Dependent (BOLD) Scores During Rapid Visual Information Processing (RVIP) Task|Mean Response Time for Correct Responses During RVIP Task|Mean Percentage of Correct Responses During RVIP Task|Percent Mean Change in BOLD Scores During Divided Attention (DIA) Task|Mean Response Time for Correct Responses During DIA Task|Mean Percentage of Correct Responses During DIA Task,02-Mar-15,https://ClinicalTrials.gov/show/NCT00657020397,Effects of Tremella Fuciformis on Improvement in Cognitive-Bio-Markers of Cognitive Functions,Completed,No Results Available,Healthy Adults With Subjective Memory Complaints,Dietary Supplement: TF 600mg|Dietary Supplement: TF 1200mg|Dietary Supplement: placebo,Changes from baseline in neurocognitive function (neurocognitive test batteries such as CANTAB)|Changes from baseline in brain structure analyzed using the computational approach|Changes from baseline in brain function analyzed using the computational approach (Blood oxygenation level dependent (BOLD) signal intensity)|Changes from baseline in brain biochemical metabolism analyzed using the computational approach (Brain metabolite concentrations assessed using magnetic resonance spectroscopy)|Change from baseline in Subjective Memory Complaints Questionnaire scores at 8th weeks|Number of participants with adverse events,01-Jul-15,https://ClinicalTrials.gov/show/NCT02377024398,The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury,Completed,No Results Available,Neuropathic Pain|Depression|Cognitive Impairment|Somatic Neuropathy|Autonomic Dysfunction,Dietary Supplement: Omega-3|Dietary Supplement: Vegetation Protein Powder|Dietary Supplement: InflanNox|Dietary Supplement: Anti-oxidant Network|Dietary Supplement: Chlorella,Change from baseline in nerve conduction velocity of somatic nerves at 3 and 6 months|Change in baseline in autonomic function scores on the Autonomic Standards Assessment Form at 3 and 6 months|Change in baseline pain scores on the Neuropathic Pain Questionnaire at 3 and 6 months|Change in baseline concentrations of pro-inflammatory eicosanoids at 3 and 6 months|Change in baseline depression scores on the Centre for Epidemiological Studies Depression Scale at 3 and 6 months|Change in baseline concentrations of peripheral tryptophan and other large neutral amino acids at 3 and 6 months|Change in baseline episodic learning and memory scores on the California Verbal Learning Test at 3 and 6 months|Change in baseline concentrations of serum tryptophan and kynurenine levels at 3 and 6 months,30-Jul-15,https://ClinicalTrials.gov/show/NCT02099890399,A Study to Compare Two Medications With an Inactive Medication and Look at the Effect on a Person's Mental Ability,Completed,Has Results,Cognition,Drug: Solifenacin|Drug: Oxybutynin|Drug: Placebo,Change From Baseline in Cognitive Function Composite Score - Power of Attention|Change From Baseline in Cognitive Function Composite Score - Continuity of Attention|Change From Baseline in Cognitive Function Composite Score - Quality of Working Memory|Change From Baseline in Cognitive Function Composite Score - Quality of Episodic Secondary Memory|Change From Baseline in Cognitive Function Composite Score - Speed of Memory|Change From Baseline in Postural Stability Test,15-Oct-12,https://ClinicalTrials.gov/show/NCT01126424400,Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Roflumilast|Drug: Placebo|Drug: Second generation antipsychotic,Change From Baseline in Spatial Span Test Score|Change From Baseline in Hopkins Verbal Learning Test (HVLT) Score|Dorsolateral Prefrontal Cortex Activation During the Rewarded Delayed Response Working Memory|Change From Baseline in the Continuous Performance Test (CPT)|Change From Baseline in Brief Assessment of Cognition in Schizophrenia: Symbol-Coding|Change From Baseline in Category Fluency Animal Naming Scores|Ventrolateral Prefrontal (VLPF) Cortex and Orbitofrontal (OFX) Cortex Activation During the Shift Trials|Ventral Striatum Activation During the Reward Trials|Change From Baseline in P300 Amplitude at the Midline Parietal Electrode (Pz)|Change From Baseline in Mismatch Negativity (MMN) Amplitude at the Midline Frontal Electrode (Fz)|Change From Baseline in Amplitude of the C1 Component of the Visual Evoked Potentials at the Midline Occipital Electrode (Oz)|Change From Baseline in High Beta/Low Gamma Power During Resting EEG|Change From Baseline in Frontal Theta Power (EEG) During N-Back Working Memory Task|Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score|Percentage of Participants Who Experience at Least 1 Treatment-Emergent Adverse Event|Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests|Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurement,03-Oct-16,https://ClinicalTrials.gov/show/NCT02079844401,"Cognition, Functioning and Quality of Life",Completed,No Results Available,Schizophrenia,Drug: Olanzapine & Quetiapine,"Primary outcome measures include changes in neurocognitive test scores, changes in measures of community functioning and quality of life.|Secondary outcomes include changes in treatment adherence, subjective satisfaction with antipsychotic drug therapy, clinical symptoms and side effects.",11-Oct-06,https://ClinicalTrials.gov/show/NCT00182442402,Adjuvant Therapy With Pergolide in Treating Cognitive Deficits in Schizophrenia,Completed,No Results Available,Schizophrenia,Drug: Pergolide,"The D1-specific dopaminergic modulation of prefrontal functions (executive control, working memory, control of semantic association) confirmed by a complex neuropsychological battery including a non - PFC activating control task|Influence of pergolide on psychopathology symptoms and extrapyramidal symptoms in comparison to placebo measured by specific rating scales, e.g. PANSS and Calgary Depression Scale",10-Feb-10,https://ClinicalTrials.gov/show/NCT01066403403,Safety and Effectiveness of Botulinum Toxin in Elderly Patients With Dementia and Muscle Stiffness,Completed,No Results Available,Dementia|Paratonia,Drug: Botulinum Toxin|Drug: Saline,Impact on care-giver burden|Visual Analogue Scale|Joint angle measurement|Pain|Global Assessment,08-Aug-14,https://ClinicalTrials.gov/show/NCT02212119404,The Efficacy of Using Volunteers to Implement a Cognitive Stimulation Program in Two Long-Term Care Homes,Completed,No Results Available,Impaired Cognition|Geriatric Disorder|Learning Disorders|Age-Related Memory Disorders|Impairment of Attention,Other: Cognitive stimulation program|Other: Standard Friendly Visit,"Test of Memory and Learning - Senior Edition (TOMAL-SE)|Wechsler Abbreviated Scale of Intelligence - Second Edition (WASI-II; Wechsler, 2011)",16-May-14,https://ClinicalTrials.gov/show/NCT01818778405,Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults,Completed,Has Results,Memory Impairment|Alzheimer's Disease,Drug: Roflumilast|Drug: Roflumilast placebo|Drug: Donepezil|Drug: Donepezil placebo|Drug: Scopolamine,Change From Baseline in the Verbal Recall Memory (VRM) Total Number of Correct Responses for Delayed Recall at 1 Hour After Scopolamine Administration|Change From Baseline in the Verbal Recall Memory (VRM) Total Number of Correct Responses for Immediate Recall at 1 Hour After Scopolamine Administration|Change From Baseline in the Verbal Recall Memory (VRM) Total Number of Correct Responses for Immediate and Delayed Recall at 2 and 4 Hours After Scopolamine Administration|Change From Baseline in the Paired Associates Learning (PAL) Total Number of Errors Adjusted at All Time-points Assessed After Scopolamine Administration|Change From Baseline in the Rapid Visual Information Processing (RVP) A Prime Signal Detection at All Time-points Assessed After Scopolamine Administration|Change From Baseline in the Rapid Visual Information Processing (RVP) Median Latency at All Time-points Assessed After Scopolamine Administration|Change From Baseline in the Spatial Working Memory (SWM) Total Number of Between Errors at the 10-Box Stage and the 12-Box Stage at All Time-points Assessed After Scopolamine Administration|Percentage of Participants Who Experience at Least 1 Treatment Emergent Adverse Event (TEAE)|Percentage of Participants With Markedly Abnormal Safety Laboratory Tests|Percentage of Participants With Markedly Abnormal Vital Sign Measurements at Least Once Post-dose|Percentage of Participants With Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at Least Once Post-Dose,01-Feb-17,https://ClinicalTrials.gov/show/NCT02051335406,Effects of Doxycycline on Persistent Symptoms Post-neuroborreliosis,Completed,No Results Available,Fatigue|Radicular Pain|Cognitive Dysfunction|Paresthesia|Paresis,Drug: Doxycycline|Drug: Placebo,Improvement in persistent symptoms|Changes in cytokine levels in plasma/serum in patients during treatment with DOX/PBO,20-Sep-10,https://ClinicalTrials.gov/show/NCT01205464407,Neurobiological and Neurocognitive Disturbances in First-episode Schizophrenia,Completed,No Results Available,Schizophrenia,Drug: quetiapine,"5-HT2A receptor binding and occupancy (PET)|Structural MRI|Functional MRI|Information procession as measured with psychophysiological methods (P300, PPI, P50 gating ect.)|An extensive battery of neurocognitive measures|PANSS",19-Sep-11,https://ClinicalTrials.gov/show/NCT00207064408,Macronutrient Effects on Alzheimer's Disease (MEAL-2),Completed,No Results Available,Prediabetic State|Insulin Resistance|Middle Age|Prehypertension|Mild Cognitive Impairment,Other: Low Diet|Other: High Diet,Change in cerebrospinal fluid levels of Alzheimer's disease biomarkers (CSF beta-amyloid 42)|Changes in brain structure|Changes in adipose tissue distribution (Change in dual energy x-ray absorptiometry (DEXA) scan and CT measures of central and subcutaneous body fat)|Changes in cognition (Change in delayed memory and executive function composites)|Change in brain function as measured by MRI|Change in brain perfusion,06-Nov-17,https://ClinicalTrials.gov/show/NCT02463084409,Treatment With Namenda in Women at Risk for Cognitive Decline,Completed,Has Results,Dementia,Drug: Namenda,Change in California Verbal Learning Test - Second Edition Proactive Interference Test Between Time 1 and Time 2|Change in Delis-Kaplan Executive Function System (DKEFS) Verbal Fluency Category Switching Between Time 1 and Time 2,14-Jun-17,https://ClinicalTrials.gov/show/NCT00242632410,Attention and Memory Training With Video Games in Old Age,Completed,No Results Available,Ageing,Behavioral: Experimental: Non-action video game training|Behavioral: Active Comparator: Non-cognitive video game training,STROOP-Negative Priming|ODDBALL|N-BACK|CORSI BLOCK|Improvement of the performance (accuracy scores) obtained on the non-action video games (experimental group) and the non-cognitive video games (active comparator) comparing accuracy scores of the first to the last training session.|Level of motivation assessed with a questionnaire,30-Oct-17,https://ClinicalTrials.gov/show/NCT02796508411,Cognitive Effects of Inhalational Versus Intravenous General Anesthesia in the Elderly,Completed,Has Results,Lumbar Spondylosis|Cervical Spondylosis|Hip Osteoarthritis|Knee Osteoarthritis,Drug: inhalation anesthesia with isoflurane vs. TIVA with propofol,Change in Neurocognitive Performance (Z-score),26-Mar-15,https://ClinicalTrials.gov/show/NCT00788008412,Evaluation of the H1-coil Deep TMS in the Treatment of Negative Symptoms and Cognitive Deficit in Schizophrenia,Completed,No Results Available,Schizophrenia,Device: deep TMS H-coil,,06-May-10,https://ClinicalTrials.gov/show/NCT00445926413,Iowa Healthy and Active Minds Study,Completed,No Results Available,Visual Processing Speed,Behavioral: SOPT basic training|Behavioral: Crossword Puzzles|Behavioral: SOPT booster training,Useful Field of View Test|Digit Vigilance Test|Symbol Digit Modalities Test|Controlled Oral Word Association Test|Comprehensive Trail Making Test|Stroop,02-May-18,https://ClinicalTrials.gov/show/NCT01165463414,Cognitive Aging and Training With Video-games,Completed,No Results Available,Aging|Healthy,Other: Non-action video game training,Neuropsychological testing|Oddball task|Wisconsin task|Speed of processing task|Spatial working memory (WM)|Efficacy of non-action video game training,28-May-15,https://ClinicalTrials.gov/show/NCT02007616415,Effects of Napping in Sleep-Restricted Adolescents,Completed,No Results Available,Sleep Deprivation|Sleep,Behavioral: Nap,Change in sustained attention assessed with the Psychomotor Vigilance Task from morning to afternoon and then evening from baseline days to the first and second cycles of sleep restriction and recovery|Change in working memory assessed with the 1-back task from morning to afternoon and then evening from baseline days to the first and second cycles of sleep restriction and recovery|Change in executive functions assessed with the 3-back task from morning to afternoon and then evening from baseline days to the first and second cycles of sleep restriction and recovery|Change in the level of subjective sleepiness assessed with the Karolinska Sleepiness Scale from morning to afternoon and then evening from baseline days to the first and second cycles of sleep restriction and recovery|Change in positive mood assessed with the Positive and Negative Affect Scale (PANAS) from morning to afternoon and then evening from baseline days to the first and second cycles of sleep restriction and recovery|Change in negative mood assessed with the Positive and Negative Affect Scale (PANAS) from morning to afternoon and then evening from baseline days to the first and second cycles of sleep restriction and recovery|Change in speed of processing assessed with the Mental Arithmetic Task from morning to afternoon and then evening from baseline days to the first and second cycles of sleep restriction and recovery|Change in speed of processing assessed with the Symbol Digit Modalities Task from morning to afternoon and then evening from baseline days to the first and second cycles of sleep restriction and recovery|Change in total sleep duration at night assessed with polysomnography from baseline nights to the first and second cycles of sleep restriction and recovery|Change in N1 sleep duration at night assessed with polysomnography from baseline nights to the first and second cycles of sleep restriction and recovery|Change in N2 sleep duration at night assessed with polysomnography from baseline nights to the first and second cycles of sleep restriction and recovery|Change in N3 sleep duration at night assessed with polysomnography from baseline nights to the first and second cycles of sleep restriction and recovery|Change in REM sleep duration at night assessed with polysomnography from baseline nights to the first and second cycles of sleep restriction and recovery|Change in total sleep duration during daytime naps assessed with polysomnography from the first to the second sleep restriction period|Change in N1 sleep duration during daytime naps assessed with polysomnography from the first to the second sleep restriction period|Change in N2 sleep duration during daytime naps assessed with polysomnography from the first to the second sleep restriction period|Change in N3 sleep duration during daytime naps assessed with polysomnography from the first to the second sleep restriction period|Change in REM sleep duration during daytime naps assessed with polysomnography from the first to the second sleep restriction period,20-Jul-16,https://ClinicalTrials.gov/show/NCT02838095416,Deep Brain Stimulation for Patients With Dementia With Lewy Bodies,Completed,No Results Available,Dementia With Lewy Bodies,Procedure: Bilateral Nucleus Basalis Meynert DBS|Procedure: Sham Nucleus Basalis Meynert DBS,"Hopkins Verbal Learning test|Verbal Fluency|Simple & Choice Reaction time task|Wechsler Adult Intelligence scale (WAIS IV) Digit Span|Posner's Covert Attention test|Clinician's Assessment of Fluctuations scale|Minimental State Examination (MMSE)|Dementia Rating Scale (DRS-2)|Wechsler Abbreviated Scale of Intelligence (WASI)|Short Recognition Memory|Wechsler Adult Intelligence Scale IV -Letter, Number sequencing|Trail Making test|Stroop test|Wechsler Adult Intelligence Scale IV - Symbol search|Judgement of Line Orientation|North East Visual Hallucinations Interview|Neuropsychiatric Inventory|Florida Apraxia Screening test|Clinical Global Impression Scale|Hamilton Depression scale|Hamilton Anxiety Scale|Starkstein Apathy Rating scale|Movement Disorders Society- Unified Parkinson's Disease Rating Scale|Freezing of Gait- questionnaire|Scales for outcome in Parkinson's disease (SCOPA - AUT)|Quality of Life- Alzheimer's Disease|Mayo Fluctuations Composite Scale|Blessed Dementia scale|Carer Strain Index|Short Form 36",31-Oct-16,https://ClinicalTrials.gov/show/NCT02263937417,EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer,Completed,Has Results,Breast Cancer|Neurotoxicity,Drug: Ginkgo Biloba|Other: Placebo,The Level of Cognitive Dysfunction as Measured by the High Sensitivity Cognitive Screen (HSCS) Overall Score.|Median Scores for Trail Making Tests A and B (Lower Scores Are Better).|Secondary Measure of Cognitive Function Using Trail Making Tests (TMT) A and B.|Self-reported Symptoms or Side Effects Using Symptom Experience Diary (SED)|Associations Between Self-reported Cognition and the HSCS.|Associations Between Self-report Measures of Cognition and the Trail Making Test (TMT) A and B.,06-Jul-16,https://ClinicalTrials.gov/show/NCT00046891418,Nucleus Basalis Deep Brain Stimulation for Thinking & Memory Problems in Parkinson's.,Completed,No Results Available,Dementia in Parkinson's Disease,Device: NBM DBS,"Abbreviated cognitive battery|Minimental State Examination|DRS-2|SRM (Faces)|WAIS-III (Letter number sequencing, Arithmetic)|FAST|NPI|BDS|HAM-D|MDS UPDRS|PDQ39|GFQ|NMS Quest",31-Oct-16,https://ClinicalTrials.gov/show/NCT01701544419,Cytokines and Cognitive Decline in Alzheimer's Disease,Completed,No Results Available,Alzheimer's Disease,Other: blood test and cognitive tests,,11-Oct-16,https://ClinicalTrials.gov/show/NCT01351142420,Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors,Completed,Has Results,"Cognitive/Functional Effects|Metastatic Cancer|Neurotoxicity|Unspecified Adult Solid Tumor, Protocol Specific",Drug: Memantine|Other: Placebo|Radiation: Whole brain radiation therapy,"Change in the Hopkins Verbal Learning Test - Revised for Delayed Recall (HVLT-R-delayed Recall) at 24 Weeks|Change in the Hopkins Verbal Learning Test - Revised for Delayed Recall (HVLT-R-delayed Recall) at 8, 16, and 52 Weeks|Median Time to Neurocognitive Failure|Change in Functional Assessment of Cancer Therapy With Brain Subscale (FACT-Br) at 24 Weeks|Median Progression-free Survival Time|Overall Survival",21-Aug-17,https://ClinicalTrials.gov/show/NCT00566852421,VITAL - VITamins to Slow ALzheimer's Disease (Homocysteine Study),Completed,No Results Available,Alzheimer's Disease,Drug: Folate|Drug: Vitamin B6|Drug: Vitamin B12,,12-Jun-09,https://ClinicalTrials.gov/show/NCT00056225422,Intellectual Impairment in Women With Breast Cancer,Completed,No Results Available,Breast Cancer,Behavioral: Cognitive Rehabilitation|Behavioral: Neurofeedback Training (randomized)|Behavioral: Neuropsychological testing and MRI assessments,Examine the effectiveness of a cognitive rehabilitation program for improving executive function (EF) deficits and a neurofeedback training program for preventing or lessening EF impairments in women with Breast Cancer..|Identify genetic and demographic predictors of cognitive impairment in women with Breast Cancer.|Determine the profile of cognitive-behavioral impairments in women with BC related to adjuvant chemotherapy.,30-May-14,https://ClinicalTrials.gov/show/NCT00896324423,Treating Thought Problems in Patients With Schizophrenia,Completed,No Results Available,Schizophrenia,Behavioral: Cognitive Adaptation Therapy (CAT)|Behavioral: Minimal Environmental Supports (MES),Primary,09-Apr-13,https://ClinicalTrials.gov/show/NCT00051740424,Beyond Ageing Project: A Study for the Prevention of Depression,Completed,No Results Available,Depression|Depressive Disorder,Drug: Folate (400mcg) and Vitamin B12 (100 mcg)|Behavioral: mediated physical activity promotion|Behavioral: Mental health literacy|Drug: placebo|Behavioral: Nutrition information|Behavioral: pain and arthritis management information,Depression|Physical activity level|Cognitive impairment|Physical health outcomes|B12 levels|Folate status|Homocysteine,13-Sep-11,https://ClinicalTrials.gov/show/NCT00214682425,Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer,Completed,No Results Available,Cognitive/Functional Effects|Delirium|Depression|Lung Cancer|Radiation Toxicity,Dietary Supplement: vitamin E|Drug: donepezil hydrochloride|Other: placebo,Compare the interval between completion of cancer treatment that included prophylactic cranial irradiation and onset of cognitive decline in patients with small cell lung cancer (SCLC) treated with donepezil and vitamin E vs placebo|Quality of life,13-Jul-16,https://ClinicalTrials.gov/show/NCT00006349426,Neural Substrates in Nicotine Withdrawal,Completed,Has Results,Tobacco Use Disorder,Drug: Tolcapone|Drug: Placebo,"Measure of Brain Activity: Blood Oxygen Level Dependent (BOLD) fMRI Signal Change During the ""N-back"" Working Memory Task (Brain Region: Right Dorsolateral Prefrontal Cortex; Right DLPFC)|Measure of Brain Activity: Blood Oxygen Level Dependent (BOLD) fMRI Signal Change During the ""N-back"" Working Memory Task (Brain Region: Left Dorsolateral Prefrontal Cortex; Left DLPFC)|Measure of Brain Activity: Blood Oxygen Level Dependent (BOLD) fMRI Signal Change During the ""N-back"" Working Memory Task (Brain Region: Dorsal Cingulate/Medial Prefrontal Cortex; MF/CG)|Measure of Brain Activity: Blood Oxygen Level Dependent (BOLD) fMRI Signal Change During the ""N-back"" Working Memory Task (Brain Region: Posterior Cingulate Cortex; PCC)|Measure of Brain Activity: Blood Oxygen Level Dependent (BOLD) fMRI Signal Change During the ""N-back"" Working Memory Task (Brain Region: Ventromedial Prefrontal Cortex; vmPFC)|Cognitive Performance: Accuracy|Cognitive Performance: Reaction Time|Subjective Symptoms: Smoking Behavior|Subjective Symptoms: Cigarette Craving|Subjective Symptoms: Withdrawal Symptoms",02-Jul-14,https://ClinicalTrials.gov/show/NCT01001520427,A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elapraseå¨,Completed,Has Results,Hunter Syndrome,Other: Control|Drug: Idursulfase IT (1 mg)|Drug: Idursulfase IT (10 mg)|Drug: Idursulfase IT (30 mg),Number of Serious Adverse Event (SAE)|Number of Treatment Emergent Adverse Event (AE)|Safety Changes in Cerebrospinal Fluid (CSF)- White Blood Cells (WBC)|Safety: Development of Anti-idursulfase Antibodies (CSF)|Safety: Development of Anti-idursulfase Antibodies (Serum)|Clinically Significant ECG Findings at Any Time During the Study.|Change From Baseline in CSF Glycosaminoglycans [GAGs] at Week 27|Level of Idursulfase in the CSF Compartment Resulting From Monthly Idursulfase IT Administrations|Concentration of Idursulfase in Serum After Single Administration (Week 3) in Conjunction With Elaprase|Concentration of Idursulfase in Serum After Repeated Doses of Intrathecal Idursulfase-IT Given in Conjunction With Elaprase|% Change From Baseline in Urinary GAG,28-Oct-15,https://ClinicalTrials.gov/show/NCT00920647428,Psychosocial Treatment for Attention Deficit Hyperactivity Disorder in Adults,Completed,Has Results,Attention Deficit Disorder With Hyperactivity,Behavioral: Meta-Cognitive Therapy|Behavioral: Supportive Therapy,"Inattention Subscale|Time Management, Organization, and Planning Subscale|CAARS-O:L|Beck Depression Inventory|Hamilton Anxiety Rating Scale|Rosenberg Self-Esteem Inventory",04-Apr-17,https://ClinicalTrials.gov/show/NCT00278473429,Effects of LEDs on Memory in TBI Patients,Completed,Has Results,Traumatic Brain Injury,Device: MedX Health Phototherapy (light therapy),"Stroop Test for Executive Function - Trial 3 - Inhibition|Stroop Test for Executive Function - Trial 4 Inhibition Switching|California Verbal Learning Test-II (CVLT-II) Total, Trials 1-5|California Verbal Learning Test-II (CVLT-II) Long Delay Free Recall|Controlled Oral Word Association Test (FAS)|Digit Span, Forwards and Backwards",30-Sep-16,https://ClinicalTrials.gov/show/NCT01598532430,Effectiveness of Targeted Cognitive Training for Neurological Deficits in People With Schizophrenia,Completed,No Results Available,Schizophrenia,Behavioral: Targeted cognitive training (TCT)|Behavioral: Computer games,Cognitive performance as measured by a neuropsychological battery|Symptom profile as measured by clinical interviews|Quality of life as measured by clinical interviews,11-Mar-14,https://ClinicalTrials.gov/show/NCT00312962431,Activities for Cognitive Enhancement of Seniors,Completed,No Results Available,Aging,Behavioral: Tai Chi|Behavioral: Guided autobiography|Behavioral: Qigong|Behavioral: Successful aging|Behavioral: Combination|Behavioral: Comparison,Cognitive (executive function and episodic memory)|Other cognitive measures|Physical performance and other non-cognitive measures|Adherence and retention,20-Nov-14,https://ClinicalTrials.gov/show/NCT01094509432,DanceFit Prime: A Dance Based Physical Activity and Nutritional Intervention for Primary Care - A Feasibility Study,Completed,No Results Available,Cardiac Diseases|Stroke|Diabetes Mellitus|Dementia|Mild Cognitive Impairment,"Behavioral: Facilitated group-based aerobic dance|Behavioral: Online, video prompted, individual aerobic dance|Behavioral: Facilitated group-based nutritional intervention|Behavioral: Self-paced online aerobic dance activity|Behavioral: Individual self-paced nutritional intervention",Recruitment and retention rates|Activity adherence rates|Level of physical activity participation|10 year risk of cardiac or cerebral ischaemic event|10 year risk of developing diabetes mellitus,14-Oct-15,https://ClinicalTrials.gov/show/NCT02159014433,Biomarkers in Schizophrenia,Completed,Has Results,Schizophrenia|Schizoaffective Disorder,Drug: D Serine|Drug: Placebo,PANSS Total|MMN Amplitude|MATRICS|Visual P1,02-Aug-17,https://ClinicalTrials.gov/show/NCT00817336434,Comparison of Neuroprotection by Propofol and Desflurane for POCD Following Subarachnoid Hemorrhage Surgery,Completed,No Results Available,Postoperative Cognitive Function,Drug: Propofol|Drug: Desflurane,Assessment of cognitive function at one month following surgery.|Assessment of cognitive function preoperatively Assessment of cognitive function at discharge. Comparison of biomarker of cognitive dysfunction|Assessment of cognitive function preoperatively Assessment of cognitive function at the time of discharge from hospital|Comparison of biomarker (S-100B) levels,08-Dec-16,https://ClinicalTrials.gov/show/NCT02987218435,Treatment of Traumatic Brain Injury With Hyperbaric Oxygen Therapy,Completed,No Results Available,"Brain Injury, Chronic",Other: Hyperbaric oxygen @ 2.4 ATA,Computer cognitive test scores|Posttraumatic Stress Disorder Checklist - Military Version (PCL-M) scores|Functional MRI|Biomarkers,04-Mar-13,https://ClinicalTrials.gov/show/NCT00810615436,Physicians' Health Study II,Completed,No Results Available,Cancer|Prostate Cancer|Colorectal Cancer|Cardiovascular Disease|Eye Disease|Cognitive Decline,Dietary Supplement: Vitamin E|Dietary Supplement: Vitamin C|Dietary Supplement: Multivitamin|Dietary Supplement: Beta-carotene,Prostate cancer|Total cancer|Major cardiovascular events|Cataract|Age-related macular degeneration|Early cognitive decline|Myocardial infarction|Stroke|Colorectal cancer,28-Feb-18,https://ClinicalTrials.gov/show/NCT00270647437,Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder,Completed,No Results Available,Major Depressive Disorder,Drug: Vortioxetine 10-20 mg|Drug: Escitalopram 10-20 mg,Change in Digit Symbol Substitution Test (DSST)|Change in Rey Auditory Verbal Learning Test (RAVLT)|Change in Trail Making Test A (TMT-A)|Change in Trail Making Test B (TMT-B)|Change in Reaction time score; CRT attention|Change in reaction time score SRT - simple reaction time|Change in STROOP incongruent score|Change in STROOP congruent score|Change in Perceived Deficits Questionnaire - Depression (PDQ-D) total score|Change in Patient Health Questionnaire-9 (depressive symptoms) (PHQ-9) total score|Change in Clinical Global Improvement - Severity (CGI-S)|Clinical Global Improvement (CGI-I)|Change in Functioning Assessment Short Test (FAST)|Change in University of San Diego Performance-based Skills Assessment - Brief (UPSA-B) total score,28-Feb-17,https://ClinicalTrials.gov/show/NCT02272517438,The Effects of Varenicline on Cognitive Function in Patients With Schizophrenia,Completed,No Results Available,Schizophrenia,Drug: Varenicline(Chantix)|Drug: Placebo,"To examine the effects of varenicline treatment used concomitantly with antipsychotic medications, on cognitive dysfunction in people with schizophrenia.|To evaluate the effect of this combination therapy on smoking in people with schizophrenia.",06-Aug-09,https://ClinicalTrials.gov/show/NCT00523445439,A Study of LY2886721 in Healthy Participants,Completed,No Results Available,Healthy Volunteers,Drug: LY2886721|Drug: Placebo,"Number of participants with clinically significant effects|Pharmacokinetics: Plasma maximum observed concentration at steady state (Cmax,ss) of LY2886721|Pharmacokinetics: Plasma area under the concentration versus time curve (AUC) of LY2886721|Change from baseline in cerebrospinal fluid (CSF) amyloid 1-40 concentration at Day 15|Change from baseline in cerebrospinal fluid (CSF) amyloid 1-40 concentration at 24 hours post-dose",10-Aug-12,https://ClinicalTrials.gov/show/NCT01534273440,Insomnia and Cognitive Performance in Chronic Pain,Completed,No Results Available,Chronic Pain|Insomnia,Diagnostic Test: Neuropsychological assessment,Memory impairment|Executive functioning impairment,07-Mar-17,https://ClinicalTrials.gov/show/NCT03072745441,Knowing and Remembering: Cognitive and Neural Influences of Familiarity on Recognition Memory in Early Alzheimer's Disease,Completed,No Results Available,Alzheimer's Disease,Other: Neuropsychological tests|Device: A cranial MRI|Other: Experimental procedure,"Improvement of recognition memory accuracy measures under the familiarity condition as compared with the novel condition in the AD-MCI group|Significant effect of the familiarity vs novelty condition on the pattern of % BOLD signal change in across the brain in the AD-MCI group|Significant group effect on the pattern of % BOLD signal change in across the brain|Predictive validity of the brain % BOLD signal change pattern for participants clinical status (i.e. controls vs. AD-MCI)|Significant interaction between the kind of familiarity condition (i.e. novel, experimental or pre-experimental) and the estimates of recognition memory processes efficiency (i.e. respective contributions of recollection and familiarity, % correct)",23-Jan-18,https://ClinicalTrials.gov/show/NCT02492529442,Study on the Efficacy of Speed-Feedback Therapy for Elderly People With Dementia,Completed,No Results Available,Dementia,Device: Speed-feedback therapy system with a bicycle ergometer|Device: Ergometer at conventional settings,"score on a scale of cognitive function immediately after completion of the 6-week intervention and 1 month after completion of the intervention|attentiveness score immediately after completion of the intervention, and score on an ADL scale and a QOL scale immediately after completion of the intervention and 1 month after completion of the intervention",21-Mar-07,https://ClinicalTrials.gov/show/NCT00450047443,A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions,Completed,No Results Available,Parkinson Disease|Huntington Disease|Autistic Spectrum Disorders|Fragile X Syndrome|Alzheimer Disease|Mild Cognitive Impairment,Drug: [18F]FPEB,Does FPEB reliably represent the known distribution of MGLUR5 in the brain?,06-Jan-17,https://ClinicalTrials.gov/show/NCT00870974444,"The Effects of tDCS on Auditory Hallucination, Insight, Neurocognitive Function and HRV in Patients With Schizophrenia",Completed,No Results Available,"Schizophrenia|Schizoaffective Disorder|Auditory Hallucination, Verbal|Neurocognitive Dysfunction|Autonomic Imbalance|Psychosocial Impairment|Quality of Life",Device: tDCS,"Changes from baseline scores of Auditory Hallucination Rating Scale (AHRS) at the timepoint immediately after tDCS, at one month and three months after tDCS.|Changes from baseline scores of Positive and Negative Syndrome Scale (PANSS) at the timepoint immediately after tDCS, at one month and three months after tDCS.|Changes from baseline scores at Personal and Social Performance scale (PSP) at the timepoint immediately after tDCS, at one month and three months after tDCS.|Changes from baseline results of Digit span (forward and backward)|Changes from baseline results of Finger tapping test|Changes from baseline results of Continuous Performance (CPT, version 2.0)|Changes from baseline results of Wisconsin Card Sorting Test (WCST) at the timepoint immediately after tDCS and at one month after tDCS.|Changes from baseline results of Trail Making Test (TMT) at the timepoint immediately after tDCS and at one month after tDCS.|Changes from baseline results of Tower of London test at the timepoint immediately after tDCS and at one month after tDCS.|Changes from baseline heart rate variability (HRV) at the timepoint immediately after tDCS and at one month after tDCS.|Changes from baseline scores of the brief version of questionnaire of The World Health Organization Quality of Life (WHOQOL-BREF Taiwan version) at the timepoint immediately after tDCS and at one month after tDCS.|Changes from baseline scores of self-reported version of the graphic Personal and Social Performance scale (SRG-PSP) at the timepoint immediately after tDCS and at one month after tDCS.|Changes from baseline scores of the abbreviated version of the Scale to Assess Unawareness in Mental Disorder in schizophrenia (SUMD) at the timepoint immediately after tDCS, at one month and three months after tDCS.|Changes from baseline scores of the Taiwanese version of the Beck Cognitive Insight Scale (BCIS) at the timepoint immediately after tDCS and at one month after tDCS.|Changes from baseline scores of the Taiwanese version of the Self- Appraisal of Illness Questionnaire (SAIQ) at the timepoint immediately after tDCS and at one month after tDCS.",01-May-18,https://ClinicalTrials.gov/show/NCT03388554445,Long-term Follow Up of Adult Patients Treated With Extracorporeal Membrane Oxygenation for Respiratory Failure,Completed,No Results Available,Long Term Adverse Effects|Pneumonia|Acute Respiratory Distress Syndrome|Sepsis|Critical Illness|Cognitive Impairment|Extracorporeal Circulation; Complications,Radiation: High-resolution computed tomography|Radiation: Magnetic resonance imaging|Behavioral: Cognitive testing,"Number of participants with abnormal cognitive functioning assessed by the Wechsler Adult Intelligence Scale and memory tests|Number of participants with abnormal brain imaging assessed by magnetic resonance imaging|Number of Participants With Abnormal Pulmonary function|Number of Participants With Abnormal Lungs radiographic findings assessed by high-resolution CT scan|Number of participants with signs of post-traumatic stress assessed by the Trauma Screening Questionnaire|Number of participants with signs of a reduced health related quality-of-life, assessed by the Short Form-36|Number of participants with signs of a reduced Health related quality-of-life, assessed by the S:t Georgeå«s Respiratory Questionnaire|Number of participants with signs of a reduced exercise tolerance|Number of participants with signs of anxiety and depression assessed by the Hospital and Anxiety Depression Scale",25-Jan-17,https://ClinicalTrials.gov/show/NCT03031275446,Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers,Completed,No Results Available,Alzheimer's Disease,Drug: Experimental 1|Drug: Placebo Comparator,"Evolution of the volume of the Hippocampi, measured by magnetic resonance imaging (MRI), between D0 and final visit (12 months ).|Evolution of the neuropsychological scores between Day 0 and final visit.",14-Jul-14,https://ClinicalTrials.gov/show/NCT00403520447,"The Effect of Folic Acid on Atherosclerosis, Cognitive Performance and Hearing",Completed,No Results Available,Atherosclerosis|Vascular Disease|Cognitive Decline|Hearing Loss|Inflammation|Age-Related Memory Disorder,Behavioral: folic acid (0.8 mg),"Change in mean carotid intima-media thickness|Change in maximum carotid intima-media thickness|Change in carotid distension|Change in hearing levels (pure tone air conduction averages of 0.5, 1, and 2 kHz & 4, 6 and 8 kHz)|Cognitive performance at year 3 (cognitive domains: simple speed, cognitive flexibility, and memory; and information processing speed and semantic memory)|Inflammatory markers and hemostasis markers",31-Dec-08,https://ClinicalTrials.gov/show/NCT00110604448,Performances of a Brief Assessment Tool for the Early Diagnosis of Geriatric Syndromes by Primary Care Physicians,Completed,No Results Available,Cognitive Impairment|Mood Disorders|Urinary Incontinence|Malnutrition|Osteoporosis|Hearing Impairment|Visual Impairment,Other: brief geriatric assessment,Sensibility and specificity,09-Jan-18,https://ClinicalTrials.gov/show/NCT01816087449,Anti-Inflammatory Treatment for Age-Associated Memory Impairment: A Double-Blind Placebo-Controlled Trial,Completed,No Results Available,Memory Disorders,Drug: Celecoxib,,08-May-17,https://ClinicalTrials.gov/show/NCT00009230450,Brain Imaging and Mental Disorders of Aging Intervention,Completed,No Results Available,Cognition Disorders,Drug: donepezil|Drug: Placebo,"Changes in cognition and brain metabolism measured by PET and MRI scans, and neuropsychological testing",29-Aug-08,https://ClinicalTrials.gov/show/NCT00267163451,Quetiapine (Seroquel) Maintenance Treatment in Early Onset Bipolar Spectrum Disorders,Completed,No Results Available,Bipolar Disorder,Drug: Quetiapine,Proportion of treated study patients maintained on monotherapy for the duration of the trial compared to the proportion requiring systematic adjunctive medication.|Time to an episode recurrence (Montgomery-Asberg Depression Rating Scale|/Young Mania Rating Scale [MADRS/YMRS] > 15)|Time to hospitalization|Autobiographical Memory Interview (AMI) mean score over treatment|Clinical Global Impression-Bipolar Disorder (CGI-BP) score during treatment and at study completion|YMRS total score during treatment and at study completion|MADRS total score during treatment and at study completion,04-Jun-08,https://ClinicalTrials.gov/show/NCT00252226452,Efficacy of 1072nm Infrared Stimulation on Executive Functioning in Dementia,Completed,No Results Available,Dementia,Device: 1072nm infrared light stimulation,change in cerebral oxygenation as measured by infrared spectroscopy.|changes in neuropsychological and functional behaviors as observed by the primary caregivers and the subject.,24-Feb-12,https://ClinicalTrials.gov/show/NCT01059877453,Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia,Completed,Has Results,Schizophrenia,Drug: rasagiline (Pharmacodynamics)|Drug: Placebo,Change in Negative Symptoms|Cognitive Testing - Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Score|Cognitive Testing - N-Back Neurocognitive Task|Cognitive Testing - Probabilistic Learning Task|Cognitive Testing - Delayed Discounting|Extrapyramidal Symptoms|Number of Participants With Akathisia|Change in Persistent Positive Symptoms|Depressive Symptoms|Global Change in Illness Severity|Number of Participants Exhibiting Side Effects,20-Apr-18,https://ClinicalTrials.gov/show/NCT00492336454,Cognitive Remediation Therapy and Schizophrenia,Completed,No Results Available,Schizophrenia,Behavioral: cognitive remediation therapy|Behavioral: non-CRT,"cognitive deficits (attention/concentration, topological memory, logical reasoning, executive functions)|brain functioning (fMRI)|schizophrenia symptoms",25-Feb-14,https://ClinicalTrials.gov/show/NCT01078129455,Effect of Tai Chi on Osteoarthritic Knee Pain in Elders With Mild Dementia,Completed,No Results Available,"Osteoarthritis, Knee|Dementia",Behavioral: Tai Chi|Behavioral: Attention control,Change from baseline in pain at Week 5|Change from baseline in pain at Week 9|Change from baseline in pain at Week 13|Change from baseline in pain at Week 17|Change from baseline in pain at Week 21|Physical function|Cognitive function|Stiffness|Quadriceps strength|Pain level (each session),08-Feb-12,https://ClinicalTrials.gov/show/NCT01528566456,Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease,Completed,No Results Available,Alzheimer's Disease,Drug: ST101|Drug: Placebo,"Alzheimer's Disease Assessment Scale, cognitive subscale (ADAS-cog)|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|Neuropsychiatric Inventory (NPI)|Alzheimer's Disease Cooperative Study- Clinical Global Impression (ADCS-CGI)",07-Jun-12,https://ClinicalTrials.gov/show/NCT00842816457,Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease,Completed,No Results Available,Alzheimer's Disease,Drug: ST101|Drug: Placebo,"Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-cog)|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|Neuropsychiatric Inventory (NPI)|Alzheimer's Disease Cooperative Study- Clinical Global Impression (ADCS-CGI)",07-Jun-12,https://ClinicalTrials.gov/show/NCT00842673458,An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.,Completed,No Results Available,Alzheimer Disease,Drug: galantamine,"Change from baseline to the end of the study in the Alzheimer's Disease Assessment Scale - Japan cognitive subscale (ADAS-J cog) and the Clinician's Interview-Based Impression of Change plus - Japan (CIBIC plus-J)|Change from baseline to the end of the study in CIBIC plus-J subscales (Disability Assessment for Dementia [DAD], Behavioral Pathology in Alzheimer's Disease Rating Scale [Behave-AD], the Mental Function Impairment Scale [MENFIS ]).",17-May-11,https://ClinicalTrials.gov/show/NCT00301574459,Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease,Completed,No Results Available,Alzheimer's Disease,Drug: MEM 3454,,06-May-08,https://ClinicalTrials.gov/show/NCT00454870460,Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease,Completed,No Results Available,Alzheimer's Disease,Drug: MEM 1003|Drug: Placebo for MEM 1003,"Cognitive function|Other Cognitive Assessments, activities of daily living, functional assessments and safety",06-May-08,https://ClinicalTrials.gov/show/NCT00257673461,Imaging Tau in Alzheimer's Disease and Normal Aging,Completed,No Results Available,Alzheimer's Disease,Drug: 18F-THK-5351|Procedure: Lumbar Puncture (optional),"Change in 18F-THK-5351 uptake value ratio|Change in CSF concentration of inflammatory markers|Change in CSF concentration of ë_-amyloid , tau and phospho-tau",16-May-18,https://ClinicalTrials.gov/show/NCT02884492462,AIT-082 Phase 1B Study,Completed,No Results Available,Memory Disorders,Drug: AIT-082,,11-Dec-09,https://ClinicalTrials.gov/show/NCT00000180463,Markers of Alzheimers Disease After Propofol or Isoflurane Anesthesia,Completed,No Results Available,General Anesthesia,Drug: Propofol|Drug: Isoflurane,"Ratio of cerebrospinal fluid tau to amyloid beta|the relationship between anesthetic exposure and CSF biomarker changes|the relationship between anesthetic exposure and CSF biomarker changes, and demographics (age, gender, and race)|the relationship between CSF biomarker changes and serum markers of metabolic and/or inflammatory status|the relationship between anesthetic exposure and biomarker changes and serum markers of metabolic and/or inflammatory status|the relationship between anesthetic exposure and biomarker changes and neuroimaging results obtained as dictated by routine standard of care|the relationship between anesthetic exposure and biomarker changes and depth of anesthesia, based on average BIS (bispectral index) monitoring signal|the relationship between anesthetic exposure and biomarker changes and the time of day that surgery is performed|the relationship between anesthetic exposure and biomarker changes with genetic polymorphisms in ApoE (apolipoprotein E) and other genes related to inflammation, metabolism, brain function and/or Alzheimer's disease",04-Aug-15,https://ClinicalTrials.gov/show/NCT01640275464,Stroke Study: Operative Strategies to Reduce Cerebral Embolic Events During Coronary Artery Bypass Surgery,Completed,No Results Available,Stroke,Procedure: No aortic clamping|Procedure: partial occluding clamp|Procedure: single cross clamp|Procedure: cross clamp and partial occluding clamp,Cerebral embolic events measured via transcranial doppler ultrasound|Neurocognitive dysfunction,24-Jan-17,https://ClinicalTrials.gov/show/NCT01502683465,Ketasyn In Age-Associated Memory Impairment,Completed,No Results Available,Age-Associated Memory Impairment,Drug: Ketasyn,"Changes in Psychologix and Cogscreen Test Batteries, RAVLT (Rey Auditory Verbal Learning Test)|Self-reported memory improvement",11-Dec-09,https://ClinicalTrials.gov/show/NCT00355550466,Mind-motor Exercise in Older Adults With Type 2 Diabetes and Self-reported Cognitive Complaints,Completed,No Results Available,Type 2 Diabetes Mellitus,Behavioral: Square-stepping exercise,Global Cognitive Functioning|Memory composite score|Reasoning composite score|Concentration composite score|Planning (executive functioning) composite score|Gait Speed|Prosaccade reaction time|Antisaccade reaction time|Prosaccade direction errors|Antisaccade direction errors,07-Mar-17,https://ClinicalTrials.gov/show/NCT02292511467,"Clinical Trial on Alzheimer Disease, Presbycusis and Hearing Aids",Completed,No Results Available,Alzheimer Disease|Presbycusis,Device: Hearing aids used : PHONAK Savia and Valeo,"Cognitive benefit evaluated thanks to the ADAS-Cog scale|Cognitive scales: MMSE, Grober and Buschke, Digit symbol test|Behavioural scales: IADL, NPI|Quality of life scales: Zarit scale and ADRQL|Consumption questionnaire",30-Aug-16,https://ClinicalTrials.gov/show/NCT00488007468,A Non-drug Methods Study in Participants With Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Other: PET scan using florbetapir|Other: MRI Scan,Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Brain Boundary Shift Integral (BBSI) and Ventricular Boundary Shift Integral (VBSI)|Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Hippocampus Volume Average Percent (%) Change (Chg)|Change From Baseline in Resting State Functional Magnetic Resonance Imaging (rsfMRI)|Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA)|Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD)|Baseline Brain Amyloid Load Using Positron Emission Tomography (PET) and Florbetapir|Number of Participants With Vasogenic Edema on MRI Scan at a Field Strength of 3 Tesla (3T)|Number of Participants With Microhemorrhage on MRI Scan at a Field Strength of 3T|Change From Baseline in the Mini Mental State Examination (MMSE) Total Score|Change From Baseline in the Alzheimer's Disease Assessment Scale Extended Cognitive Subscale (ADAS-Cog14) Total Score|Change From Baseline in the Clinical Dementia Rating (CDR) Total Score,13-Feb-17,https://ClinicalTrials.gov/show/NCT01459016469,Donepezil in Preventing Delirium in Hospitalized Elderly,Completed,No Results Available,Postoperative Complications|Delirium,Drug: Donepezil,"Postoperative cumulative incident cases of delirium, as defined by the Confusion Assessment Method (CAM) administered at baseline prior to surgery and daily until discharge|delirium severity as measured by the Memorial Delirium Assessment Scale (MDAS)|Cognitive status as measured by the Mini Mental Status Exam (MMSE)|behavioral status using the Rating Scale for Aggressive Behavior in the Elderly (RAGE)|length of stay in hospital postoperatively|discharge site|adverse effects|use of psychotropic medications",03-Mar-08,https://ClinicalTrials.gov/show/NCT00182884470,Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study,Completed,No Results Available,Cognitive Disorders,Drug: GSK1034702,Volume of distribution of [11C]GSK1034702 at tracer and pharmacological doses.|The kinetic rate constants at tracer and pharmacological doses.|GSK1034702 PK parameters: Cmax; tmax; AUC(0-t).|Safety and tolerability endpoints consisting of: AEs; 12-lead ECG; 12 lead digital Holter and lead II telemetry; vital signs; clinical laboratory evaluations.,27-Jun-17,https://ClinicalTrials.gov/show/NCT00937846471,The Effect of Different Sedation Regimes on Cognitive Function in Lower Gastrointestinal System Endoscopy,Completed,No Results Available,Gastrointestinal Dysfunction|Alteration of Cognitive Function,Drug: Midazolam|Drug: Meperidine|Drug: Remifentanil|Drug: Propofol,Change in Cognitive Function|Change in VAS scores|Change in Heart rate|Change in Mean arterial pressure|Change in Peripheral oxygen saturaion,01-Jul-15,https://ClinicalTrials.gov/show/NCT02486328472,Working Memory Training in Huntington's Disease,Completed,No Results Available,Huntington's Disease,Behavioral: Cogmed QM,"Adherence to training (defined by completing the intervention within the recommended time frame)|Digit Span subtest from the Wechsler Memory Scales - third edition|Spatial Span subtest from the Wechsler Memory Scales - third edition|Auditory Working Memory from the Woodcock Johnson Tests of Cognitive Ability - third edition|Symbol span subtest from the Wechsler Memory Scales - fourth edition, reported in raw score units (total correct responses)|Verbal Fluency subtest from the Delis-Kaplan Executive Function System|Symbol Digits Modalities Test (oral administration)|Word List Learning from the Hopkins Verbal Learning Test -Revised|Trail Making Test - Parts A and B",10-Oct-16,https://ClinicalTrials.gov/show/NCT02926820473,Phenytoin and Driving Safety,Completed,No Results Available,Cognitive Measures|Driving Simulator Performance,Drug: Phenytoin,Number of driving simulator crash events|Measures of cognition assessed in the on-phenytoin condition,10-May-17,https://ClinicalTrials.gov/show/NCT00581893474,Adjunctive Treatment for Decreasing Symptoms of Schizophrenia,Completed,No Results Available,Schizophrenia|Schizoaffective Disorder,Drug: d-cycloserine|Drug: glycine|Drug: placebo,"changes from baseline in negative symptoms measured on SANS at 4,8,12 and 16 weeks.|change from baseline on neurocognitive battery measured at 16 weeks.|change in psychotic and depressive symptoms measured at 4,8,12, and 16 weeks.|changes in extrapyramidal side effects at 4,8,12 and 16 weeks.",25-Nov-13,https://ClinicalTrials.gov/show/NCT00222235475,Effects of Biofeedback in Patients With Acute Cerebral Infarction,Completed,No Results Available,"Acute Ischemic Stroke|Biofeedback|Autonomic Dysfunction, Cognitive Function|Psychological Distress",Behavioral: heart rate variability biofeedback,Changes from Baseline Psychological distress (Anxiety and Depression) at 1 and 3 months|Changes from Baseline Cognitive function at 1 and 3 months|Changes from Baseline Capabilities of Activities of Daily Living at 1 and 3 months|Changes from Baseline Autonomic function (Heart rate variability) at 1 and 3 months,04-May-18,https://ClinicalTrials.gov/show/NCT03516227476,The Role of Perioperative Ventilation (Gas Exchange) During Intrabdominal Surgery on Cognitive Function,Completed,No Results Available,Response to Hyperoxia|Hypocapnia,Procedure: mechanical ventilation,Cognitive function|Psychological Changes|Pain perception,22-Sep-16,https://ClinicalTrials.gov/show/NCT02267031477,"The Effect of Nicotine on Arousal, Cognition and Social Cognition in Young and Elderly Healthy Subjects.",Completed,No Results Available,Schizophrenia|Cognition Disorders,Other: A643 (nicotine)|Drug: placebo,"To investigate the effect of nicotine on measures of arousal and event related potentials, especially the P50 auditory evoked potential, as well as standard cognitive tasks and social cognition.|Nicotine exposure",20-Mar-12,https://ClinicalTrials.gov/show/NCT01181934478,Efficacy Study of a ZT-1 Implant in Patients Suffering From Alzheimer's Disease,Completed,No Results Available,Moderate Alzheimer's Disease,Drug: ZT-1|Drug: Donepezil,Change in the MMSE score from baseline to week 25|Responder rate as defined by at least 2 points improvement in the MMSE score;|Change on the ADAS-Cog 11 items subscale;|Change in the NPI-Q;|Change on the IADL scale;|Patient's convenience questionnaire.,14-Jan-15,https://ClinicalTrials.gov/show/NCT00423228479,Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID),Completed,No Results Available,Dementia,Procedure: FDG-PET brain scan,"change from baseline in neuropsychological (cognitive,functional) test results|utilization of healthcare resources|PET results, compared with working diagnoses made before and after time of PET|rates of prescription of AD-specific therapies",02-May-17,https://ClinicalTrials.gov/show/NCT00329706480,Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx),Completed,No Results Available,Alzheimer Disease|Cognition Disorders,Drug: Rivastigmine,,09-Dec-05,https://ClinicalTrials.gov/show/NCT00000174481,Subclinical Hypothyroidism and Mind in the Elderly,Completed,No Results Available,Subclinical Hypothyroidism,Drug: levothyroxine sodium|Drug: excipient without levothyroxine (placebo),"Change in cognitive ability measured by NEUROPSI increase of 10 points|ejection fraction, left ventricular diastolic capacity|Lipid profile and body composition by DEXA|clinical assessment v.g. significant changes in cardiac frequency and rhythm (if needed able to take EKG to confirm)|Free tiroxina and TSH (assessed by investigator other than treatment physician)|Changes in EKG",28-Jun-12,https://ClinicalTrials.gov/show/NCT00921050482,Enhancing Synaptic Plasticity and Cognition in Schizophrenia,Completed,No Results Available,Schizophrenia,Other: Exercise|Other: TableSoccer,Hippocampal volume|Verbal Learning Memory|Positive and negative symptoms,27-May-15,https://ClinicalTrials.gov/show/NCT01776112483,"The Effect of Nicotine on Arousal, Cognition and Social Cognition in Schizophrenic Patients",Completed,No Results Available,Schizophrenia|Cognition Disorders,Other: A643 (nicotine)|Drug: placebo,"Event related potentials (P50, P300, N100) and measures of standard cognition and social cognition|Nicotine exposure",20-Mar-12,https://ClinicalTrials.gov/show/NCT01186471484,Evaluation of Consumption Safety and Effect of Mulberry Leaves and Vietnamese Coriander Based Instant Polyherbal Porridge on Working Memory and Bone Formation Markers,Completed,No Results Available,Healthy,Dietary Supplement: Placebo|Dietary Supplement: MP 50 mg/day|Dietary Supplement: MP 1500 mg/day,"Attention (N100) and cognitive processing (P300) determine by using Event Related Potential (Auditory oddball paradigm).|Accuracy and time response of working memory by using computerized batteries test (CDR)|Bone formation marker by using serum calcium, serum alkaline phosphatase and serum osteocalcin|Acetylcholinesterase and monoamine oxidase type A ,B activities in serum|Psychological symptom by using SCL-90 questionnaire|Consumption safety of MP product by using the electrocardiogram (ECG), hematology, blood chemistry and blood pressure measurement.",01-Mar-16,https://ClinicalTrials.gov/show/NCT02562274485,Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia,Completed,No Results Available,Schizophrenia Disorders,"Drug: Placebo (single and multiple doses)|Drug: AQW051 2 mg (single and multiple doses)|Drug: AQW051 15mg (single and multiple doses)|Drug: AQW051 100mg (single dose), and 50mg (multiple doses)","Effects of single oral doses of AQW051 versus placebo on cognitive function as measured by selected CogState tests|Effects of single oral doses of AQW051 versus placebo on cognitive function as measured by selected MATRICS Consensus Cognitive Battery (MCCB) tests|Effects of multiple oral doses of AQW051 versus placebo on cognitive function as measured by selected CogState tests and selected MCCB tests|Correlation of the cognitive domains measured by MCCB versus CogState|Pharmacokinetics, safety and tolerability of single and multiple doses of AQW051 as compared to placebo",14-Mar-13,https://ClinicalTrials.gov/show/NCT01163227486,Study of Social Cognition by Morphological and Functional Imaging in Multiple Sclerosis Patients,Completed,No Results Available,Multiple Sclerosis,Other: Brain MRI - Clinical and cognitive evaluation|Device: MRI,Brain activation networks during MRI|Reduction of volume of deep brain structures and reduction of cortical thickness|White matter skeleton on Fractional Anisotropy (FA) maps established by voxel-based.,04-Apr-17,https://ClinicalTrials.gov/show/NCT02290587487,Clinical Trial of Dipyridamole in Schizophrenia,Completed,No Results Available,Schizophrenia|Schizoaffective Disorder|Schizophreniform Disorder,Drug: Dipyridamole|Other: Olanzapine,"To provide preliminary estimates of effect sizes of dipyridamole on positive symptoms, negative symptoms, and cognitive deficits differ between schizophrenia patients treating with dipyridamole, and schizophrenia patients treated with olanzapine.|To determine if dipyridamole, a clinically available adenosine agonist, has efficacy for treating positive and negative symptoms and cognitive deficits of schizophrenia.",14-Jan-13,https://ClinicalTrials.gov/show/NCT00349973488,Mindful Awareness Program for the Prevention of Dementia: A Randomized Controlled Trial,Completed,No Results Available,Dementia,Behavioral: Mindful Awareness Program|Behavioral: Health Education Program,Change from baseline Mini-Mental State Examination (MMSE) at 3 months and 9 months|Change from baseline Clinical Dementia Rating (CDR ) at 3 months and 9 months|Change from baseline Rey Auditory Verbal Learning Test (RAVLT) at 3 months and 9 months|Change from baseline Digit Span Task at 3 months and 9 months|Change from baseline Colour Trails Tests (CTT) at 3 months and 9 months|Change from baseline Block Design at 3 months and 9 months|Change from baseline Semantic Verbal Fluency (Animals) at 3 months and 9 months|Change from baseline fMRI scan at 3 months|Change from baseline Biomarkers: blood sample at 3 months and 9 months|Change from baseline Biomarkers: urine sample at 9 months|Change from baseline Biomarker - fecal sample at 3 months and 9 months|Change from baseline Biomarker - saliva sample at 3 months and 9 months|Change from baseline Basic Health Screen at 3 months and 9 months|Change from baseline Activities of daily Living (ADL) at 3 months and 9 months|Change from baseline Instrumental Activities of Daily Living (IADL) at 3 months and 9 months|Change from baseline Geriatric Depression Scale (GDS) at 3 months and 9 months|Change from baseline Geriatric Anxiety Inventory (GAI) at 3 months and 9 months,18-Aug-15,https://ClinicalTrials.gov/show/NCT02286791489,Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia,Completed,Has Results,Schizophrenia,Drug: PF-04958242|Drug: Placebo,"Maximum Observed Plasma Concentration (Cmax) (Single Dose)|Cmax (Steady State)|Time for Cmax (Tmax) (Single Dose)|Tmax (Steady State)|Area Under the Concentration-Time Profile From Time 0 to Time Tau (ìã), the Dosing Interval, Where ìã = 12 Hours (AUCìã) (Single Dose)|AUCìã (Steady State)|Apparent Oral Clearance (CL/F) (Steady State)|Apparent Volume of Distribution (Vz/F) (Steady State)|Terminal Half-Life (t1/2) (Steady State)|Observed Accumulation Ratio (Rac) (Steady State)|Observed Accumulation Ratio for Cmax (Rac, Cmax) (Steady State)|Peak-to-Trough Ratio at Steady State (PTR)|Number of Participants With Abnormal Clinical Laboratory Measurements|Number of Participants With Vital Signs Data Meeting Criteria of Potential Clinical Concern|Number of Participants With Electrocardiogram Data Meeting Criteria of Potential Clinical Concern|Number of Participants With Abnormalities in Neurological Examination|Number of Participants With Abnormalities in Physical Examination|Number of Participants With Adverse Events (AEs)|Number of Participants With Positive Response to Columbia-Suicide Severity Rating Scale (C-SSRS)",14-Jun-16,https://ClinicalTrials.gov/show/NCT02332798490,Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease,Completed,No Results Available,Alzheimer's Disease,"Biological: Etanercept|Dietary Supplement: Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.",Difference in effects of treatment for 6 weeks with etanercept + nutritional supplements versus nutritional supplements alone on the Mini-Mental Status Examination (MMSE) score.|Difference in the effects of treatment for 6 weeks with etanercept + nutritional supplements versus nutritional supplements alone on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) score.|Difference in the effects of treatment for 6 weeks with etanercept + nutritional supplements versus nutritional supplements alone on the Montreal Cognitive Assessment (MoCA) score.,12-May-16,https://ClinicalTrials.gov/show/NCT01716637491,AST-120 Used to Treat Mild Hepatic Encephalopathy,Completed,No Results Available,Mild Hepatic Encephalopathy,Drug: AST-120,"Neurocognitive improvement, defined as the change in the global summary score of the RBANS at Week 8 compared to Baseline.",18-Jun-14,https://ClinicalTrials.gov/show/NCT00867698492,Evaluation of a Cognitive Adaptive E-treatment in Schizophrenia-diagnosed Adults,Completed,No Results Available,Schizophrenia,Other: Plasticity-based Cognitive Training|Other: Non-plasticity-based Training,"Evaluation of the effects of plasticity-based, adaptive cognitive remediation on cognitive abilities, functional status and quality of life.|Demonstration of equivalency in safety effects reported between treatment groups.",08-Feb-16,https://ClinicalTrials.gov/show/NCT01422902493,"Pulmonary Rehabilitation: Effects on Cognitive Functioning, Mood, Anxiety, and Quality of Life in Patients With COPD",Completed,No Results Available,Chronic Obstructive Pulmonary Disease COPD,Other: Extensive Pulmonary Rehabilitation Program,Change in Objective Cognitive functioning|Change in Mood and Anxiety|Change in Quality of Life|Change in 6 Minute Walking distance Test(6-MWT)|Change in Subjective Cognitive Functioning|Adherence to pulmonary rehabilitation|Change in Fatigue|Dropout from pulmonary rehabilitation,31-Oct-17,https://ClinicalTrials.gov/show/NCT01682447494,Recovery From General Anesthesia,Completed,No Results Available,"Anesthesia, General|Recovery Period, Anesthesia",Procedure: BIS monitoring,Cognitive function|Inflammation|Memory function|Depression|Anxiety,17-Apr-07,https://ClinicalTrials.gov/show/NCT00165971495,"Problem Adaptation Therapy (PATH) vs. Supportive Therapy in Treating Depressed, Cognitively Impaired Older Adults",Completed,Has Results,Depression,Behavioral: PATH|Behavioral: ST-CI,Montgomery Asberg Depression Scale (MADRS)|WHO Disability Assessment Schedule (WHODAS)-II|Hamilton Depression Rating Scale|Sheehan Disability Scale.,24-Jul-17,https://ClinicalTrials.gov/show/NCT00368940496,Cognitive Rehabilitation in Parkinson's Disease,Completed,Has Results,Parkinson's Disease,Behavioral: PC based training,"Reaction Time and Variability for Movement Task|Neuropsychological Measures of Cognitive Function, Including Reaction Time and Time to Completion|Task Errors and Variability|Functional Dexterity Test (FDT)|Symbol Digit Modality Test (SDMT)",11-Oct-16,https://ClinicalTrials.gov/show/NCT01085968497,An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Drug: Placebo|Drug: Galantamine 16 mg/day|Drug: Galantamine 24 mg/day,Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog)|Distribution of Clinician's Interview-Based Impression of Change Plus - Japan (CIBIC Plus-J)|Change From Baseline in the Disability Assessment for Dementia (DAD)|Change From Baseline in the Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD)|Change From Baseline in the Mental Function Impairment Scale (MENFIS),17-Apr-14,https://ClinicalTrials.gov/show/NCT00814801498,Risk Assessment for Postoperative Delirium,Completed,No Results Available,Postoperative Delirium,Other: Tablet computer application,Incidence of POD.|Severity of POD.,25-Apr-18,https://ClinicalTrials.gov/show/NCT02377115499,Endothelial Facilitation in Alzheimer's Disease,Completed,No Results Available,Alzheimer's Disease,Drug: Simvastatin + L-Arginine + Tetrahydrobiopterin,Increase in regional cerebral blood flow over 4 months on studied medications|Psychometric evaluation,06-Mar-18,https://ClinicalTrials.gov/show/NCT01439555500,Clinical Trial of CNS-targeted HAART (CIT2),Completed,Has Results,HIV Infections,Drug: FDA Approved Antiretroviral Therapy (see list below),Neuropsychological Performance Change,23-Apr-14,https://ClinicalTrials.gov/show/NCT00624195501,Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression,Completed,Has Results,Depression,Drug: Citalopram|Drug: Methylphenidate (MPH)|Drug: Placebo,Hamilton Depression Rating Scale (HDRS) Maintained Scores at Week 16|Quality of Life Assessment,11-Jan-18,https://ClinicalTrials.gov/show/NCT00602290502,Clinical Trial of Gabapentin to Improve Postoperative Pain in Surgical Patients,Completed,No Results Available,Postoperative Pain,Drug: Gabapentin,Postoperative delirium and cognitive decline|Postoperative opioid doses and pain scores,15-Jul-15,https://ClinicalTrials.gov/show/NCT00221338503,A Study to Determine if Carbon Dioxide Lavage During Total Knee Surgery Reduces Intraoperative Embolic Events,Completed,Has Results,Postoperative Complications|Memory Disorders,Device: pulsatile saline lavage|Device: carbon dioxide lavage,The Number of Cerebral Emboli During Surgery as Measured by Transcranial Doppler (TCD)|Number of Patients With Emboli in the High Category|Changes in Neurocognitive Tests Following Surgery|Delirium During Hospital Stay|Changes in Pulmonary and Renal Function|Cardiac Injury|Systemic Inflammatory Response (SIRS) Markers|Biomarkers of Neuronal Damage,19-Apr-13,https://ClinicalTrials.gov/show/NCT00736125504,Evaluating Neuroprotection in Aneurysm Coiling Therapy,Completed,Has Results,Stroke,Drug: NA-1|Drug: Placebo,Volume of New FLAIR Lesions(MRI)|Number of New DWI Lesions (MRI)|Number of New FLAIR Lesions (MRI)|Volume of New DWI Lesions (MRI)|National Institutes of Health Stroke Scale (NIHSS).|Modified Rankin Scale (mRS).,17-Oct-13,https://ClinicalTrials.gov/show/NCT00728182505,fMRI Guided TMS Enhancement of Associative Memory Networks,Completed,No Results Available,Epilepsy,Device: MagStim RapidStim2,Change in score on cognitive testing face recognition task|fMRI Connectivity,17-May-18,https://ClinicalTrials.gov/show/NCT02749422506,Impact of Remote Ischemic Preconditioning Preceding Coronary Artery Bypass Grafting on Inducing nEuroprotection,Completed,No Results Available,Brain Ischemia|Postoperative Confusion,Procedure: Remote ischemic preconditioning|Procedure: Control,Composite structural and functional neurological outcome|Brain connectivity profiles|Peri-operative brain injury|Postoperative neurocognitive decline,25-Apr-18,https://ClinicalTrials.gov/show/NCT02177981507,Varenicline Adjunctive Treatment in Schizophrenia,Completed,Has Results,Schizophrenia|Schizoaffective Disorder|Schizophreniform Disorder,Drug: Varenicline|Drug: Placebo,"Hamilton Depression Rating Scale (Ham-D)|Memory Saccadic Positional Error, Degrees|Predictive Pursuit Gain|Maintenance Pursuit Gain|Digit Symbol Test|Conner's Continuous Performance Test (CPT) Detectability Score|Antisaccade Error Rates|P50",04-Jan-18,https://ClinicalTrials.gov/show/NCT00492349508,Improving Caregiver Mediated Medication Management- The 3M Study,Completed,No Results Available,Medication Management,Behavioral: Intervention,Medication management assessed by investigator developed Medication Deficiency Checklist- post-treatment|Medication management-assessed by investigator developed Medication Deficiency Checklist- post maintenance|Medication management-assessed by investigator developed Medication Deficiency Checklist- post followup|Patient outcomes- medical utilization-Investigator developed Unscheduled Event Checklist|Caregiver outcome- Improved quality of life via Medical Outcome Short Form (SF-36),04-May-17,https://ClinicalTrials.gov/show/NCT03127930509,Exercise Treatment of Mild-Stage Probable Alzheimer's Disease,Completed,No Results Available,Alzheimer Disease|Memory Disorders|Dementia,Behavioral: Participation in a monitored exercise program|Behavioral: Personalized aerobic and strength training.,"For the intervention group: Change in cognitive performance relative to baseline|Group differences in cognitive performance following intervention and relative to wait-list control group|For the intervention group: Change in attitudes, including self-report of well-being and cognitive abilities relative to baseline|Group differences in attitudes, including self-report of well-being, following intervention and relative to wait-list control group|For the intervention group: Change in knowledgeable informant's ratings of function, behavior, and attitudes|Group differences in knowledgeable informant's ratings of function, behavior, and attitudes following intervention and relative to wait-list control group",11-May-11,https://ClinicalTrials.gov/show/NCT00403507510,Risk Evaluation and Education for Alzheimer's Disease,Completed,No Results Available,Alzheimer's Disease,Behavioral: APOE Disclosure,Center for Epidemiological Studies-Depression Scale (CES-D)|Beck Anxiety Inventory (BAI)|Impact of Events Scale (IES)|Future Attitudes Scale (FAS)|Positive and Negative Affect Schedule (PANAS),23-Jul-09,https://ClinicalTrials.gov/show/NCT00571025511,Treatment Resistant Geriatric Depression in Primary Care,Completed,No Results Available,Major Depressive Disorder,Drug: Memantine,Mean Differences in NAAG Levels between Subject Groups at Baseline and Week 8|Relationship of NAAG Levels and MADRS Scores between Subject Groups at Baseline and Week 8|Cognitive Impairment between Subject Groups at Baseline and Week 8,01-Feb-17,https://ClinicalTrials.gov/show/NCT01392287512,D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia,Completed,Has Results,Schizophrenia,Drug: D-cycloserine|Drug: Placebo|Behavioral: Cognitive Remediation,Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS)|Scale for Assessment of Negative Symptoms (SANS)|Auditory Discrimination Task: Interstimulus Interval (ISI)|Positive and Negative Syndrome Scale (PANSS)|Global Assessment of Functioning Scale (GAS)|Heinrich Quality of Life Scale (QoL)|Calgary Depression Scale for Schizophrenia (CDSS)|Clinical Global Impression (CGI)|Side Effects Checklist (SEC),06-Feb-18,https://ClinicalTrials.gov/show/NCT00963924513,Hypercapnia: Cognitive Effects and Monitoring,Completed,No Results Available,Hypercapnia|Exercise|Nitrogen Narcosis|Diving|Immersion,Other: NO exercise at depth|Other: exercise at depth,"Is cognitive ability different while resting versus compared to cognitive ability while diving, breathing different gas mixtures and while exercising?|How does exhaled (end tidal) carbon dioxide compare with arterial carbon dioxide?",25-May-16,https://ClinicalTrials.gov/show/NCT01782625514,"Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers",Completed,Has Results,Healthy,Drug: PF-04958242|Drug: Placebo,Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) Post-Baseline|Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Laboratory Abnormalities Meeting the Criteria for Potential Clinical Concern|Number of Participants With Potentially Clinically Significant Vital Signs Findings|Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Findings|Number of Participants With Abnormal Physical Examination Findings|Number of Participants With Abnormal Neurological Examination Findings|Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)|Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)|Apparent Clearance (CL/F)|Apparent Volume of Distribution (Vz/F)|Terminal Elimination Half-Life (t1/2)|Dose Normalized Cmax (Cmax[dn])|Dose Normalized AUClast (AUClast[dn])|Dose Normalized AUCinf (AUCinf[dn]),17-Dec-15,https://ClinicalTrials.gov/show/NCT02228395515,"A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease",Completed,No Results Available,Alzheimer Disease,Drug: galantamine,"To measure the differences between galantamine and donepazil for sleep and attention, explore methods of measuring sleep in patients with Alzheimer's Disease (AD)and their caregivers and attention in AD patients; GI tolerance|To assess the tolerability, overall effect, quality of life and safety of galantamine compared with donepezil",08-Jun-11,https://ClinicalTrials.gov/show/NCT00035204516,IMaging Della PLAcca Carotidea,Completed,No Results Available,Carotid Artery Plaque|Atherosclerosis|Ischemic Stroke,Drug: Visipaque 320 and SonoVue,"Changes of total cerebral white matter lesions from baseline (T2-weight lesions, in terms of number and total volumes indexed to the total brain volume)|Changes of total brain volume and grey matter volume from baseline|Changes of ipsilateral cerebral white matter lesions from baseline (T2-weight lesions, in terms of number and total volumes indexed to the total brain volume)|Changes of the carotid total plaque area and extent of CEUS positive plaques|Compare the esteem of the degree and the characteristics of the main plaque with standard Duplex scan versus CEUS using contrast enhanced carotid CT scan as gold standard",16-Feb-18,https://ClinicalTrials.gov/show/NCT03333330517,A D1 Agonist For Working Memory,Completed,No Results Available,Schizotypal Personality Disorder|SPD,Drug: DAR 0-100A|Drug: Placebo,The Modified AX-CPT (d'),09-Apr-18,https://ClinicalTrials.gov/show/NCT02507206518,Neuroimaging Markers of Alzheimer Disease: a Longitudinal Population Study,Completed,No Results Available,Dementia|Alzheimer Disease,Other: Neuroimaging,Measures of volume and diffusion parameters in the gray matter (hippocampus and cingular posterior cortex)|Performance on neuropsychological and daily life cognitive tests,04-Apr-17,https://ClinicalTrials.gov/show/NCT01582919519,Assessment of Social-emotional Functioning in Neurological Diseases,Completed,No Results Available,Alzheimer Disease|Stroke|Parkinson's Disease|Lewy Body Dementia|Huntington Disease,Behavioral: Computerized tests and Electrophysiological measurements,"Empathy ability|Empathy for pain|pattern of empathy disorders according to the disease (stroke, Mild cognitive impairment, Alzheimer disease and Parkinson disease",07-Sep-15,https://ClinicalTrials.gov/show/NCT01339130520,CRT-Guanfacine for SPD,Completed,No Results Available,Schizotypal Personality Disorder|SPD,Behavioral: Cognitive Remediation Therapy|Drug: Guanfacine|Drug: Placebo,MATRICS Consensus Cognitive Battery Score|Modified version of AX-Continuous Performance Test (AX-CPT) Score|UCSD Performance Based Skills Assessment (UPSA) Score|Social Skills Performance Assessment (SSPA) Score|Reading of the Mind in the Eyes Score,28-Feb-17,https://ClinicalTrials.gov/show/NCT02524899521,A Change in Diet May Decrease the Negative Consequences of Chronic Sleep Deprivation,Completed,No Results Available,Sleep Deprivation,Drug: Controlled Dietary Intervention,"Resting Metabolic Rate|Weight|Percent Body Fat|Waist Circumference|Lipid Profile|C-reactive Protein Levels|Fasting serum glucose|Fasting serum insulin|Urinary neurotransmitter levels|Salivary a.m. cortisol levels|Cognitive scores on: Stroop Test, Hopkins Verbal Learning Test, Trail Making Test, Digit Span, Block Design, Dynamic Visual Acuity, Short Form 36",27-Jun-06,https://ClinicalTrials.gov/show/NCT00123214522,Multicenter Vitamin E Trial in Aging Persons With Down Syndrome,Completed,No Results Available,Alzheimer's Disease|Down Syndrome,Drug: Alpha-Tocopherol|Drug: Sugar Pill,The Brief Praxis Test|The Fuld Object Memory Test|New Dot Test|Orientation Test|Vocabulary Test|Behavior and Function|Clinical Global Impression|Incident Dementia,09-May-12,https://ClinicalTrials.gov/show/NCT01594346523,Diet and the Aging Brain,Completed,No Results Available,Healthy,Behavioral: diet,implicit visual-motor learning of a finger sequence of the hand.|implicit learning of an artificial language|several plasma levels related to cognitive functions,08-Nov-11,https://ClinicalTrials.gov/show/NCT00463255524,Family-Directed Cognitive Adaptation Program for Individuals With Schizophrenia,Completed,No Results Available,Schizophrenia|Schizoaffective Disorder|Schizophreniform Disorder,Behavioral: Family-Directed Cognitive Adaptation Program,"Social Adaptive Functions Scale (P)|Multnomah Community Ability Scale (P)|Global Assessment of Functioning (P)|Brief Psychiatric Rating Scale, Positive and Negative syndrome Scale, Scale for the Assessment of Negative symptoms|Interpersonal Affectivity Scale (P, F); Knowledge Questionnaire (P, F), Independent Living Skills Survey (P, F),Ind Living Self Care Checklist (P, F|Clinical Global Impression of Cognition in Schizophrenia (P, F)|Patient Rejection Scale (F)|Modified Family Resources Interview (F)|Family Self-Efficacy Scale (F)|Caregiving Gains and Benefits/ Gratifications Module (F)|Beck Depression and Anxiety Inventories (F)|Client Satisfaction Questionnaire (P, F)",14-Mar-17,https://ClinicalTrials.gov/show/NCT00434980525,Improvement in Memory With Plasticity-Based Adaptive Cognitive Training (IMPACT),Completed,No Results Available,Aging,Other: Computerized Plasticity-Based Adaptive Cognitive Training|Other: Educational DVDs,Cognitive effects of training|Safety effects of computer-based training,02-Nov-15,https://ClinicalTrials.gov/show/NCT00283010526,Effects of Physical Activity on the Brain in Impaired Glucose Tolerance (IGT),Completed,No Results Available,Impaired Glucose Tolerance,Behavioral: Exercise,Auditory Verbal Learning Task|Functional/Structural brain changes|Plasma biomarkers,16-Mar-16,https://ClinicalTrials.gov/show/NCT01219231527,Training-induced Cerebral Reorganization in Schizophrenia,Completed,No Results Available,Schizophrenia,Behavioral: Brain Fitness Program|Behavioral: Cogpack,"Event related potential MEG, test scores in word fluency and verbal learning tasks|Symptom severity, GAF score",13-Apr-10,https://ClinicalTrials.gov/show/NCT00695708528,IDEA Study Cognitive Stimulation Therapy (CST) Trial in Tanzania,Completed,Has Results,Dementia,Behavioral: CST Intervention,World Health Organization Brief Quality of Life Scale|Identification and Intervention for Elderly Africans Cognitive Screen|Adapted Alzheimer's Disease Assessment Scale-cognitive Scale|Hospital Anxiety and Depression Scale|Zarit Burden Interview,09-Apr-18,https://ClinicalTrials.gov/show/NCT02229474529,A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers,Completed,No Results Available,Healthy,Drug: 3 mg PF-06412562|Drug: 10 mg PF-06412562|Drug: 25 mg PF-06412562|Drug: PF-06412562 TBD mg,"Safety and toleration assessed by: adverse events, supine and standing vital sign measurements, electrocardiogram (ECG) standard 12 lead, blood and urine safety laboratory tests ,CogState and C-SSRS.|Pharmacokinetics: Cmax, Tmax, AUCìã Ctrough, PTR, Rac on Cmax and AUCìã t1/2, CL/F, PTR,|CogState at followup",28-Mar-14,https://ClinicalTrials.gov/show/NCT01959594530,Direct Current Brain Polarization in Frontotemporal Dementia,Completed,No Results Available,Pick Disease of the Brain,Procedure: Direct Current Polarization,,04-Mar-08,https://ClinicalTrials.gov/show/NCT00077896531,Effects of Brain Stimulation During a Daytime Nap on Memory Consolidation in Older Adults,Completed,No Results Available,Older Adults (50-90 Years),Device: brain stimulation|Device: Sham Stimulation,"Retention of declarative memories after 0.75 Hz stimulation during SWS, vs after sham stimulation during SWS|1. Amount of Slow wave Sleep|2. sleep spindels|3. EEG-correlates|4. further memory systems",30-Jan-18,https://ClinicalTrials.gov/show/NCT01840839532,Impact of Systematic Tracking of Dementia Cases on the Rate of Hospitalization in Emergency Care Units,Completed,No Results Available,Dementia in Nursing Home,Other: MultiDisciplinary Team Meetings (MDTM),Incidence of hospitalizations in emergency care units|Prevalence of antipsychotic prescription|Incidence of inappropriate hospitalizations|Prevalence of neuropsychiatric symptoms evaluated by NPI-nursing staff version|Dependency evaluated by AGGIR and IADL-4 items|Quality of life evaluated by QOL-AD|Number of nursing staff's time off work|Number of days off work by nursing staff|Presence of advanced care planning in patients medical records|Overall healthcare costs,24-Aug-15,https://ClinicalTrials.gov/show/NCT01569997533,Parent Nurse Controlled Analgesic in Pediatric Patients With Developmental Delay,Completed,Has Results,Post Operative Pain,Other: Pain and standard side effect management for PNCA with basal method.|Other: Pain and standard side effect management with PNCA without basal|Other: Pain and standard side effect management with IV on an as needed basis method.,"Median Pain Score During Shift 1, as Measured With the Face, Legs, Activity, Cry, Consolability Scale|Side Effect Profile (Administration of Medications to Treat Side Effects)|Parent Satisfaction With the Administration Technique",28-Nov-17,https://ClinicalTrials.gov/show/NCT00743730534,Treatment of Post-Traumatic Brain Injury (Post-TBI) Fatigue With Light Therapy,Completed,No Results Available,Traumatic Brain Injury|Fatigue,Device: Bright White Light (BWL)|Device: Dim Red Light (DRL),Multidimensional Assessment of Fatigue (MAF)|TBI-QOL Fatigue|Neuro-QOL Depression and Sleep|Epworth Sleepiness Scale (ESS)|CNS Vital Signs TBI Rehab Toolbox|Cognitive Failures Questionnaire|Neuro-QOL Anxiety|Actiwatch Spectrum|Satisfaction with Life Scale|Treatment Satisfaction Questionnaire for Medication|Credibility/Expectancy Questionnaire,20-Mar-18,https://ClinicalTrials.gov/show/NCT01725750535,Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia,Completed,Has Results,Frontal Lobe Dementia|Frontotemporal Lobe Dementia|Semantic Dementia,Drug: memantine|Drug: Placebo pill,"Change in Neuropsychiatric Inventory (NPI)|Clinical Global Impression of Change (CGIC)|CDR-FTD, MMSE, FAQ, TFLS, EXIT25, UCSF FTD-Neuropsychological Test Battery: CVLT, Verbal Fluency, Modified BNT, Backward Digit Span, Digit Symbol Test, Modified Trails B, Modified Unified Parkinson's Disease Rating Scale, Antipsychotic Therapy",05-Feb-14,https://ClinicalTrials.gov/show/NCT00545974536,DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury,Completed,Has Results,"Brain Injuries|Craniocerebral Trauma|Trauma, Nervous System|Traumatic Brain Injury",Drug: IV Propranolol and Per Tube Clonidine|Drug: Placebo,Ventilator-free Days|Plasma Norepinephrine Levels,17-Aug-17,https://ClinicalTrials.gov/show/NCT01322048537,Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia,Completed,No Results Available,Schizophrenia,Behavioral: TARA computer-based exercises,Source Memory Test|Temporal Experience of Pleasure Scale|Quality of Life Scale|Social Functioning Scale|Global Social and Role Functioning Scale|Theories of Intelligence|Faux Pas test|Behavioral Inhibition/Behavioral Activation Scale|Wechsler Test of Adult Reading|Penn Facial Memory Test|Measure of Insight into Cognition|Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT),30-Sep-16,https://ClinicalTrials.gov/show/NCT01773239538,Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS),Completed,No Results Available,"Hepatitis C, Chronic|Cognition Disorders|Fatigue Syndrome, Chronic|Major Depressive Disorder",Drug: Interferon and ribavirin,"Neuropsychological test results, cytokine profile and MRI findings|Interferon-induced depression",11-Jan-13,https://ClinicalTrials.gov/show/NCT00788918539,Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy Subjects,Completed,No Results Available,Healthy Subjects,Drug: Ketamine|Drug: Nicotine|Drug: Placebo|Drug: Ketamine and Nicotine,ERP recording procedures: Brain wave activity during tasks involving in processing auditory and visual stimuli with different degrees of attentional and memory demands will be recorded.|IntegNeuro is a computerized battery that consists of an automated stimulus presentation to measure cognitive function.|Positive and Negative Syndrome Scale will be used to measure psychotic symptoms.,09-May-12,https://ClinicalTrials.gov/show/NCT00690170540,Efficacy of Cognitive Training in Subjective Memory Impairment,Completed,No Results Available,Memory Loss,Behavioral: cognitive training|Behavioral: lifestyle modification,"Paired associates learning test|Rapid visual information processing test|Pattern recognition memory test|Spatial working memory test|cognitive failure questionnaire|Mini-mental state examination|Geriatric depression scale|Beck anxiety index|Seoul instrumental activities of daily living|Rey complex figure copy test|Digit symbol test|Seoul verbal learning test, immediate recall|Seoul verbal learning test, delayed recall|Logical memory test, delayed recall",12-Apr-18,https://ClinicalTrials.gov/show/NCT02555774541,Imaging of Brain Receptors in Healthy Volunteers and in Patients With Schizophrenia,Completed,No Results Available,Schizophrenia,Drug: SPECT Imaging of Nicotinic Acetylcholine Receptors in Brain,,04-Mar-08,https://ClinicalTrials.gov/show/NCT00061789542,Cognitive Effects of Aerobic Exercise for IGT Adults,Completed,No Results Available,Impaired Glucose Tolerance,Behavioral: Aerobic exercise,"Change in cognitive scores|Change in insulin sensitivity|Change in biomarkers assayed from blood|Correlation between cognitive scores, insulin sensitivity, biomarkers",30-Jul-08,https://ClinicalTrials.gov/show/NCT00220441543,Huperzine for Cognitive and Functional Impairment in Schizophrenia,Completed,No Results Available,Schizophrenia,Drug: placebo|Drug: huperzine 0.2 mg BID|Drug: huperzine 0.4 mg BID|Drug: huperzine 0.8 mg BID,MATRICS battery|UPSA,01-Mar-13,https://ClinicalTrials.gov/show/NCT00963846544,Brain and Cognitive Changes After Reasoning or Physical Training in Cognitively Normal Seniors,Completed,No Results Available,Hearing Impaired,Behavioral: SMART- Strategic Memory and Reasoning Training|Other: Physical Exercise,Cognitive Scores|MRI images,11-Jul-16,https://ClinicalTrials.gov/show/NCT00977418545,A Study of Memantine Hydrochloride (Namendaå¨) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders,Completed,Has Results,Autism Spectrum Disorders,Drug: Memantine,Number of Participants With Reduction in ASD Symptom Severity as Defined by the Social Responsiveness Scale (SRS)|Number of Participants With Reduction in ASD Symptom Severity as Defined by the NIMH Clinical Global Impression for Pervasive Developmental Disorders (CGI-PDD) Improvement Score,24-Mar-16,https://ClinicalTrials.gov/show/NCT01333865